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Resorcylic acid lactones (RALs) are macrocyclic natural products produced by 
a variety of fungal strains. This class of natural products has been recognized as 
privileged scaffolds for drug discovery. Our interest in the RALs stems from the early 
reports that a number of RALs are kinase inhibitors. Intriguingly these RALs show 
varying potencies and certain selectivity against various kinases, suggesting that there 
is much scope in the exploration of RALs and analogues as kinase inhibitors. 
Specifically this thesis is focused on investigating the chemistry and the biological 
activities of RALs and designed analogues against CDK2, MNK1/2 and FLT3 et al 
kinases. The main achievements of this thesis are summarized below. 
Our initial interest in RALs arose from aigialomycin D as antimalarial agent 
and CDK1/5 inhibitor. Despite these reports, the inhibitory activity of aigialomycin D 
and related analogues against other kinases are not known. In Chapter 2, we 
synthesized aigialomycin D and a number of its macrocyclic analogues, and evaluated 
their inhibitory activities against CDK2 and other potential kinase targets.  From our 
study, aigialomycin D and other two analogues were identified as moderately potent 
compounds in the inhibition of CDK2/cyclin A complex with IC50 values at ca 20 µM 
range. In view of the moderate inhibitory activity against CDK2, other kinase targets 
were sought. From the kinase profiling of aigialomycin D, MNK1/2, FLT3, PLK4 et 
al were identified as more promising targets. Among these, MNK1/2, as the emerging 
kinase targets for cancer therapy, were selected for further investigation.  
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In Chapter 3, we have synthesized and examined the inhibitory activities of 
some acyclic analogues of aigialomycin D. We found that contrary to our expectation, 
these acyclic compounds were essentially inactive against MNK1/2. 
Naturally occurring cis-enone RALs have been reported to be covalent kinase 
inhibitors with highly potent activities however plagued by the problems of multi-
targeting. Inspired by the two recently approved drug compounds (i.e., Afatinib and 
Ibrutinib) which are covalent kinase inhibitors, we embarked on a programme 
directed at investigating RAL analogues as covalent kinase inhibitors. Specifically, a 
series of conveniently accessible enamide-based RAL analogues were designed and 
synthesized as novel covalent inhibitors of MNK kinases. In this study, we 
successfully demonstrated that the covalent binding ability of RAL enamides can be 
tuned by attaching an electron-withdrawing motif such as an N-acyl group to increase 
the electrophilicity of the enamide thereby enhancing its reactivity towards the 
cysteine residues of the kinases. 
1
H NMR spectroscopy and protein mass analysis 
were employed as a useful tools for assessment of covalent binding activity of the 
enamides. Modification of the initial hits led to the discovery of enamides with in 
single-digit micromolar activity. These enamide RAL analogues displayed attenuated 
covalent binding abilities to the target proteins whilst showed equipotent cellular 
activities as compared to the natural product L-783277 in the growth inhibition of 
several cancer cells. 
Besides MNK kinases, another important kinase target is FLT3, which is 
commonly implicated in hematologic diseases espeically in acute myeloid leukemia 
(AML). In Chapter 5 of this thesis, a series of simplified ring-opened resorcylic acid 
lactone (RAL) derivatives targeting FLT3 and its mutants were developed. The design 
of the covalent FLT3 inhibitors was based on β-resorcylic acid as the core structure 
x 
 
with various functional substitutions and Michael acceptors (i.e., acrylamide, 
vinylsulfonamide and maleimide) as potential covalent traps. Overall, 26 compounds 
were synthesized and evaluated for their inhibitory activities against wt-FLT3, FLT3-
D835Y and FLT3-ITD in a kinase binding assay. It was shown that the maleimides 
are potent irreversible FLT3 inhibitors with IC50 values at nanomolar range. However 
at the cellular level, a lack of specificity was observed and this could be attributed to 
the high reactivity of the maleimide Michael acceptor. In contrast, synthetic 
acrylamides and vinylsulfonamides proved to be reversible towards FLT3 binding but 
they are more potent and selective inhibitors of mutant FLT3-ITD versus wt-FLT3, 
and specific to FLT3-ITD expressing cell line MV-4-11 than wt-FT3 expressing cell 
line THP-1 and non-FLT3 cell lines (K562, HL60 and Hek-293T). The latter suggests 
that these compounds can be further developed as potent and selective inhibitors of 
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Chapter One General Introduction 
 
1.1 Cancer and its chemotherapy in drug discovery 
Cancer is defined as a group of diseases characterized by uncontrolled growth 
and spread of abnormal cells.1 Cancer is a leading cause of disease worldwide. 
According to estimates from the International Agency for Research on Cancer (IARC), 
there were an estimated 14.1 million new cases of cancer in the world with 7.4 million 
(53%) in males and 6.7 million (47%) in females In 2012.2 Among over 200 known 
cancer types, prostate (28%) and breast (29%) cancers are ranked among the top, 
whilst lung and bronchus cancers are the top two cancers that cause death in both 
males (28%) and females (26%). Other leading types of cancers include colon and 
rectum, ovary, pancreas and leukemia.3  
Cancer is usually treated with surgery, chemotherapy and radiation. More 
advanced hormone therapy, biological therapy, and targeted therapy are also used.1 Of 
the above, chemotherapy, especially targeted chemotherapy, plays a very important 
role in the treatment of cancers. Consequently, the development of anti-cancer drugs 
is the main focus of many drug discovery research efforts. Anti-cancer drugs include 
small molecular weight compounds, biologics (antibodies), hormone therapies and 
others. In this thesis, only small molecules which constitute the largest group of anti-
cancer drugs are discussed.  
Small molecular weight drugs can be either natural or of synthetic origin. 
Compounds of natural origin have often provided new leads in terms of the novelty of 
structures possessing anticancer activity.4 For example, the cancer chemotherapeutic 
drug vincristine (1.1, Figure 1-1) is derived from the periwinkle plant Vinca rosea, 
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and taxol (1.2) originated from the Pacific Yew, Taxus brevifolia.5 Similarly, 
doxorubicin (1.3) is a semi-synthetic molecule derived from fermentation of the 
bacteria Streptomyces; rhizoxin (1.4) is derived from the fungus Rhizopus chinensis, 
and cytarabine (1.5) was discovered from the marine sponge Cryptotethya crypta. 
Analogues of natural or unnatural compounds are often synthesized to improve their 
efficacy, pharmacokinetic profiles or toxicity profiles.5 For example, 9-
alkylmorpholinyl anthracyclines are analogues of doxorubicin that have been 
synthesized to target the cellular efflux protein, P-glycoprotein. Carboplatin (1.6) was 
developed as an analogue of cisplatin with reduced renal toxicity. 
Figure 1-1. Representative anticancer drugs and candidates 
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In recent decades, the discovery of new anti-cancer agents by chemical 
synthesis has evolved from high throughput screening to rational design based on 
drug–receptor or drug–enzyme interactions.5, 6 A large amount of drugs was 
discovered through the rational design approach from de novo structures or from 
existing drugs through the exploration of molecular mechanisms and interactions with 
drug targets. Representative examples include apaziquone (or EO9) (1.7),7, 8 an 
indoloquinone derivative, which was developed from mitomycin C that acted against 
hypoxic tumors and non-muscle invasive bladder cancer via DNA alkylation. Imatinib 
(1.8, Figure 1-3) was approved as the first kinase inhibitor drug developed from a 
phenylaminopyrimidine lead compound. It was initially designed to target protein 
kinase C and was later found to be a potent inhibitor of BCR-ABL1, KIT and PDGFR. 
Gefitinib (1.9) was developed as an ATP competitive EGFR inhibitor for the 
treatment of non-small-cell lung cancer.9 The success of these anti-cancer drugs 
demonstrated the effectiveness of rational design approach in drug discovery.  
Since the US FDA began its expedited drug programmes in June 2012, the US 
regulatory pathway for ‘breakthrough therapies’ has yielded its first two approvals, 
and more than 26 designations for 30 candidates in 22 indications.10 Of these, cancer 
drugs score highly, accounting for 12 (46%) of the designations. The latest approved 
anti-cancer drug as of July 2014 is belinostat11, 12 (1.10, Figure 1-1) which is a histone 
deacetylase inhibitor for the treatment of T-cell lymphoma. Other very recent small-
molecule drugs include ceritinib (1.11, Figure 1-3)13 and crizotinib (1.12),14, 15 both 
are ALK kinase inhibitors approved for the treatment of some non-small-cell lung 
carcinoma (NSCLC); ibrutinib (1.13),10, 16 a Bruton's tyrosine kinase (BTK) inhibitor 
for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia; and 
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vismodegib (1.14), the first Hedgehog signaling pathway targeting agent for the 
treatment of basal-cell carcinoma.17-19 
 
1.2 Introduction to protein kinases and kinase inhibitors as drugs 
 
1.2.1 Protein kinases 
Kinases are one of the largest gene families whose function is to catalyze the 
transfer of the gamma-phosphate from ATP to a specific target molecule bearing 
nucleophilic hydroxyl or amino groups including proteins, lipids and carbohydrates.20 
Among the different types of kinases, protein kinases that specifically add phosphate 
groups to the proteins are the most predominant. Protein phosphorylation can induce a 
myriad of consequences including modulation of enzymatic activity of the target 
protein, causing conformational changes in proteins, affecting stability and cellular 
localization, or the association of proteins with other protein or small molecules.21 A 
collection of human genomic data early in the year 2001 recognised a repertoire of 
over 500 protein kinases. To date, approximately 530 kinase genes have been found in 
the human genome and this number could still be higher.20 Up to 30% of all human 
proteins may be modified by kinase activity, and kinases are known to regulate the 
majority of cellular pathways, especially those involved in signal transduction and co-
ordination of complex functions such as cell cycle progression. Protein kinases are 
also found in bacteria and plants.22 
The approximately 530 kinases present in the human genome have been 
named the ‘‘kinome’’ and include 420 serine/threonine, 94 tyrosine, 25 atypical, and 
49 ‘‘pseudo kinases’’ that putatively lack the ability to catalyze the phosphotransfer 
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reaction.23 Protein kinases have also been classified according to their sequence and 
structure, which frequently correlates with their biological functions. Of about 518 
human protein kinases, 478 belong to a single superfamily whose catalytic domains 
are related in sequence. These can be clustered into groups, families and sub-families 
of increasing sequence similarity and biochemical function. There are ten distinct 
kinase groups, including eight major groups – AGC, CAMK, CK1, CMGC, GYC, 
STE, TK, TKL and two atypical groups.24 
 
Biologically, protein kinases regulate virtually all biochemical pathways and 
complex behaviours.25 A few of the main roles of protein kinases include:  
 Cell cycle control: e.g., cyclin dependent kinases (CDKs) that control the 
various checkpoints in a cell cycle.  
 Response to extracellular stimuli: e.g., receptor kinases receive extracellular 
signals, and intracellular kinase cascades, such as the MAPK cascade, 
transduced the signal to various cellular components, including transcriptional 
machinery.  
 DNA damage response: For example, the PIKK family are key mediators that 
perceive damaged DNA and co-ordinate the repair response.  
 Metabolic control  
As key regulators, protein kinases have strong effects when deregulated. It is 
therefore not surprising that deregulation of kinase function through environmental 
and genetic alterations is regarded as a hallmark of many pathological conditions.26, 27 
Since the mid-1980s when v-SRC was initially discovered to be a tyrosine kinase and 
capable of functioning as an “oncogene”, basic research and clinical investigation 
have implicated the deregulation of approximately 180 kinases in diverse pathologies 
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associated with metabolism, immunology, cancer, and infectious diseases.28 The 
development of kinase inhibitors has attracted an enormous amount of attention, 
primarily in the area of oncology and inflammatory diseases. Currently, 
approximately 40 kinases are actively being pursued as therapeutic targets, and many 
more are currently being investigated by pharmaceutical companies. In addition, 
besides inhibition of kinase activities, targeting inhibition of kinase activation is 
another topic that has generated much interest of late.20  
Structurally, there are a number of conserved regions in the catalytic domain 
of protein kinases. In the N-terminal extremity of the catalytic domain there is a 
stretch of glycine-rich residues in the vicinity of a lysine amino acid, which has been 
shown to be involved in ATP binding. In the central part of the catalytic domain, there 
is a conserved aspartic acid, which is important for the catalytic activity of the 
enzyme.29 ATP binds in the cleft located between the two lobes with the adenine ring 
forming hydrogen bonds with the kinase ‘hinge’ — the segment that connects the 
amino- and carboxyl-terminal kinase domains (Figure 1-2). The ribose and 
triphosphate groups of ATP bind in a hydrophilic channel extending to the substrate 
binding site that features conserved residues essential for catalysis.30 All kinases have 
a conserved activation loop, which is important in regulating kinase activity and is 
marked by conserved DFG and APE motifs at the start and end of the loop, 
respectively.30, 31 The activation loop can exhibit a large number of conformations 
with the extremes being a conformer that is catalytically competent and usually 
phosphorylated, and an ‘inactive’ conformer in which the activation loop blocks the 










Figure 1-2. Typical example of ATP-kinase (AKT1) binding mode30 
 
1.2.2 Kinase inhibitors as drugs 
Studies on the inhibition of protein kinase signalling pathways over the last 
two decades have developed into a major paradigm for the discovery of new drugs, 
primarily in the area of oncology, and others such as inflammation and cardiovascular 
diseases.32 As of July 2014, there are 28 kinase inhibitors that have been approved to 
be used as drugs by US FDA for various indications (Figure 1-3) and Appendix 
Table-1).33 Among them, 12 kinase inhibitor drugs were approved from 2012 to 2014 
alone, due to the implementation of expedited drug programmes. Hundreds more 











Figure 1-3. Structures of 28 US FDA approved protein kinase inhibitors (as of July 




Figure 1-3 (Contd). Structures of 28 US FDA approved protein kinase inhibitors (as 
of July 2014) – part II 





The current popularity of kinases as drug targets is driven by the combination 
of several factors.30 First, with approximately 530 kinases encoded in the human 
genome, virtually every signal transduction process is wired through a 
phosphotransfer cascade, suggesting that inhibition of kinase activity can cause 
certain physiological responses. Second, despite a high degree of conservation in the 
ATP binding site, highly selective small molecules with favourable pharmaceutical 
properties can be developed through rational design and a clear understanding of the 
structural and biological mechanism. Third, inhibition of kinase activity in normal 
cells can surprisingly often be tolerated, presenting a therapeutic window for the 
selective killing of tumour cells.30 For example, dasatinib (1.15), a drug recently 
approved for the treatment of imatinib-resistant CML, potently inhibits all nine 
members of the Src family of kinases (and numerous other tyrosine kinases), yet 
exhibits a more favourable side effect profile than conventional cytotoxic 
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chemotherapy.35, 36 Fourth, drugs such as imatinib (1.8) have had high-profile success, 
exhibiting up to 80% positive response rates in chronic-phase CML patients.37 
However, despite these motivating factors, this area faces significant challenges due 
to drug resistance to these inhibitors, lack of inhibitor selectivity, lack of inhibitor 
efficacy and difficulty in drug target validation for particular disease settings. 
Therefore, the discovery of new kinase inhibitors, especially inhibitors with new 
scaffolds, is still actively being sought.  
Based on the different binding modes of inhibitors with the target proteins, 
there are four classifications of kinase inhibitors.30 Type 1 inhibitors constitute the 
majority of ATP-competitive inhibitors and recognize the so-called active 
conformation of the kinase, a conformation ready for transfer of the phosphate moiety. 
Type 1 inhibitors typically consist of a heterocyclic ring system that occupies the 
purine binding site, while its side chains occupy the adjacent hydrophobic regions I 
and II. The preponderance of type 1 inhibitors may be a consequence of many 
compounds being discovered using enzymatic assays in which kinases were 
introduced in their active form. Examples of Type 1 inhibitors are PD166326 (1.16, 
Figure 1-1) (ABL1 inhibitor), dasatinib (1.15, Figure 1-3) (Src family inhibitor), 
lapatinib (1.17) (EGFR and ERBB2),30 gefitinib (1.9) and erlotinib (1.18) (EGFR 
inhibitor).38 In contrast, type 2 kinase inhibitors are non-ATP competitive and they 
recognize the inactive conformation of the kinase. The latter is sometimes referred to 
as DFG-out conformation due to the rearrangement of this motif. Examples of non-
ATP competitive inhibitors are imatinib (1.8), nilotinib (1.19) (ABL1, KIT, PDGFR 
inhibitors) as well as sorafenib (1.20)  (KIT, PDGFR and Raf inhibitor).39, 40 Type 3 
inhibitors bind at an allosteric site and are therefore called the allosteric inhibitors. 
Inhibitors of this category tend to have the highest degree of kinase selectivity as they 
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exploit binding sites and regulatory mechanisms that are unique to a particular kinase. 
The well-known allosteric kinase inhibitor is CI-1040 (1.21, Figure 1-1), which 
inhibits MEK1 and MEK2 by occupying a pocket adjacent to the ATP binding site.30 
Another example is GnF2 (1.22), which binds to the myristate binding site of BCR–
ABL1.41 Type 4 kinase inhibitors – covalent inhibitors, are capable of forming an 
irreversible, covalent bond to the kinase active site, most frequently by reacting with a 
nucleophilic cysteine residue. The clinically advanced irreversible kinase inhibitor 
HKI-272 (or neratinib) (1.23) (against kinases EGFR and Her2) 42 was developed to 
target a relatively rare cysteine residue located at the lip of the ATP binding site. 
Interestingly, two of the latest (in 2013) approved anti-cancer drugs by US FDA are 
irreversible kinase inhibitors. These are afatinib (1.24, Figure 1-3) for the treatment 
of NSCLC that targets EGFR and Her2, and ibrutinib (1.13) for the treatment of 
mantle cell lymphoma that irreversibly inhibits Bruton's tyrosine kinase (BTK) 
activity.  
Some other interesting irreversible kinase inhibitors come from a class of 
natural products called resorcylic acid lactones (RALs). These kinase inhibitors 
possess a cis-enone moiety for covalent modification of cysteine residues. As part of 
this PhD work, this class of compounds were studied. Generally, we are interested in 
studying both reversible and irreversible kinase inhibitors derived from RALs.  
1.3 Overview of resorcylic acid lactones (RALs) 
1.3.1 Biosynthesis and isolation of RALs from natural sources 
Resorcylic acid lactone (RAL) is a group of macrolactone natural products 
produced by a variety of fungal strains. This group of compounds has attracted much 
interest from both academic and pharmaceutical R&D in terms of lead compounds for 
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kinase inhibition and other biological targets.43-46 Structurally the RALs are 
characterized as β-resorcylic acid derivatives possessing a 14-membered 
macrolactone ring with various degrees of hydroxylation and unsaturation. Since the 
isolation of radicicol in 1953, nearly 40 naturally occurring RALs have been reported 
thus far and a broad range of biological activities, such as estrogenic, antifungal, 
cytotoxic, antimalarial, and nematicidal properties have been reported. More 
importantly, these natural products have been shown to be potent inhibitors of a 
number of protein kinases, especially those related to cancer targets.47 
Naturally occurring RALs are mycotoxins produced by a variety of different 
fungal strains via polyketide biosynthesis. The iterative type I polyketide synthases 
(IPKS) are major enzymes responsible for the biosynthesis of diverse natural products 
including RALs in fungi. The PKS are multi-domain enzymes that catalyse the 
synthesis of structurally diverse RALs via a series of decarboxylative condensations 
of nine-unit thioacetates or malonates, followed by -keto reduction or dehydration to 
produce different RALs in a highly programmed manner.43 The proposed biosynthesis 
of zearalenone involves two PKSs, the first of which is responsible for the assembly 
of the first five acetate units and further processing to arrive at the appropriate 
oxidation state for each carbon. The second one performs the remaining three steps of 
condensation without carbonyl reduction. The ketones are highly reactive and engage 
in cyclisation and aromatization reactions.43 Different combinatorial arrangements of 
the biosynthesis involved in the whole processing of the -ketones accounts for the 
structural diversity of the RAL macrocycles.  
The first reported isolation of RAL was radicicol (formerly known as 
monorden) (Figure 1-4) in 1953.48  It was isolated from a mould sample of soil from 
the Belgian Congo, belonging to the species Monosporium bonorden. This substance 
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was found to have strong antifungal properties. LL-Z1640-2 (or 5Z-7-oxozeaenol) 
was first isolated in 1978 from an unidentified fungus49 and was of no particular 
interest until 2003 when it was rediscovered in a screen for TAK1/MAPK activity.50 
Hypothemycin was initially isolated from Hypomyces trichothecoides in 1980 as an 
antibiotic macrolide51 and was also later isolated from the mangrove fungus Aigialus 
parvus together with a series of aigialomycins (A-F) reported in 2002 and 2009 
respectively.52, 53 Pochonins A to F, which are structurally similar to radicicol, were 
isolated from Pochonia chlamydosporia in 2003.54 Recently six β- resorcylic acid 
lactones, named Paecilomycin A-F in 2010,47 followed by another four new 
paecilomycins (J-M) in 2013,55 were isolated from the mycelial solid culture of 
Paecilomyces sp. SC0924. It is believed that with the significant progress made over 
the past years in understanding fungal PKS genes and their biosynthetic mechanisms, 
as well as the availability of advanced analytical and fermentation techniques, more 
new RALs will be produced via bioengineered fungi strains and identified. This will 
further extend the diversity of this important class of natural products. 
 
Figure 1-4. Representative naturally occurring RALs 
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1.3.2 Biological activities of RALs 
Despite the core structural similarity, RALs have been reported to possess a 
broad spectrum of biological activities, especially as potent and selective protein 
kinase inhibitors.  
Radicicol is a potent and selective inhibitor of heat shock protein Hsp90,56 
although it was originally reported to have sedative activity, moderate antibiotic 
activity and is an inhibitor of the oncogenic kinase Src.57 As many protein kinases 
rely on functional Hsp90 for proper folding, radicicol indirectly affects cellular 
protein kinase activity by inhibition of Hsp90. This is reflected by the fact that 
radicicol directly blocks the ATP binding of Hsp90 but is not effective in binding to 
the ATP binding sites of affected protein kinases.58 It is important to note that 
although radicicol potentially has two different reactive sites (Michael acceptor for 
nucleophilic attack of enzyme and epoxide as alkylating agent), it does not react 
covalently with Hsp90. Despite the potent activities of radicicol in protein binding 
and its effectiveness in killing cells, radicicol loses its activity in animal models due 
to metabolic instabilities,43 which is most probably due to the two reactive sites.  
Among all the reported RAL natural products, the most extensively studied are 
those containing a cis-enone moiety, such as hypothemycin,59-61 LL-Z-1640-250, 62-64 
and L-783,277 (Figure 1-4).65, 66 These compounds have been reported to irreversibly 
inhibit mitogen activated protein kinases (MAP kinases) and are competitive with 
ATP. The irreversible inhibition is attributed to the covalent formation of a Michael 
adduct with a cysteine residue that is located adjacent to the conserved DFG motif of 
the kinase activation loop. A bioinformatic analysis  of the human kinome by 
Schirmer et al revealed that 46 out of about 510 kinases have this particular cysteine 
that could potentially be targeted by cis-enone RALs.67 It was revealed that 
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hypothemycin inhibits a variety of kinases at low nanomolar levels, including 
MEK1/2 (Kd: 17 nM and 38 nM), PDGFRb (Kd: 900 nM), FLT-3 (Kd: 90 nM), 
VEGFR1 (Kd: 70 nM) and VEGFR2 (Kd: 10 nM), and at low micromolar levels, 
including extracellular-signal-regulated kinase (ERK) (Kd: 8.4 mM).67 The 
biochemical study with human ERK kinase revealed that hypothemycin is an ATP-
competitive irreversible inhibitor and covalently modifies Cys164 of ERK through the 
cis-enone moiety. This irreversible binding mode was also confirmed by an X-ray 
crystal structure of hypothemycin with ERK2.60 
LL-Z1640-2 was initially revealed to have kinase inhibitory activity against 
TAK1 with IC50 of only 8 nM.
50 TAK1 has been implicated as a key regulator in pro-
inflammatory signaling pathways and is a validated anti-cancer target. The TAK1 
inhibition by LL-Z1640-2 was found to be ATP competitive and time-dependent, 
again suggesting that enzyme inhibition is based on the covalent modification of an 
active site cysteine residue, which was confirmed by a crystal structure of the 
complex between Cys166 of ERK2 and LL-Z1640-2.68 The study showed that LL-
Z1640-2 inhibits ERK2 with IC50 of 80 nM, whilst its analogue, without the cis-enone 
moiety has much weaker activity with IC50 of 440 nM, highlighting the dramatic 
effects of the presence of a Michael acceptor in the observed activities. 
Other cis-enones such as L-783,277 and hypothemycin as reported by Zhao et 
al, were found to be potent MEK1 inhibitors with IC50 values of 4 nM and 15 nM 
respectively.65 Interestingly, the corresponding 7´,8´-trans analogue of L-783,277 was 
found to be significantly less active against MEK1 (IC50 at 300 nM). The irreversible 
binding properties of cis-enone RALs is particularly interesting in light of resurging 
interests in drug discovery using the “targeted covalent inhibition” (TCI) strategy. 
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Aigialomycins, the more recently isolated RALs, were discovered from a 
screen for anti-malarial activity together with hypothemycin.52 Interestingly, although 
aigialomycin D does not bear a cis-enone moiety, it was found to have similar 
antimalarial activity and cytotoxicity (low mM) as hypothemycin. Other closely 
related aigialomycins were inactive in these assays. Aigialomycin D was also 
screened against a panel of kinases and was found to be a moderate kinase inhibitor 
(low µM) of CDK1 and CDK5 as well as GSK3, which could account for its 
cytotoxicity.69 Interestingly, it was not an inhibitor of the plasmodium analogue of 
GSK3. Our group has been interested in aigialomycin D in terms of both its chemistry 
and biology. Our studies showed that aigialomycin D and its analogues are moderate 
inhibitors of CDK2/cyclin A with IC50 values of ca. 20 μM. Subsequent kinase 
profiling of aigialomycin D against a panel of 96 kinases revealed that it is in fact a 
potent inhibitor of MNK2 (IC50 = 0.45 μM) and a few other kinases.70 Detailed results 
of these activities will be addressed in Chapters 2 and 3.  
1.3.3 Representative total synthesis of naturally occurring RALs 
Not surprisingly, due to their diverse biological properties and the therapeutic 
potential of RALs, there is a growing interest in the synthesis of these compounds and 
their analogues. The first synthesis of RAL was reported in 1968 for zearalenone.71 It 
was later re-synthesized using the Corey-Nicolaou macrolactonization reaction as an 
exemplification of methodology development.72 Following that, a number of total 
synthesis of RALs including LL-Z-1640-2, hypothemycin, L-783,277, radicicols (A 
and C), pochonins (C and D), aigialomycin D have been reported.43, 45 Examples of 
the total synthesis of selected RALs are discussed here. 
 
LL-Z1640-2 and hypothemycin 
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The first total synthesis of a cis-enone-containing resorcylic acid lactone was 
reported by Tatsuta and co-workers in 2001 for LL-Z1640-2.73 The key elements of 
the retrosynthesis conceived by Tatsuta for this target structure included the 
Mukaiyama macrolactonization of 1.29 to form the macrocycle (Scheme 1-1). 1.29 
was obtained from alkyne 1.28 by epoxide ring opening from (S)-propylene oxide 
followed by selective hydrogenation using Lindlar’s catalyst. The alkyne intermediate 
1.28 was derived from Corey-Fuchs triple-bond formation of the aldehyde precursor 
which was obtained by Swern oxidation of 1.27. The trans double bond at 1',2' 
position of 1.28 was installed using another Lindlar hydrogenation followed by 
reductive double bond isomerization from Z to E geometry under Tsuji’s condition. 
The construction of the aliphatic/aromatic bond connection in 1.27 was achieved 
through Sonogashira coupling between iodobenzene 1.25 and alkyne 1.26. The 
stereochemistry of the two hydroxyl groups of LL-Z-1640-2 was derived from D-
ribose at the beginning of the synthesis (Scheme 1-1).  
 
Scheme 1-1. Retro-synthetic route of the first total synthesis of LL-Z1640-2 by 
Tatsuta and co-workers in 2001.73 
 
 
The synthesis of LL-Z1640-2 together with its conversion into hypothemycin 
has also been reported by Sellès and Lett in 2002.74, 75 According to Sellès and Lett’s 
retrosynthetic analysis, the macrocyclic framework of LL-Z1640-2 and hypothemycin 
  Chapter 1 
18 
 
can be constructed through Mitsunobu-based macrolactonization of 1.30 (Scheme 1-
2), which was obtained by Suzuki coupling between bromobenzene 1.32 and the 
vinyldisiamylborane prepared in situ from alkyne 1.31. The key fragment 1.31 was 
synthesized by nucleophilic attack of vinyl iodide 1.33 upon lithiation to aldehyde 
1.34. The synthesis of these two fragments (1.33 and 1.34) were achieved according 
to the reaction steps shown in Scheme 1-2. The final transformation of LL-Z1640-2 
into hypothemycin (to introduce the epoxide) using MCPBA/NaHCO3 in Lett’s 
synthesis was severely hampered by the low reactivity of the C1´/C2´ double bond 
and could only be achieved in 17% yield (Scheme 1-3). This epoxide formation in the 
synthesis of hypothemycin was improved slightly by Winssinger in 2009 wherein the 
epoxidation of LL-Z1640-2 was carried out with DMDO with 25% yield.59  
 














L-783,277 has a very similar structure to LL-Z-1640-2 except that the 1',2'-
double bond is saturated in L-783,277. Altmann and the co-workers reported the first 
total synthesis of L-783,277 starting with D-erythrono-1,4-lactone (1.41) as the chiral 
starting material in 2008.76 The key steps of the synthesis involved the Suzuki-
Miyaura coupling (Scheme 1-4), the Mitsunobu-based macrolactonization and 
selective allylic oxidation of the macrocyclic triol with polymer-bound IBX. A 
detailed synthesis of L-783,277 is described in Scheme 1-4. DIBAL-H reduction of 
1.41 gave a hemiketal intermediate which was subjected to a Wittig reaction followed 
by hydrogenation of the olefin to give rise to 1.42. Protection of the primary alcohol 
in 1.42 with the TBS protecting group followed by a second DIBAL-H reduction gave 
1.43, which was further elaborated to 1.44 via oxidative elimination, deprotection and 
Swern oxidation. Subsequent acetylide addition under strong base and protection of 
the formed secondary alcohol afforded the intermediate 1.45 as a mixture of isomers. 
Methyl ester 1.46 was converted to the corresponding 1.47, which underwent Suzuki-
Miyaura coupling reaction with olefin 1.45 in the presence of 9-BBN to give the 
alkyne 1.48. Lindlar hydrogenation of the alkyne gave the corresponding cis-olefin, 
which after deprotection afforded the carboxylic acid 1.49. Macrocyclization by 
Mitsunobu reaction and subsequent acidic deprotection of the MOM group followed 
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by selective oxidation of allylic alcohol using polymer-supported IBX gave the cis-
enone L-783,277. However, the IBX oxidation was inefficient as the major C-6´ 
isomer gave only 25% of the desired product even though the minor C-6´ isomer gave 
the desired cis-enone product in high yield. 





Among all the total synthesis of RALs, aigialomycin D is the most studied 
target. To date, there are eight reported total synthesis of aigialomycin D. The first 
synthesis of aigialomycin D was reported by Danishefsky and co-workers in 2004,77 
two years after its first isolation. Danishefsky’s synthesis featured an unconventional 
‘‘ynolide’’ Diels-Alder reaction between alkyne 1.53 and diene 1.54 for the 
construction of the aromatic ring as a key step (Scheme 1-5). The macrolactone 1.53 
was synthesized from 2-deoxy-D-ribose (Scheme 1-5). Protection of the diol group of 
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1.53 with an acetonide followed by a series of transformations (Wittig olefination, 
pivaloyl protection of the primary alcohol, hydroxylation via hydroboration and 
oxidation) gave the intermediate 1.51. Further chain extension via Reformatsky-type 
nucleophilic propargylation, protection/deprotection, another oxidation of alcohol to 
aldehyde, and Wittig olefination furnished the acetylene 1.52. Carboxylation of the 
terminal alkyne using butyl lithium in the presence of dry ice gave the crucial 
carboxylic acid which underwent Mitsunobu esterification with (R)-4-hydroxy-1-
pentene followed by protection of the alkyne functionality with Co2(CO)8 to provide  
a diene intermediate, which then underwent RCM reaction to afford the desired E 
olefin. It should be noted that the Co-complexation of the alkyne is crucial for the 
success of RCM reaction. Subsequent decomplexation of the RCM products with 
CAN gave the desired ynolide 1.53 smoothly. Diels-Alder reaction of the ynolide 1.53 
with diene 1.54 resulted in the formation of resorcylic acid lactone 1.55 in high yield. 
Dehydration of the TBS-deprotected secondary alcohol with Martin sulfurane 
followed by deprotection of the MOM group gave the final product aigialomycin D in 
19 steps and 5% overall yield.  
 
Scheme 1-5. Synthesis of aigialomycin D by Danishefsky and co-workers.77  
 





Winssinger’s group reported the second synthesis of aigialomycin D in 2006.69 
The key step involved the use of a thio- or selenoether at the benzylic position of the 
resorcylic ester precursor (1.57) to facilitate the alkylation chemistry as well as to 
provide a potential attachment point for solid-phase synthesis (retro-synthesis in 
Scheme 1-6). The synthesis began with 2,4-dihydroxy-6-methylbenzoic acid (1.56), 
and polymer-supported Mitsunobu reagents were used for the esterification of (R)-
pent-4-en-2-ol with 1.56. Subsequent protection of the phenolic groups using EOM-Cl 
followed by phenylselenylation at the benzylic position provided the benzyl selenide 
1.57. Alkylation of 1.57 with alkyl bromide 1.58 using LDA as the base resulted in a 
diene intermediate which was then subjected to RCM reaction with Grubbs-II catalyst 
to give the desired 7´,8´-E alkene 1.59 with >10/1 selectivity. Alkylbromide 1.58 was 
synthesized in a convergent manner from 5-bromo-1-pentene via a series of reactions, 
which involved cross-metathesis, Sharpless asymmetric epoxidation, Wittig 
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olefination and epoxide hydrolysis catalyzed by Lewis acid Sc(OTf)3 (Scheme 1-6). 
Oxidation of the selenide 1.59 with hydroperoxide followed by base-induced 
elimination of phenylselenic acid and subsequent global deprotection by treatment 
with polymer-supported sulfonic acid gave rise to aigialomycin D, with a total yield 
of 23% for the longest linear sequence. Having achieved this, Winssinger and co-
workers also elaborated the chemistry to synthesise a small library of aigialomycin D 
analogues for evaluation of their kinase inhibitory activities.69  
 




In the same year as Winssinger’s synthesis, Lu and Pan et al reported another 
synthesis of aigialomycin D.78 Here the key macrocylisation step of aigialomycin D 
synthesis was achieved by employing a Yamaguchi esterification of 1.61, albeit in 
moderate yield (51%) (Scheme 1-7). Interestingly, the carboxylic acid group of the 
resorcylic acid portion was introduced only in the late stage of the synthesis. In 
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addition, a Julia-Kocienski olefination was utilized twice for the installation of the 
olefin linkages present in both 1.61 and 1.62 (Scheme 1-7).  
 
Scheme 1-7. Pan's retro-synthesis of aigialomycin D.78 
 
 
In 2007, our group developed a concise and convergent route to aigialomycin 
D which began with D-(-)-erythronolactone as a chiral building block.79 This 
synthetic route yielded aigialomycin D with a linear sequence of 11 steps and 19% 
overall yield. The synthesis of aigialomycin D using this strategy was further 
optimized in our hands and extended to the synthesis of its analogues. The detailed 
work will be addressed in Chapter Two.  
A few other total synthesis of aigialomycin D and analogues were also 
reported. For example, Chrovian and Montgomery reported  a method in 2008 that 
employed a nickel-catalyzed ynal macrocyclization as the key step;80 Bajwa and 
Jennings reported their synthesis of epi-aigialomycin D and deoxy-aigialomycin C in 
2008 via a diastereoselective ring closing metathesis macrocyclization in the same 
year;81 Baird et al synthesized aigialomycin D using a Ramberg-Backlund/RCM 
strategy in 2009;82 and Calo et al achieved the same synthesis through a one-pot, 
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cascade sequence consisting of ketene generation, alcohol trapping, aromatization and 
ring-closing metathesis.83 
1.3.4 Representative RAL analogues and their applications 
Inspired by the diverse biological activities of this class of natural products, 
many RAL derived analogues (Figure 1-5) have been synthesized and their biological 
activities evaluated. 
An earlier example of synthetic RAL analogues was reported by Danishefsky 
and co-workers.84 Due to reactivity issues surrounding the labile epoxide group in 
radicicol, a radicicol analogue (1.64, Figure 1-5) wherein the epoxide was replaced 
by a cyclopropyl group was synthesized and this compound showed similar activity to 
radicicol. Winssinger’s group synthesized some pochoximes (e.g. 1.65) by converting 
the ketone functionality to an oxime. These oximes were found to have attenuated 
electrophilicity as Michael acceptors of the cysteine residues.85 Also in 2009, the 
same group reported the synthesis of a library of cis-enone RAL analogues using a 
diversity orientated fluorous-mixture synthesis and evaluated their activities against a 
panel of 19 kinases. Two compounds (1.66 or L783,277 and 1.67) were also profiled 
for their selectivity against a panel of 402 kinases, providing a broad evaluation of the 
selectivity of this class.86 To further modulate the Michael acceptor of cis-enone 
RALs, Winssinger proposed that a fluorine substituent at the α-position of the enone 
might accentuate the Michael acceptor properties and may also help to stabilize the 
cis configuration which is more biologically active than the trans isomer. The 
resulting synthetic fluoroenone analogue (1.68) is well tolerated in vitro but did not 
enhance the cellular efficacy of VEGF-R2 inhibition. Very recently, Winssinger’s 
group synthesized a small library of compounds as chemical probes based on the 
resorcylic acid lactone scaffold with ring-opened substitutions replacing the 
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macrocyclic ring. These analogues (e.g. 1.69 to 1.71) were designed to possess 
Michael acceptor moieties (e.g. acrylamide) as electrophilic traps. The utility of these 
RAL derived covalent inhibitors was demonstrated as these compounds were used as 
new probes for the imaging of EGFR localization and ERBB2 inhibition in live 
cells.87  
Moody et al also reported that RALs are Hsp90 inhibitors. In one of the 
examples, Some simplified analogues of radicicol and a series of novel macrolactones 
that incorporate a 1,2,3-triazole ring via click chemistry (e.g. 1.72) were studied.88 
However, the introduction of the triazole ring into the macrocyclic lactone was found 
to be detrimental to Hsp90 inhibition. More recently, the same group demonstrated 
the synthesis, structural, binding and cellular studies of some novel macrolactam 
analogues (e.g. 1.73) of radicicol.89 The synthesis involved the ring opening of an 
isocoumarin intermediate, followed by a ring-closing metathesis reaction as key steps 
to form the macrocycle. The manipulation of the ester group into a range of amides 
allowed access to a range of new macrolactams. These resorcylic acid lactams exhibit 
greater metabolic stability than their related lactone counterparts.89 
Apart from the first total synthesis of L-783,277 in 2008, Altmann’s group 
reported thereafter the synthesis of the deoxy analogues of L-783,277 and also 
investigated their kinase inhibitory activities. It was found that the 5´-deoxy analogue 
(1.74) retained almost the full inhibitory potency in the tested kinases, whilst the 
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Figure 1-5. Examples of synthetic RAL analogues of biological interest 
  
 
Among all of the reported RALs and their analogues, the clinically most 
advanced compound is E6201 (1.82), a drug candidate derived from LL-Z1640-2 
which has entered clinical trial for anti-inflammatory90 and anti-cancer91 applications. 
E6201 was developed from a library of synthetic analogues of LL-Z1640-2 and 
extensive SAR studies in vitro and in vivo by Eisai’s researchers (Scheme 1-8).62, 63, 92 
In the early stage of their research, it was recognized that although the natural product 
LL-Z1640-2 exhibited very potent inhibitory activities in vitro (IC50 = 11 nM), it was 
rapidly inactivated in human or mouse microsome and plasma. Analysis of the 
metabolites indicated that cis to trans isomerization of the enone is the major cause of 
deactivation as the trans-isomer was found to be approximately 30-fold less potent 
(IC50 = 349 nM) than the parent cis-isomer. To prevent isomerization, a chemical 
modification on C-9´ of LL-Z1640-2 was implemented and this led to ER-803064 
(1.75) with increased metabolic stability but reduced potency. Further modifications 
on C-1',2', and C-4 with the attempts to resume the potency (as exemplified in 
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analogues 1.76) failed, but some improvements were observed when the methoxy 
group at C-4 was replaced with an ethoxy group (Scheme 1-8). Upon exploration of 
the C-4 binding pocket, analogues with extended alkyl side chains were synthesized, 
which gave rise to 1.80 that showed both in vitro and in vivo potency (IC50: 15 nM in 
vitro; ED50: 6.5 mg/kg). However, this compound was found to have very low oral 
bioavailability. Further exploration on the aromatic ring including substitution with 
benzimidazole (1.81) and various substituted anilines at C-4 led to the discovery of 
the clinical candidate E6201 (1.82) that has desirable in vitro and in vivo 
pharmacological properties.  
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1.4 Statement of research purpose and objectives 
 
As mentioned above in the introduction, Resorcylic acid lactone (RAL) is a 
group of natural products that have attracted much attention from both pharmaceutical 
R&D and academic groups due to their interesting chemistry and their biological 
properties. However, in view of this unique chemical scaffold with structural 
complexity, the biological activities, and particularly the kinase inhibitory activities of 
this class of natural products and analogues have yet to be extensively explored. The 
only RAL-derived clinical candidate, E6201, was developed from LL-Z-1640-2 using 
cell-based study and pharmacodynamics/pharmacokinetic optimization. However, 
rational design and in-silico assisted development of RAL analogues is still lacking, 
although such approaches have been successfully used with other heterocyclic kinase 
inhibitors. This PhD research, therefore, aims to develop novel RAL-based analogues 
or derivatives as potent inhibitors of protein kinases using above mentioned 
approaches. Specifically, we are interested in three classes of protein kinases, namely 
CDK2, MNK1/2 and FLT3, and our SAR study will be focused on but not limited to 
the biochemical binding affinities of the compounds to the kinases of interest. 
 In our initial study, we are particularly interested in the natural product 
aigialomycin D. Aigialomycin D was reported to be a CDK1 and 5 inhibitor with IC50 
values of 5.7 and 5.8 M respectively.69 In addition, despite the absence of a cis-
enone system as compared to the cis-enone RAL inhibitors, e.g., hypothemycin, L-
783,277 and LL-Z-1640-2, aigialomycin D shows comparable cytotoxicity as 
hypothemycin against several cell-lines.52 This suggests that different RAL scaffolds 
may inhibit different kinases via various mechanisms. CDK1 and 5 are the known 
targets of aigialomycin D, however, little is known of the biological activity of 
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aigialomycin D on CDK2, a well-known and validated protein target for anti-cancer 
drug development. In order to explore aigialomycin D as inhibitor of CDK2, SAR 
studies of aigialomycin D and its analogues were planned (see Chapter 2). 
Investigation of these cyclic analogues in the inhibition of CDK2 activity however 
revealed that they are only moderate inhibitors of CDK2/cyclin A complex. 
Subsequent kinase profiling studies identified aigialomycin D as a more potent 
inhibitor of MNK1/2. 
Chapter 3 describes our efforts directed towards the understanding of MNK1/2 
inhibition by aigialomycin D and its analogues through screening of these compounds 
and their respective simplified acyclic analogues. 
In Chapter 4, our interest extended to covalent kinase inhibitors derived from 
the RAL family.  It is known that cis-enone RALs, e.g. hypothemycin, L-783,277 and 
LL-Z-1640-2, are highly potent irreversible inhibitors of a sub-family of 46 kinases 
including MNK1/2, FLT3, KIT, MEKs, VGFRs, PDGFR2 and TAK1 etc.67 The high 
potency of these cis-enone RALs is attributed to the presence of an α,β-unsaturated 
ketone moiety which can covalently modify cysteine residues located within the ATP 
binding site of certain kinases. Our efforts in Chapter 4 focused on the development 
of RAL analogues having a macrocylic cis/trans-enamide system as covalent 
MNK1/2 inhibitors. We hypothesized that these enamide RAL analogues could serve 
as a mild Michael acceptor (instead of a highly reactive group) and their covalent 
binding abilities can be further tuned by chemical modifications. In doing so, these 
novel RAL analogues could potentially be developed into better drug candidates that 
combine the features of both the naturally occurring cis-enone RALs as well as the 
known acrylamide-based covalent kinase inhibitors.93 
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As mentioned above, the irreversible inhibition of cis-enone RALs against the 
subset of kinases is due to the covalent binding of the cis-enone Michael acceptor 
towards a suitably positioned cysteine. We next reasoned that a resorcylic acid 
derivative bearing an electrophilic trap linked via a proper spacer to the resorcylic 
ring can also function similarly as a Michael acceptor to the desired cysteine residue 
of target kinase, e.g. FLT3 and MNK2. In Chapter 5, we report our attempts at the 
development of a series of simplified ring-opened derivatives of RALs containing 
different types of Michael acceptors (e.g., acrylamide, vinylsulfonamide and 
maleimide) as FLT3 covalent inhibitors. The target selectivity of these FLT3 
inhibitors among different isoforms of FLT3 and their cellular activities will also be 
investigated in this study.  
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Chapter Two Exploring aigialomycin D and its analogues as CDK2 kinase inhibitors 
 
2.1 Introduction 
2.1.1 Cyclin-dependent kinases as therapeutic targets 
In the past few decades, there has been much interest in proteins that drive and 
control cell cycle progression. These proteins have been implicated in the 
development of various types of tumors through dysregulation of cell proliferation.94 
A key class of cell cycle proteins is the cyclin-dependent kinases (CDKs). CDKs are a 
family of 13 protein kinases that are involved in the regulation of cell cycle and/or 
transcription at different stages.95 A CDK is activated and regulated by its 
complexation with cyclin to form a kinase complex which selectively phosphorylates 
proteins on serine and threonine residues. Each CDK/cyclin complex is believed to 
act at a specific stage of the cell cycle. For example, CDK2/cyclin A promotes S 
phase of the cell cycle. Disruption of the function of CDK2/cyclin A leads to either 
cell cycle arrest, or to uncontrolled cell proliferation.94  
Since the 1990’s, small molecules that inhibit the CDKs have been extensively 
sought as cancer chemotherapeutics, and many of these inhibitors have entered or 
undergone various stages of clinical trials. Nevertheless, no CDK inhibitor has yet 
been approved for clinical use to date. The recent identification of the CDK 4/6 
pathway in oncology has led to the development of several CDK4/6 inhibitors as 
promising drug candidates as represented by Palbociclib (Pfizer), a first-in-class drug 
for the treatment of late-stage breast cancer (phase II). Other drug candidates include 
Bemaciclib (Lilly) for mantle cell lymphoma (MCL), non-small cell lung cancer 
(NSCLC), and breast cancer (phase I), and LEE011 (Novartis) for melanoma.96  
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Most of the CDK inhibitors developed to date are heterocyclic compounds. 
The CDK inhibitory activities of RALs are essentially unknown until recently when 
Winssinger’s group revealed that aigialomycin D (2.1) inhibits CDK1 and CDK5 at 
submicromolar levels.69 These preliminary yet encouraging results suggest that 
systematic screening and structure-activity relationship studies of the RAL class of 
compounds may potentially lead to the identification of promising compounds for 
cancer chemotherapy.     
2.1.2 Hypothesis and objectives 
Despite the studies reported above, there is little or no report on the inhibitory 
activities of aigialomycin D and its analogues on CDK2, another kinase member 
within the CDK family and also a validated protein target for anti-cancer drug 
development. CDK2 is among the most well- studied kinase of the CDK family, as 
exemplified by the many reports on CDK2 inhibitors and CDK2-inhibitor crystal 
structures.97 Interestingly, a number of clinical candidates targeting to the CDK 
family are multi-targeting which show inhibitory activities against more than one 
CDK members. For example, AT-7519 (refractory non-Hodgkin’s lymphoma) is an 
inhibitor of CDK 1, 2, 4 and 5.95 As mentioned in section 1.3.2, aigialomycin D was 
reported to be a moderate kinase inhibitor (low µM) of CDK1 and CDK5. Based on 
the structural similarity among the CDK kinases, and also based on our preliminary 
docking studies, we hypothesize that aigialomycin D could also be an inhibitor of 
CDK2.95 In this chapter, we discuss our efforts directed towards the investigation of 
CDK2 inhibitors based on the RAL structure. Specifically, aigialomycin D and a 
number of its macrocyclic analogues were synthesized for the study of structure-
activity relationships against CDK2 kinase inhibition. We also extended our studies to 
identify other potential kinase targets for aigialomycin D.  
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2.2 Synthesis of aigialomycin D and its analogues 
2.2.1 Retro-synthetic analysis of aigialomycin D  
 The total synthesis of aigialomycin D was proposed based on improvments of 
the route developed previously in our group.79 Based on the retrosynthetic analysis for 
aigialomycin D (Scheme 2-1), the key steps of the synthesis included a Mitsunobu 
esterification to install the top ester fragment, acylation of the aromatic fragment 2.2 
with the Weinreb amide 2.4, and a ring-closing olefin metathesis (RCM) to form the 
trans-olefinic macrocycle. We commenced the synthesis of aigialomycin D using 
three key precursors, 2,4-dihydroxy-6-methylbenzoic acid (2.2), (R)-4-penten-2-ol 
(2.3) and a Weinreb amide (2.4) which could be derived from D-(-)-erythronolactone 
(2.5) (Scheme 2-1).  
 
Scheme 2-1. Retrosynthesis of aigialomycin D 
 
2.2.2 Synthesis of Weinreb amides 2.4 and 2.9 
 The syntheses of aigialomycin D and its analogues were carried out in a 
convergent and concise manner. To achieve this, we first carried out the synthesis of 
the key fragments, the Weinreb amides 2.4 and 2.9.  
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The synthesis of 2.4 began with D-(-)-erythronolactone (2.5) (Scheme 2-2). The 
diol 2.5 was first protected as an acetonide using 2,2'-dimethoxypropane. Reduction 
of the lactone 2.17 using DIBAL at low temperature gave the hemiacetal 2.18, which 
then underwent Wittig olefination with ethyl(triphenylphosphoranylidene)acetate to 
afford 2.19 in high yield. Hydrogenation of the olefin 2.19 under standard Pd/C 
catalytic conditions afforded the saturated ester 2.20. Oxidation of the primary alcohol 
of 2.20 with PCC/NaOAc gave the aldehyde 2.21 in 72% yield. The second Wittig 
reaction of 2.21 with methyltriphenylphosphonium bromide using n-butyllithium (n-
BuLi) as base however, resulted in very poor yield (< 10%) of 2.22 on a gram-scale, 
although the yield of the desired product was reasonable (60%) on a milligram-scale. 
When potassium tert-butoxide was used as the base instead, the yield of 2.22 
improved to 72% in a gram-scale synthesis. Furthermore, the reaction proceeded 
smoothly at 0 ºC instead of -78 ºC when using n-BuLi. Subsequent transformation 
from the ester to the Weinreb amide 2.4 was carried out using an excess of cyclohexyl 
magnesium chloride in the presence of methoxymethylamine HCl salt to give the 
desired product in 91% yield.  
In order to prepare the AD analogue 2.16 (Scheme 2-3), Weinreb amide 2.9 
was prepared from ethyl 6-heptenoate following a similar procedure for the 
preparation of 2.4 (Scheme 2-2). 
 
Scheme 2-2. Synthesis of Weinreb amide 2.4.a  





a Reagents and conditions: (a) (CH3)2C(OMe)2, p-TsOH, acetone, rt, 16 h, 94%. (b) DIBAL, DCM, -
78 °C, 3 h, 93%. (c) Ph3P=CHCO2Et, PhCO2H, DCM, reflux, 16 h (d) H2, 10% Pd/C, EtOH, rt, 4 h, 80% 
(2-steps). (e) PCC, NaOAc, 4Å MS, DCM, 74%. (f) Ph3PCH3Br, tBuOK, THF 0 °C - rt, 3 h, 72%. (g) 
MeNHOMe.HCl, CyMgCl, -20 °C, 3 h, 91 - 93%. 
 
2.2.3 Synthesis of aigialomycin D and analogues 2.14 – 2.16 
 Having obtained the key fragments above, the assembly of the macrocylic 
products began from 2,4-dihydroxy-6-methylbenzoic acid (2.2), which was first 
protected with MOMCl followed by saponification of the methoxymethyl ester to 
furnish the desired carboxylic acid 2.6. With the acid 2.6 in hand, coupling with 
different alcohols (2.7a-c) via the Mitsunobu reaction gave the benzoates (2.8a-c) in 
good yields (70%-90%). These benzoates constituted precursors to the respective 
aigialomycin D (2.1) and analogues 2.14 – 2.16.  
 Alkylation at the benzylic positions of the benzoates 2.8a-c was problematic 
using commercial lithium diisopropylamide (LDA) as early attempts failed to give 
any desired product. We later discovered that freshly prepared LDA was crucial to the 
success of the reaction. Slow addition of LDA was also critical so as to avoid the 
second deprotonation at the benzylic position. Under these conditions, the benzoates 
2.8a-c were alkylated with the Weinreb amides (2.4 and 2.9) to give the dienes 
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(2.10a-d). With the dienes 2.10a-d in hand, cyclisation using ring-closing metathesis 
(RCM) with Hoveyda-Grubbs 2nd generation catalyst in refluxing 1,2-dichloroethane 
gave the respective macrocyclic compounds 2.11a-d in high yields and excellent 
stereoselectivity. Reduction of the C-2' carbonyl group by NaBH4 followed by one-
pot mesylation and elimination installed the trans 1', 2'-double bond in 2.13a-d.  
 In the case of aigialomycin D, the final global deprotection step with 2.13a was 
sluggish when carried out under conditions reported previously.79 To improve the 
efficiency of this reaction, a few conditions including MeSO3H, TFA and different 
concentrations of HCl were screened. The best condition found was the use of 2N 
HCl in methanol at a slightly elevated reaction temperature of 40 oC, which 
significantly reduced the reaction time from 2 days to 6 hours, and gave the desired 
compound 2.1 in 90% yield. Similar deprotection conditions were used to access 
compounds 2.14 – 2.16. Overall, aigialomycin D (2.1) and its analogues 2.14 – 2.16 
were achieved in six steps from 2.6.  
 
Scheme 2-3. Synthesis of aigialomycin D (2.1) and its analogues 2.14 – 2.16a  
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a Reagents and conditions: (a) diisopropylazodicarboxylate (DIAD), PPh3, THF, rt, 2-3 days, 70%-90%. 
(b) LDA, THF, -78 °C, then 2.4 or 2.9, 15 min, 19-65%. (c) Hoveyda-Grubbs II (5-10 mol%), 1,2-
dichloroethane, reflux, 1 h, 71-99%. (d) NaBH4/MeOH, 0 °C, 30 min. (e) i. MsCl, Et3N, 4-
dimethylaminopyridine (DMAP), CH2Cl2, 0 °C-rt, 3 h. ii. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 
toluene, reflux, 16 h, 31-50% (2 steps). (f) 2 N HCl, MeOH, 40 °C, 6 h, 62% to quantitative.   
2.2.4 Synthesis of analogues derived from 2.11a 
To probe into the effects of functional groups and conformation of aigialomycin 
D on its bioactivity, eight more analogues were obtained by various transformations 
using the key intermediate 2.11a (Scheme 2-4). Global deprotection of 2.11a under 
the conditions as described in the previous section provided 2.23, which was further 
hydrogenated to give 2.24.  Reduction of the carbonyl group in 2.11a using NaBH4 
followed by global deprotection yielded 2.25 as a C-2' epimeric mixture which was 
further hydrogenated to give 2.26. The N-oxime 2.27 was obtained by treating 2.23 
with hydroxylamine hydrochloride to give 2.27 as a mixture of cis and trans 
compounds. 7', 8'-Dihydro aigialomycin D 2.28 was prepared from 2.11a by a 
sequence of reactions, i.e., reduction of the carbonyl group followed by saturation of 
7', 8'-double bond, elimination and then deprotection.  
Taking advantage of the pivotal intermediate 2.11a, two C2-phenol methylated 
analogues 2.29 and 2.30 were also prepared. Since the C2-phenol is less reactive than 
the C4-phenol due to intramolecular hydrogen bonding, the synthesis of 2.29 and 2.30 
required a sequence of multi-step transformations. In the sequence of transformations 
to 2.29 from 2.31, the more reactive C2-methoxymethyl (MOM) group and the 
acetonide group were selectively removed using 0.2 M TFA in methanol to give the 
intermediate 2.32. The latter possessed a MOM protected phenol at the C4 position 
which remained intact during this process. The C2-phenol of 2.32 was then 
methylated using trimethylsilyldiazomethane followed by the deprotection of the C4-
MOM group in HCl/MeOH to provide analogue 2.29. Compound 2.30 was obtained 
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through a sequence of similar reactions from ketone 2.11a although the order of 
transformations was not the same. The synthesis began with the 7', 8'-dihydro 
intermediate of 2.28 followed by selective deprotection of the MOM group at the C-2 
position and acetonide protecting groups, methylation of the C-2 phenol, and finally 
deprotection of the MOM group at the C-4 position.  
 
Scheme 2-4. Synthesis of aigialomycin D analogues 2.23 – 2.30 from 2.11aa 
 
 
a Reagents and conditions: (a) 2 N HCl, MeOH, 40 °C, 6 h. (b) H2, 10%Pd/C, EtOH, rt, 20 h. (c) 
NH2OH.HCl, NaOAc, dioxane, 100 °C, 3 h, quantitative; (d) NaBH4/MeOH, 0 °C, 30 min. (e) i. MsCl, 
Et3N, DMAP, CH2Cl2, 0 °C-rt, 3 h. ii. DBU, toluene, refluxing, 16 h. (f) 0.2 M trifluoroacetic acid, 
MeOH, rt, 3 h. (g) Me3SiCHN2 (2 eq.), iPr2NEt, MeOH/MeCN (2:3), rt, 18 h. 
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2.2.5 Synthesis of derivatives 2.33 – 2.36 directly from aigialomycin D 
Starting from aigialomycin D (2.1), four derivatives were accessed (Scheme 
2-5). Full saturation of the two double bonds in 2.1 afforded tetrahydro-aigialomycin 
D (2.33). Attempted methylation of the 2, 4-phenolic groups of 2.1 using excess 
Me2SO4 in acetone did not provide either the mono- or the di-methylated product. 
Unexpectedly, the acetonide 2.34 was obtained as the sole product in high yield 
(94%). As acetonide protection of diol is known to occur via acid catalysis, it was 
speculated that the dimethylsulfate used may have partially decomposed to give 
sulfuric acid. Alternative methods for the methylation of the phenolic groups in 2.1 
were sought. Using trimethylsilyldiazomethane in the presence of methanol and N, N-
diisopropylethylamine,98 a mixture of mono- (at C-4, 2.36) and di-methylated 
products (2.35) was obtained in a ratio of 1:1 (by 1H NMR spectroscopy). The two 
compounds 2.35 and 2.36 were successfully separated by preparatory HPLC.   
 
Scheme 2-5. Synthesis of aigialomycin D analogues 2.33 – 2.36a 
 
a Reagents and conditions: (a) Me3SiCHN2 (3 eq.), iPr2NEt, MeOH/MeCN (2:3), rt, 18 h.  (b) H2, 
10%Pd/C, EtOH, rt, 20 h. (c) Me2SO4, K2CO3, acetone, rt, 1 h 
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2.3 Structure-activity relationship studies against CDK2/Cyclin A  
 Having synthesized aigialomycin D and fifteen of its analogues (Figure 2-1), 
the competitive inhibition of these compounds at the ATP-binding site of 
CDK2/cyclin A was initially assessed using an IMAP (Immobilized Ion Affinity-
based Fluorescence Polarization) enzyme assay.99  
 
Figure 2-1. Structures of all synthetic analogues of aigialomycin D 
 
 
 In an IMAP binding assay, a fluorescent labeled peptide substrate that 
specifically binds to CDK2, a large M(III)-based nanoparticle, ATP, and the test 
kinase are incubated together (Figure 2-2). In the absence of a kinase inhibitor, the 
fluorescent substrate is phosphorylated under catalysis by the active kinase, enabling 
its binding to the large M(III)-based nanoparticles, and resulting in a decrease of the 
rotational rate of the labeled substrate. This leads to an increase of the substrate’s 
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fluorescent polarization (FP). In the presence of a kinase inhibitor, the kinase activity 
is inhibited and phosphorylation will be reduced. Consequently there is minimal 
formation of the substrate-metal complex and thus the readout of the FP is low. The 
inhibitory activity of a compound against the kinase can be determined by measuring 
the changes in the FP readout in the presence or absence of the compound. 
 
Figure 2-2. Principle of IMAP assay – (from Molecular Devices) 
 
 
In our studies, purvalanol A, a highly potent CDK inhibitor, was used as the 
positive control and the percentage inhibition by aigialomycin D and analogues were 
measured first (Figure 2-3). From this screen, the most potent inhibitors with 
percentage inhibition higher than 50% at 10 M were identified as aigialomycin D 
(2.1), 2.14 and 2.36. Several conclusions can be drawn from this study. The critical 
functionality on the resorcylic ring that is needed for CDK2 inhibition is a free 
hydroxyl group at the C-2 position. This is evident when comparing the percentage 
inhibition of the monomethylated (at C-2 position) compound 2.29 to aigialomycin D. 
This observation is in agreement with the results obtained from other known CDK2 
inhibitors (e.g. flavopiridol and purvalanols) wherein a motif containing a hydrogen 
bond donor adjacent to a hydrogen bond acceptor has been found to be essential for 
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their CDK2 binding activity.100 In contrast, monomethylation of the C-4 hydroxy 
group of the resorcylic ring (i.e. compound 2.36) showed comparable activity as 
aigialomycin D. The lack of activity of dimethylated compound 2.35 is also consistent 
with this conclusion. 
From the SAR studies, the essential functional groups on the macrolide ring 
were also identified. Replacement of 1', 2'-double bond with other functionalities e.g. 
either carbonyl, alcohol or oxime groups (2.23, 2.25 and 2.27 respectively) all caused 
significant losses in activity. Similarly, saturation of either 7', 8'-double bond (2.28 vs 
2.1, 2.24 vs 2.23 and 2.30 vs 2.29) or both double bonds (2.33 vs 2.28 and 2.1) led to 
reduced activities. This may be due to major conformational and/or shape differences 
resulting from the saturation of the double bonds, leading to poorer binding 
interactions with the active site of CDK2. Other essential functionality that is critical 
for activity is the 5', 6'-diol of the macrocycle, since masking the diol as an acetonide 
(i.e. compound 2.34) or the deletion of this functionality (i.e. compound 2.16) led to 
large losses in activities. A similar observation for compound 2.34 has also been 
reported by Winssinger’s group in their studies with CDK1 and CDK5.69 Interestingly, 
the stereochemistry of the methyl group at C-10' is not critical as inversion of the 
configuration at C-10' (i.e., compound 2.14) has no adverse effect on its inhibitory 
activity as compared to aigialomycin D. Removal of the C-10' methyl group (i.e., 2.15) 
only reduces the potency slightly.  
The IC50 values were measured for three of the most potent inhibitors 2.1, 2.14 
and 2.36 (Table 2-1). These compounds have very similar IC50 values of ca 20 M, 
indicating that they are only moderate CDK2/cyclin A inhibitors.  
 
Figure 2-3. Percentage Inhibition of CDK2/cyclin A by aigialomycin D (2.1) and its 
analogues at 10 µM. Values are the average +/- SD of 3 independent experiments 
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except in a few cases the means of 2 experiments are given.  Purvalanol A (1 µM) 




Table 2-1. IC50 values of 2.1, 2.14 and 2.36 against CDK2/cyclin A 
Compound 2.1 2.14 2.36 
IC50 (µM)
a 21±5 19±2 19 
a Data are expressed as averages ± SDs from dose response curves of 3 independent experiments,  
except for 2.36 which is the mean value of 2 experiments. 
 
2.4 Computational docking study using a CDK2 crystal structure 
  In order to estimate the binding mode of these compounds with CDK2, 
docking studies for all the tested RAL compounds were carried out using ICM-VLS 
(Molsoft, LLC, La Jolla). The holo structure of the active-form of CDK2/cyclin A 
complexed with a ligand (indirubin-5-sulfonate) (pdb: 1E9H)101 was used for the 
docking experiment. The cyclin-bound CDK2 crystal structure is known to be in the 
active conformation for binding of ligands and it has been shown that this form often 
gives the best reproducibility of pose in comparison to the inactive form.102 This 
model is also consistent with our bioassay that directly measures the phosphorylation 
abilities of the CDK2/cyclin A complex.  
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For preliminary docking, the exact method (Lennard-Jones 12-6) gave a good 
trend between observed inhibitory activities and the theoretical scoring function for 
binding. The use of either a soft docking model (LJ 9-6) or a multiple receptor 
conformation (MCR) approach resulted in poorer correlation between activities and 
the binding scores. The predicted binding poses from exact docking were further 
refined by adjusting both the ligands and side-chains to obtain the refined score, and 
re-ranked based on the conformations with the lowest energies (Table 2-2). Aside 
from 2.15, the other three compounds (aigialomycin D, 2.14 and 2.36) ranked 
similarly in their docking scores and bioactivities. The binding poses of all the docked 
compounds show similarities in that the aromatic ring is located at the edge of the 
hinge region and the rest of the macrocycle resides in the binding pocket, which is 
exemplified by the binding pose of aigialomycin D (Figure 2-4). The variations in the 
binding poses are influenced by the number of hydrogen bonding interactions with the 
protein residues (Table 2-2). The protein residues most commonly found to be 
involved in hydrogen bonding are L83 (via NH as well as carbonyl) and D86. 
Interestingly, only the C-2 hydroxyl group in compound 2.15 was found to interact 
with E81. This is the residue that is very often implicated in hydrogen-bonding with 
many types of known CDK2 inhibitors (Table 2-2).100, 102 In addition, no π-π stacking 
was observed between the aromatic ring of the ligands and F82 although they are 
close to each other. Among the top four scored compounds, aigialomycin D is 
predicted to form the most number of H-bonds (i.e., 5) with the residues (Figure 2-4), 
which is possibly the cause of its higher binding affinity. Compounds 2.14 and 2.15 
are both predicted to have only three H-bonding interactions with the protein, while 
2.16 and 2.36 have two H-bonding interactions (see Table 2-2 for residues involved). 
As such, a docking outcome that matches fairly well with the inhibitory activities of 
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the test compounds was achieved by performing a rigid docking in the ATP-binding 
site of the active-form of CDK2. The differences in the ICM scores of the top ranked 
compounds may be due to the strength and number of H-bond interactions. 
 
Table 2-2. Binding properties of top-five ranked inhibitors based on exact docking to 
CDK2  













2.1 21 1 -23.4 √ √  √  √ √ 
2.15 --a 2 -22.2   √  √ √  
2.14 19 3 -18.3 √    √ √  
2.36 19 4 -15.9      √ √ 
  a Not tested, its percentage inhibition of CDK2/cyclin A is 38%.                       
 




2.5 Kinase profiling of aigialomycin D and the discovery of new kinase targets 
As discussed above, aigialomycin D and its cyclic analogues were found to be 
only moderate inhibitors of CDK2/cyclin A with IC50 values in the low µM range. In 
Hinge region 
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order to identify other possible kinase targets, aigialomycin D (2.1) was screened 
against a panel of 96 kinases at 10 µM (Results obtained from KinomeScanTM, 
DiscoveRx. See full list of percentage inhibition values and selectivity score in Table 
2 and 3 of the Appendix). Of these, five kinases, MNK2, FLT3, AXL, PLK4, 
PRKCE, were found to be inhibited by aigialomycin D at the level of below 10% as 
compared to the negative control (i.e., DMSO, which is set as 100%) (Figure 2-5, 
Table 2-3). Among these five, FLT3 (or FMS-like tyrosine kinase 3)103-105 and PLK4 
(or polo-like kinase 4)106-108 are important targets for oncology drug development, and 
MNKs (or mitogen-activated protein kinases interacting kinases, or MKNK)109-111 are 
emerging and yet attractive targets which are known to phosphorylate and regulate the 
oncogene eIF4E.111-113 In comparison, aigailomycin D inhibit CDK2 at only 63% over 
negative control. 
 
Figure 2-5. Kinase treespot of aigialomycin D (2.1) showing the distribution of 
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We next obtained the Kd values (from KinomeScan
TM) of the five kinases 
against aigialomycin D in order to validate the targets (Table 2-3). Consistent with 
the percentage inhibition, MNK2 is the most inhibited kinase with percentage 
inhibition of 0.15% relative to the control and possessed the lowest Kd value of 160 
nM. FLT3 and PLK4 are also inhibited at nanomolar levels (Kd at 300 and 260 nM 
respectively). Due to the high potency of aigialomycin D in the inhibition of 
oncogenic target MNK2, further studies of this kinase were pursued in Chapter 3.  
Table 2-3. Kinase targets inhibited by 2.1 below 10% of negative control and their Kd 
values 
Kinase AXL FLT3 MNK2 PLK4 PRKCE 
% Controla 4.7 7.1 0.15 9.6 7.2 
Kd (nM) 1000 300 160 260 1200 
a Determined at 10 µM with DMSO as a negative control. A lower value indicates a stronger inhibition.  
 
2.6 Summary 
In summary, we have synthesized aigialomycin D and a series of its 
macrocyclic analogues based on a convergent synthetic route. The synthesis of 
analogues 2.14 - 2.16 were accomplished by a total synthetic approach starting from 
easily accessible starting materials, while the rest of the analogues were synthesized 
either from the key intermediate 2.11a, or by derivatizing  aigialomycin D itself.  
Enzymatic assays have identified aigialomycin D and two of its analogues 
(2.14 and 2.36) as moderate inhibitors of CDK2/cyclin A complex with IC50 values of 
about 20 µM. Computational docking studies were implemented to study the protein-
ligand interactions involved in CDK2 binding. Kinase profiling of aigialomycin D led 
to the discovery that MNK2, FLT3 and PLK4 as more promising targets. Among 
these, aigialomycin D has the highest affinity to MNK2 with a Kd value of 160 nM (or 
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IC50 of 450 nM). In view of this discovery, the inhibitory activities of the synthetic 
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Chapter Three Kinase inhibition studies of aigialomycin D analogues on MNK1/2 
and further development of acyclic analogues as MNK1/2 inhibitors 
 
3.1 Introduction 
3.1.1 Overview of mitogen-activated protein kinase interacting kinases (MNKs) 
Mitogen-activated protein (MAP) kinase interacting kinases (MNKs) were 
first discovered by virtue of their ability to interact with or to be phosphorylated by 
MAPKs, e.g., p38 and ERK (Figure 3-1).114, 115 MAPKs phosphorylate two threonine 
residues (Thr197/202) within the activation or T-loop of the MNKs leading to their 
activation. There are two human MNK genes, MNK1 and MNK2. Although there is 
~80% sequence similarity between the two isoforms, the slight differences in the 
amino acid sequences within their catalytic domain (T-loop) as well as the C-terminal 
domains determine their different binding behaviors to MAPKs, as well as their 
different activities and regulatory properties.116 Although both MNK1 and MNK2 can 
bind to and be subsequently phosphorylated and activated by ERK, MNK2 binds to 
ERK more effectively. Furthermore, MNK2 can bind to phosphorylated ERK, 
whereas MNK1 cannot. Close inspection of the amino acid sequences of the catalytic 
domains of mouse MNK2 and MNK1 revealed that the Asp191 in MNK2 is replaced 
by Ser191 in MNK1. Since the negatively charged aspartic acid is found to be crucial 
to the binding of MNKs to ERK, the replacement of Asp191 with Ser191 in MNK1 
may account for its lower binding activity to ERK. Another recent study on MNK 
structures revealed that although MNK1-KR (kinase region) shows similar structural 
features to MNK2-KR, the N-terminal lobe of MNK2-KR is tilted by approximately 
10 degrees, making the kinase binding pocket slightly more open to accommodate 
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ATP or a small molecule inhibitor as compared to MNK1-KR.110 In this context, it 
should be possible to design inhibitors that show selectivity between the two isoforms 
of MNK. 
 




On the other hand, MNK1/2 is also known to phosphorylate and activate its 
downstream protein eIF4E on Ser209. eIF4E is a component of the eIF4F complex 
that promotes initiation of the translation process of mRNA (Figure 3-1).112, 117 As a 
canonical initiation factor involved in the recruitment of mRNA to the ribosome, 
eIF4E has the potential to influence the expression of virtually every protein in the 
cell.118 Overexpression of eIF4E is oncogenic and has been shown to correlate with a 
variety of human cancers.111 Recent research has highlighted the importance of eIF4E 
phosphorylation at Ser209 specifically in the context of targeting the MNK1/2 kinases 
as a way to prevent eIF4E-mediated oncogenic transformation.119-121 In mammalian 
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cells, phosphorylation of Ser209 is not essential for the activity of eIF4E in normal 
cells but is required in cancer cells. Thus, targeting MNKs could be an effective 
therapeutic approach that selectively affects cancer cells and not normal cells.122  
Very recently, MNKs have also been shown to be linked with specific 
pathways such as MNK-eIF4E-β-catenin pathway and thus targeting MNKs may also 
be a potential method for the treatment of blast crisis (BC) CML111  and AML.123 
3.1.2 Hypothesis and objectives 
As mentioned in Chapter 2, we have identified MNK2 as the promising target 
of aigialomycin D from the profiling of a panel of 96 kinases. In this study, we 
investigate the structure-activity relationship of aigialomycin D and related analogues 
in the context of MNK1/2 inhibition. Based on the structural differences of MNK1 
and MNK2, it is expected that these compounds could be selective to MNK2 versus 
MNK1. We also hypothesized that simpler acyclic analogues such as resorcylic esters 
or amides that bear the desired functionalities could be potential MNK1/2 inhibitors.  
3.2 Kinase inhibition activities against MNK1/2 
In order to study the structure-activity relationship of aigialomycin D in the 
inhibition of MNK1/2, the IC50 values of all sixteen synthetic compounds (from 
Chapter 2) against MNK1/2 were determined using a similar IMAP assay as described 
in Chapter 2. In the context of the current work, a MNK specific fluorescent peptide 
(5-FAM-TATKSGSTTKNRFVV-NH2) was utilized instead of a CDK2 specific 
peptide. It should be noted that the biological assays on MNK1/2 in this Chapter were 
carried out by our collaborators in ETC.  
From the MNK2 inhibitory studies, it was shown that compounds 2.1, 2.16, 
2.28 and 2.34 have the best activities with IC50 values in the range of 450 –1600 nM 
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while the remainder of the compounds were much less active (IC50 values >10000 nM) 
(Table 3-1). These results indicated that an unprotected resorcinol unit together with 
the 1',2'-double bond and the (S)-10'-methyl group (2.1, 2.16, 2.28 and 2.34) are 
critical for good activity. Loss of any of the three functionalities abolished the 
inhibitory activities against MNK2. Saturation of 7',8'-double bond (2.28) caused a 3 
fold decrease in activity. On the other hand, although removal of 5',6'-diol (2.16) is 
detrimental to the potency (ca 4 fold), masking the diol as an acetonide (2.34) 
surprisingly only gave marginal effects. This implies that the 5',6'-diol substituent 
does not contribute as hydrogen donors in its interactions with MNK2 within the 
binding site.  
In the study of MNK1 activity, it was found that with the exception of 2.15 
(MNK1 IC50 = 1230 nM), all other compounds showed essentially very weak 
inhibitory activities against MNK1 (IC50 values >10000 nM, data not shown). This is 
consistent with the kinase profiling study wherein aigialomycin D was found to 
possess a Kd value of 40 M against MNK1 only. It is interesting to note that the only 
active compound 2.15 from our MNK1 assay bears no methyl group at the C-10' 
position on the macrocycle. As it is known that MNK1 has a narrower ATP binding 
pocket as compared to MNK2,110 we postulate that 2.15 may fit into the binding 
pocket of MNK1 more easily than aigialomycin D and other analogues due to the 
absence of this particular methyl group.  
Table 3-1. IC50 values of AD analogues against 
MNK2 
Compound IC50 (nM)a Compound IC50 (nM)a 
2.1 450 ± 20 2.27 >10,000 
2.14 >10,000 2.28 1350 ± 70 
2.15 >10,000 2.29 >10,000 
2.16 1610 ± 810 2.30 >10,000 
2.23 >10,000 2.33 >10,000 
2.24 >10,000 2.34 580 ± 360 
2.25 >10,000 2.35 >10,000 
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2.26 >10,000 2.36 >10,000 
a Data are expressed as averages ± SD from dose response  
curves of 2 independent experiments. 
 
3.3 Computational docking of aigialomycin D and its analogues to MNK2 3D 
structure 
With the results of the biological assay in hand, the 16 compounds studied in 
the previous section were docked using ICM-VLS onto MNK2 using the PDB data 
for MNK2-staurosporine (PDB ID: 2HW7)124 but with the staurosporine removed. 
There are only two reported crystal structures of MNK2 (the other one is 2AC5, 3.2 
Å),125 and 2HW7 was chosen for these modeling studies as the resolution (2.7 Å) was 
reported to be better. Importantly, the MNK2 protein is in its active form (DFG-in) 
and thus higher accuracy of prediction could be expected. The same exact docking 
method as employed for CDK2 docking was implemented here.  
 
Figure 3-2. Predicted binding poses of top four MNK2 inhibitors onto the pocket of 
MNK2-staurosporine crystal structure (with original ligand removed) (PDB ID: 










On average, the predicted ICM binding scores (-20.0 to -28.1) for MNK2 are 
lower than those for CDK2 (-12.9 to -23.4) (lower scores indicate stronger binding 
strength), and this is in agreement with the observation that these compounds are 
more potent inhibitors of MNK2 as compared to CDK2. We then examined the 
binding poses and the binding energies of the top four MNK2 inhibitors (i.e., 2.1, 2.16, 
2.28 and 2.34) (Figure 3-2). As shown in Figure 3-2, the four compounds all exhibit 
orientations similar to that observed for docking of aigialomycin D to CDK2. The 
resorcylic rings reside near the hinge region that occupies the purine binding site of 
ATP and the macrocyclic rings are pointed toward the ribose binding site and also 
occupies the adjacent hydrophobic regions I and II. The binding energies of the four 
inhibitors are similar (-52 to -53 KJ/mol). 
To further investigate the 3D structures of the four inhibitors, their best 
conformations were superimposed (Figure 3-3a). Not surprisingly, the resorcylic ring 
of the four compounds overlapped closely in the hinge region. However, the 
conformations of the macrocyclic rings differ from each other. For example, the 5',6'-
diol of aigialomycin D (Figure 3-3a, yellow-red colors) is projected downwards 
closer to the ribose binding site, and mimics the ribose binding, whereas the acetonide 
group of 2.34 (orange color) is tilted upwards to the hydrophobic pocket II, and is 
therefore expected to have hydrophobic interactions with the residues within this 
region. In comparison, compound 2.16 (cyan color) and 2.28 (purple color) adopt very 
similar conformations and their macrocyclic rings are flatter and occupy less space 
within the binding pocket as compared to 2.1 and 2.34, indicating less interactions to 
the binding site residues. 
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Figure 3-3. (a) Overlapped conformations of the four MNK2 inhibitors: 2.1: yellow-
red; 2.16: cyan; 2.28: purple; 2.34: orange. (b) Predicted H-bond interactions of 
aigialomycin D (2.1) with the binding site residues of MNK2: C-2 OH- with C=O of 
E160; C-4 OH with C=O of M162; C-5' OH with C=O of E209. Note: aigialomycin D 
is shown as yellow-red stick in the center.  
 
 
The hydrogen bonding interactions of aigialomycin D with the amino residues 
in the binding site were then examined (Figure 3-3b). From the model, three H-bonds 
are likely to form, i.e., the H-bond between the phenolic OH at C-2 of 2.1 with C=O 
of E160 (with a distance of 2.34 Å), the phenolic OH at C-4 with C=O of M162 (2.58 
Å) and the hydroxyl at C-5' with C=O of E209 (1.92 Å).  
In summary, by performing the docking studies above, the binding behaviors 
of the most active aigialomycin D and its analogues in MNK2 structure were 
illustrated. These results enabled some understanding of the structural basis of their 
MNK2 inhibitory activities in the protein assays.    
3.4 Design and synthesis of acyclic analogues based on aigialomycin D  
3.4.1 Design of Group I and Group II analogues 
From our previous SAR studies of the macrocyclic AD analogues against 
MNK1/2 kinases (see Section 3.2), the resorcinol motif, 1',2'-double bond and (S)-10'-
methyl group were found to be critical for inhibitory activity. As part of our aim to 











Hydrophobic pocket I  
Hydrophobic pocket II  
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aigialomycin D analogues were targeted. To test the hypothesis that acyclic analogues 
that retain the key functional groups on the macrocycle could also retain the MNK 
activity, Group I analogues (Figure 3-4) were designed and synthesized. Specifically, 
compounds 3.8, 3.10 and 3.12 (Scheme 3-1) in Group I were synthesized as acyclic 
mimics of the macrocycle 2.34 having an acetonide group. 2.34 was previously shown 
to be as potent as aigialomycin D in the enzymatic assay. For comparison, compounds 
3.9 and 3.11 would retain the free diol functionality whilst bearing either cis 1',2'-
double bond or its saturated form. As an expansion of the analogue diversity, Group II 
analogues with altered side chains linked to the resorcinol ring were also designed. 
These analogues are designed to have a phthalimide moiety linked via an ether bond 
at C-6 position of the resorcinol ring with a 3-carbon spacer (Figure 3-4). We propose 
that such phthalimide group (with a spacer) could bring both flexibility and certain 
degree of bulkiness required for its occupancy to the binding site as well as provide 
the desired properties as hydrogen acceptor. Different ester (3.19a & b, 3.21, 3.23) or 
amide (3.26 – 3.28) substituents were also incorporated into the C-1 position at the 
top side chain to mimic the corresponding hydrophobic group of aigialomycin D 
(Scheme 3-2). These ester/amide groups bearing acyclic side chain are proposed to 
occupy the hydrophobic pocket II as shown in Figure 3-3a. 
 
Figure 3-4. General structures of Group I and Group II compounds 
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It was interesting to note that in the course of our study, Barrett’s group 
reported the synthesis of similar ring-opened resorcylic acid derived compounds – O-
aminoalkyl resorcylates, which showed activities against a selection of receptors and 
kinases, including 5-HT and CDK2/7.126 
3.4.2 Synthesis of acyclic analogues 
Group I: 
As shown in Scheme 3-1, the synthesis of the target compounds started from 
the triflate 3.1. Sonogashira coupling with alkyne 3.2 gave 3.3 which was then 
protected as the TBS ether. The resultant 3.4 was subjected to selective hydrogenation 
using Lindlar’s catalyst to give the cis-alkene 3.5 as the main product and alkane 3.6 
as a minor product (ratio 10:1 by 1H NMR spectroscopy). Transesterification of 3.5 
with (S)-4-penten-2-ol followed by TBS deprotection using TBAF gave 3.5, whilst 
global deprotection of the same intermediate 3.7 using HCl in methanol gave 3.9. 
Similarly, compounds 3.10 – 3.12 were prepared in two steps from compounds 3.6 
and 3.13 respectively in 66% - 74% yields (Scheme 3-1). 
 
Scheme 3-1. Synthesis of acyclic AD analogues – Group I: 3.8 – 3.12. 





The synthesis of Group II analogues began with the protection of 2,4,6-
trihydroxybenzoic acid (3.14) as the acetonide 3.15 in the presence of TFA and TFAA 
in 63% yield. Taking advantage of the lower reaction of the hydrogen-bonded 2-
phenol, selective MOM protection of the 4-phenol in 3.15 was achieved using 
triethylamine as a mild base at 0 °C to give 3.16 in 90% yield. Alkylation at the C-6 
phenol of 3.16 was attempted using either (3-bromopropyl)phthalimide under basic 
conditions, or (3-hydroxypropyl)phthalimide under Mitsunobu conditions. While the 
first method failed, the Mitsunobu reaction gave the desired product 3.17 in 93% yield 
upon optimization. With the intermediate 3.17 in hand, transesterification was carried 
out with different alcohols leading to 3.19 a-b, 3.21 and 3.23. The yields of 3.19 a-b 
were much lower than those of 3.21 and 3.23 due to the ring-opening of the 
phthalimide moiety under basic conditions, which gave rise to the by-products 3.24 a-
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b respectively as evidenced by 1H NMR spectroscopy and mass spectrometry. 
However, the ring-opening of the phthalimide moiety was not observed in the 
synthesis of 3.21 and 3.23.  
In the synthesis of amide analogues, i.e. 3.28, more problems were 
encountered. Transamidation of 3.17 using sodium hydride with allylamine was not 
successful. Screening with other bases (i.e., tBuONa and LiHMDS) found that the use 
of LiHMDS gave the best result and the desired compound 3.27 was isolated, albeit in 
only 4% yield after HPLC purification. Two other products, i.e., 3.25 and 3.26 were 
also isolated. Further monitoring of the reaction at -78 °C showed that 3.25 was 
initially formed as evidenced by MS analysis and TLC monitoring. Compounds 3.26 
and 3.27 were only detected when the reaction temperature was increased slowly to 
room temperature. Attempts to optimize this further using microwave conditions and 
neat allylamine in the absence of base gave similar results. A mixture of the three 
above mentioned products were also isolated. These results suggested that the 
phthalimide group is more susceptible to nucleophilic attack than the ester group. 
Deprotection of the MOM group of 3.27 gave the target compound 3.28. 
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Scheme 3-2. Synthesis of acyclic AD analogues – Group II: 3.19 (a, b), 3.21, 3.23, and 3.26 – 3.28. 
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3.5 Biological evaluation of acyclic AD analogues against MNK1/2 
The above synthesized acyclic AD analogues (3.8 – 3.12, 3.19a, 3.19b, 3.21, 
3.23, 3.26 – 3.28) were tested in the IMAP-MNK assay as described in Section 3.2. 
Unfortunately, none of the compounds showed strong inhibitory activities against 
both MNK1 and MNK2 kinases (IC50 >10 μM) as compared to aigialomycin D (IC50 
= 0.45 μM on MNK2). These results suggest that despite the presence of the key 
functional substituents, the macrocyclic structure is essential for inhibitory activity 
against MNK1/2.  
3.6 Summary 
In this Chapter, we evaluated the MNK1/2 inhibitory activities of the 
macrocyclic analogues of aigialomycin D. The SAR study revealed that an 
unprotected resorcinol motif, 1',2'-double bond and the S configuration of the C10'-
methyl group are critical for MNK2 activity, whilst the diol functionality has only 
marginal influence on the activity. Computational docking was carried out to illustrate 
the binding behaviors of the inhibitors to MNK2, and the structural features of the top 
four inhibitors were examined in more detail.  
Based on the hypothesis that acyclic analogues of aigialomycin D that bear the 
resorcylic esters or amides motif could also be MNK1/2 inhibitors, twelve acyclic 
compounds were synthesized and evaluated. However, none of these resorcylic 
derivatives showed good MNK activities as compared to the parent natural product. 
These results suggest that the macrocyclic ring system of aigialomycin D is important 
for its binding to MNK1/2.  
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Chapter Four Enamide-based resorcylic acid lactone (RAL) analogues as covalent 
inhibitors of MNK1/2 kinases 
4.1 Introduction 
4.1.1 Overview of covalent kinase inhibitors (other than RALs) 
Historically, small molecules that are capable of covalently modifying proteins, 
DNA and other biological targets are disfavored candidates for drug development due 
to their potential off-target reactivities. Consequently, compounds containing a 
potentially reactive functionality would often be intentionally filtered off at the early 
stage of a drug discovery program as this could avoid indiscriminant reactivities that 
may lead to unfavorable toxicological events and unpredictable idiosyncratic adverse 
effects.127 However, with recent advances in bio-informatics, structure-guided drug 
design, pharmacokinetics, preclinical metabolism and toxicology, targeted covalent 
inhibitors (TCIs) have emerged as an attractive approach for drug design and 
discovery.93 The renewed interest in covalent kinase inhibitors was initially driven by 
the small yet innovative pharmaceutical R&D, as represented by Parke-Davis 
Pharmaceutical Research.128 To date, many other irreversible inhibitors have been 
developed and are at various stages of evaluation (Figure 4-1).20, 38, 93, 127, 129-131 In 
2013 alone, two targeted covalent kinase inhibitors were approved as anti-cancer 
drugs, namely, Afatinib (EGFR inhibitor)132-134 for the treatment of non-small-cell 
lung carcinoma (NSCLC) and Ibrutinib (Bruton’s tyrosine kinase inhibitor)10, 16, 135 for 
the treatment of mantle cell lymphoma. 
 
 








As compared to non-covalent inhibitors, covalent drugs have distinct 
advantages in that they often have significantly improved potency, prolonged duration 
of action and are more effective against drug resistance caused by mutations.93  
An efficient design of target-specific covalent inhibitor is essentially guided 
by two facts (Ki and k2). As shown in Scheme 4-1, to achieve high potency as well as 
selectivity/specificity, careful optimization of both the non-covalent binding affinity 
(Ki) and the reactivity of the electrophilic warhead (k2) is required.
93 Firstly, the ligand 
must possess a favorable skeleton and conformation to be able to enter the binding 
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pocket of its target and form non-covalent interactions (Ki). At the same time the 
ligand needs to orientate itself and brings its reactive electrophilic warhead close to a 
specific nucleophile on the protein. Secondly, when the electrophilic warhead of the 
covalent inhibitor is close enough to the target nucleophile, nucleophilic attack occurs 
and this results in a covalent interaction with the target amino acid residue. A 
completely irreversible inhibitor has a k-2 value of zero, while a reversible covalent 
inhibitor has a k-2 value larger than zero.  
 
Scheme 4-1. Equation of irreversible binding of inhibitor to enzyme 
 
 
Examples of reactive electrophiles as warheads include epoxides, quinones, β-
lactams, acetylenes, nitriles, Michael acceptors such as acrylates, acrylamides, 
acrylsulfonamides, and vinyl sulfonates (Figure 4-2)20, 131 while the reaction 
mechanism could be acylation/alkylation, Michael reaction, hemiketal formation and 
Pinner reaction et al.127 Choice of a proper electrophilic warhead is critical in order to 
avoid very reactive groups. Recently, the acrylamide moiety has been shown to be a 
privileged functionality for covalent binding to cysteine residues. Such moiety is a 
relatively weak electrophile, and its reactivity towards the nucleophile depends on its 
proximity to the target cysteine residue. Thus high selectivity can be achieved for 
inhibitors containing this type of functionality.93 Examples of this type of irreversible 
kinase inhibitors include Neratinib (or HKI-272, Pfizer) as a Pan-ERBB inhibitor in 
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phase III clinical trials,42 and the two recently approved drugs Afatinib and Ibrutinib 
as noted above. 
 
 
Figure 4-2. Electrophilic functionalities used in irreversible kinase inhibitors 
 
The potential nucleophilic residues in the target proteins that are capable of 
electrophilic attack by small molecules are essentially the highly conserved lysine and 
cysteine residues within the binding sites. Besides these two, there is no report to date 
on any covalent kinase inhibitors that form adducts with other amino acid residues, 
such as serine or threonine38 although such amino acid residues in many other protein 
targets can be covalently modified by small molecules.127 Due to the high abundance 
of lysine and its involvement in phosphotransfer machinery, lysine is not an ideal 
trapping agent although there are a few examples of lysine targeted inhibitors.38 In 
addition, the desired nucleophilicity of lysine can only be maintained when it is in 
neutral form, while in many cases of a biological system, lysine is present in 
protonated (charged) form. In contrast, development of covalent kinase inhibitors 
(Figure 4-1) that target the non-catalytic cysteine residues has been the subject of 
much interest.128, 136-139 For example, Taunton’s group has recently developed a 
cyanoacrylamide-based pyrrolopyrimidine as a covalent yet reversible inhibitor, 
which has opened opportunities for the rational design of reversible covalent 
inhibitors.140, 141 Gray et al reported a perspective informatics assessment of the 
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potential “protein kinase cysteinome” within the whole kinome range for the 
development of irreversible inhibitors.20 Similar studies have also been carried out by 
Winssinger’s142 and Santi’s groups67. With the knowledge above, there are many 
opportunities for the development of new covalent inhibitors as therapeutic agents 
against various kinase targets.   
4.1.2 Hypothesis and objectives 
As discussed in Chapter 3, the acyclic analogues of aigialomycin D are 
inactive towards MNK inhibition. As a continuation of the work on the development 
of RAL-based MNK inhibitors, we extended our studies to the development of 
covalent kinase inhibitors. The inspiration for this arose from the previous observation 
that the acrylamide substituent is a Michael acceptor that can potentially modify 
cysteine residues. In addition, cis-enone RALs such as hypothemycin, L-783,277 and 
LL-Z-1640-2 are highly potent covalent inhibitors of certain kinases (e.g., MEKs, 
VEGFRs, PDGFR2, MNK1/2, FLT3, KIT and TAK1).67 Thus, we hypothesized that 
RAL analogues possessing a cis/trans-enamide system on the macrolide could serve 
as a mild Michael acceptor of the abovementioned kinases, in particular, MNK1/2 as 
the target of our interest. Such enamide RAL analogues, upon further tuning of both 
non-covalent and covalent interactions, could be developed into drug candidates that 
combine the features of both the naturally occurring cis-enone RALs as well as the 
known acrylamide-based covalent kinase inhibitors as reviewed in Section 4.1.1. To 
test this idea, we initiated the study by designing and synthesizing a series of cis and 
trans enamide RAL compounds. 
4.2 Design and synthesis of enamide RAL analogues as novel covalent inhibitors of 
MNK1/2 kinases 
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4.2.1 Design of enamide RAL analogues as covalent inhibitors of MNK1/2 
Our design of enamide-based covalent inhibitors of MNK began with the 
analysis of MNK1/2 amino acid sequences and their X-ray crystal structures. As 
noted previously, hypothemycin is a cis-enone RAL with potent kinase inhibitory 
activities. The crystal structure of hypothemycin complexed with ERK2 revealed that 
C164 of ERK2 covalently binds to the β-carbon of cis-enone within hypothemycin.60 
In the alignment of amino acid sequences of MNK1 and MNK2 with ERK2 (Figure 
4-3), the C225 of MNK2 and C190 of MNK1 were found to align at the same position 
as the C164 of ERK2. All of the three cysteines are adjacent to the highly conserved 
and functionally important DFG/DFD motif within the ATP binding site.  
We next investigated the crystal structures of MNK2-staurosphorine complex 
(pdb ID: 2hw7)125 and ERK2-hypothemycin (pdb ID: 3c9w) (Figure 4-4). 
Superimposition of the two structures indeed generated good overlap between the 
ATP binding regions of the two kinases. In particular, there is a good match between 
the C164 of ERK2 with C255 of MNK2 (Figure 4-4).  
 
Figure 4-3. Sequence alignment of MNK2, MNK1 and ERK2 kinases.  
The conserved CDFG/D motif is highlighted in the box. 
 





Figure 4-4. Structure superimposition of MNK2 (2HW7, green ribbon, SH of C225 is 
shown as a yellow sphere) with ERK2–hypothemycin (3C9W, sky-blue ribbon for 
ERK2, yellow/red stick model for hypothemycin)  
 
 
Based on these analysis, it should be possible to design RAL analogues as 
MNK kinase inhibitors. This rationale is also supported by our recent study showing 
that L-783277, which is structurally similar to hypothemycin, has an IC50 value of 61 
nM against MNK2. This information, together with the fact that substituted 
acrylamides have been shown to be privileged electrophiles (Michael acceptors) in the 
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design of covalent inhibitors, prompted us to design novel enamide-based RAL 
macrolides with the general Structure I (Figure 4-5), in which the cis-enone moiety of 
the RAL natural products (e.g., L-783,277) is replaced with an enamide functionality. 
It is expected that the enamide functionality could also functions as a Michael 
acceptor and thus covalently bind to C225 of MNK2 and C190 of MNK1. The 
advantages of introducing the enamide functionality are that it could serve as a 
moderate Michael acceptor warhead with the potential to tune the reactivity by 
chemical modification of its N-H motif so that desirable activity and selectivity could 
be achieved. For example, N-acylation of the enamide nitrogen atom should increase 
the reactivity of the -carbon of the enamide system thereby allowing adjustment of 
its potency.  In this work, the initially designed compounds will be synthesized and 
tested in the biochemical assay, and the results will be used to guide further 
optimization of the lead compounds.  




4.2.2 Synthesis of trans-enamide RAL analogues 
4.2.2.1 Proposed retro-synthesis of trans-enamides  
The enamide analogues of RAL compounds can be divided into two sub-
groups according to the double bond geometry, i.e. cis and trans enamides. We 
initially designed a synthetic route to the more easily accessible trans -enamide RAL 
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(Scheme 4.2), and proposed that the cis-enamide could be obtained from the trans 
form by photo-catalyzed isomerization, which has been shown in the synthesis of 
other RAL compounds.143 
 
Scheme 4-2. Retrosynthesis of trans-enamide RAL 
 
 
As shown in Scheme 4-2, the trans-enamide 4.8 could be assembled via three 
key steps including Heck coupling, transesterification and ring closing olefin 
metathesis (RCM). The three key fragments, i.e. 2,4,6-trihydroxy benzoic acid (3.14), 
3-buten-1-ol (4.9) and (S)-4-penten-2-ol (4.10) are commercially available starting 
materials. The primary alcohol can be converted to the primary amine after 
installation of the resorcylic ester. By virtue of the general strategy, other analogues 
can also be accessed by employing different building blocks such as acid chlorides. 
     
4.2.2.2 Synthesis of trans-enamide RAL analogues 4.8 and 4.13 
The synthesis of trans-enamide 4.08 began with compound 3.16 which was 
prepared previously (see Section 3.4.2). 3.16 was converted to its triflate 4.1 in 78% 
yield by treating with Tf2O (1.2 eq) and pyridine. The crucial Heck coupling of 4.1 
with 4-buten-1-ol was then tested and it was found to give a mixture of alcohols 4.11, 
4.12 as well as the aldehyde 4.13 (Scheme 4-4) in a ratio of ca 5:3:3 (by 1H NMR 
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spectroscopy). These results indicated that the double bond of the coupled product 
4.11 must have migrated in the presence of the palladium catalyst. Indeed, similar 
double bond migrations under Pd catalysis conditions have also been reported by Tan 
et al.144  
 
Scheme 4-3. Synthesis of trans-enamide 4.8a 
 
 
a Reagents and conditions: (a) acetone, TFA (1 eq), TFAA (3 eq), rt, 16 h, then reflux, 4 h, 63%; (b) 
MOM-Cl (1.1 eq), Et3N (2 eq), THF, 0 °C~rt, 6 h, 90%; (c) Tf2O (1.2 eq), pyridine (3 eq), DCM, 0 ºC 
~rt, 3 h, 78%; (d) i) 4-buten-1-ol , Pd2(dba)3 (4mol%), iPr2NEt, DMF, 90 °C, 2 h; ii) 10% Pd/C, H2, 
EtOAc, rt, 16 h; iii) NaBH4 (5 eq), MeOH, rt, 1 h, 90% in 3 steps; (e) (PhO)2PON3 (1.7 eq), DIAD (1.7 
eq), PPh3 (2 eq), THF, rt, 18 h, 82%; (f) (S)-4-penten-2-ol, NaH (8 eq), THF, 0 °C, 77 %; (g) PPh3 (2 
eq), H2O (4 eq), THF, rt, 16 h, then acetic acid, 76%; (h) Crotonyl chloride (1.2 eq), TEA (3 eq), DCM, 
-15 °C, 1 h, 78%; (i) Grubbs II (20 mol%), DCM, reflux, 8 h, 60%; (j) 2N HCl/MeOH/DCM (1:4:1), 
50 °C, 8 h, quantitative yield. 
 
Scheme 4-4. Heck coupling of 4.1 with 4-buten-1-ol 
 
   Chapter 4   
73 
 
To avoid this problem, the TBS protected 1-buten-4-ol was used to couple 
with triflate 4.1 (Scheme 4-5). However, the rearranged by-product 4.15 was still 
observed albeit in an improved ratio. Taking consideration the number of steps for 
TBS protection and deprotection, this route is as inefficient as the previous one that 
utilised unprotected alcohol. Subsequently the synthesis of 4.2 was achieved via a 2-
pot, 3-step reactions that involved coupling, hydrogenation and reduction. The desired 
compound 4.2 was obtained in 90% overall yield (Scheme 4-3).  
 
Scheme 4-5. Heck coupling of 4.1 with TBS-protected 4-buten-1-ol 
 
With the intermediate 4.2 in hand, it was converted to the azide 4.3 using 
diphenylphosphoryl azide under Mitsunobu conditions in 80% yield. 
Transesterification of 4.3 with (S)-4-penten-2-ol (4.10) using NaH as a base led to 
concomitant phenol deprotection upon acidic work up, providing ester 4.4 in 77% 
yield. The azido group in 4.4 was reduced to the corresponding amine in the presence 
of triphenylphosphine and water. As isolation of the free amine was difficult due to its 
high polarity, the amine was converted to the acetate salt 4.5 which was successfully 
isolated and used in the next step without further purification. Compound 4.5 was 
acylated with crotonyl chloride in the presence of Et3N at -15 °C to give crotonamide 
4.6 without affecting the phenolic group. Ring-closing olefin metathesis of 4.6 using 
Grubbs II catalyst gave the desired trans-enamide 4.7 as the sole isolated product in 
60% yield. The trans-olefin bond configuration of 4.7 was confirmed by the coupling 
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constant of 15.2 Hz between the α-H and β-H on the α,β-unsaturated carbonyl group 
in 1H NMR spectrum. Final deprotection of the MOM group on 4.7 under acidic 
conditions accomplished the synthesis of the first trans-enamide RAL analogue 4.8. 
Similarly, the intermediate 4.5 was acylated with metacryloyl chloride to 
provide the corresponding amide 4.16. The yield of 4.16 was lower (31%) than that of 
4.6 due to the formation of an unknown by-product. Analysis of the 1H NMR 
spectrum of this by-product indicated that the substrate metacryloyl chloride is likely 
to have undergone partial polymerization. Compound 4.16 was cyclized under RCM 
conditions as described for 4.7 to provide enamide 4.17  which was deprotected of the 
MOM protecting group to give the α-methyl substituted enamide 4.18 (Scheme 4-6). 
 
Scheme 4-6. Synthesis of trans-enamide 4.18 
 
 
4.2.3 Synthesis of cis-enamides 
4.2.3.1 Attempted synthesis of cis-enamides via photo-isomerization  
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The initial plan to access the cis-enamide analogue 4.19 from the trans-
enamide 4.8 was to utilize a photoisomerization method reported for a RAL 
compound 4',5'-deoxy L-783,277 (Scheme 4.7)143.  
 
Scheme 4-7 Reported trans to cis photo-isomerisation to 4',5'-deoxy L-783,277143  
 
 
Various conditions for the photo-isomerization of 4.8 were attempted (Table 
4-1). The reactions were carried out in deuterated solvents and monitored directly in 
NMR tube or aliquots were removed from reactions carried out in quartz vial 
irradiated under two wavelengths at 365 and 254 nm respectively. Reactions carried 
out using 365 nm wavelength (Entry 6 – 8) remained unchanged whereas those with 
254 nm wavelength resulted in decomposition of the starting materials despite the 
observation of minor cis-olefinic signals for entries 1 and 3 by 1H NMR spectroscopy. 
From the observations above, it was concluded that photoisomerization is not suitable 
for the isomerization of enamide 4.8, possibly due to the presence of the nitrogen lone 
pair of the amide functionality which may stabilize the conjugated trans double bond.      
 
Table 4-1. Attempted photo-isomerization conditions of 4.8 to cis-enamide 4.25a 
 




Conditions  Result  
1  UV 254 nm, CDCl3 in NMR tube, 16 h Minor conversion (cis : trans < 1:5)  
2  UV 254 nm, CDCl3 in quartz vial, 16 h  Starting material decomposed  
3  UV 254 nm, MeCN-d3 in NMR tube, 3 h  Minor conversion (cis : trans < 1:10)  
4  UV 254 nm, MeCN-d3 in NMR tube, 16 h  Starting material decomposed  
5  UV 254 nm, CDCl3 in quartz vial, 2 h  Starting material decomposed  
6 UV 365 nm, CDCl3 in NMR, 16 h  No reaction, starting material only 
7 UV 365 nm, MeCN-d3, NMR tube, 16 h  No reaction, starting material only 
8 
9-fluronene (sensitizer), UV 365 nm, CDCl3 in 
quartz vial, 16 h 
No reaction, starting material only 
 
4.2.3.2 Alternative synthesis of cis-enamides by selective alkyne hydrogenation 
In light of the unsuccessful photo-isomerization of trans-enamide, an 
alternative approach was required to access the cis-enamide analogues. It was 
envisioned that the cis-enamide RAL (e.g. 4.25a) (Scheme 4-8) could be accessed by 
cis-selective Lindlar hydrogenation of alkyne 4.22 followed by macrolactonization 
reaction. The cyclization precursor 4.22 could be synthesized via amide coupling of 
4.21 and 4.20, whilst the acid fragment 4.20 can be derived from ethyl propiolate and 
(S)-propylene oxide. 
    
Scheme 4-8. Retrosynthesis of cis-enamide RAL 4.25a based on cis-selective alkyne 
hydrogenation 





The chiral acid fragment (S)-5-hydroxyhex-2-ynoic acid 4.20 was prepared 
from ethyl propiolate and (S)-propylene oxide following literature procedures 
(Scheme 4-9).145 The reaction involved the deprotonation of terminal alkyne followed 
by nucleophilic attack of alkyne carbanion to the Lewis acid activated epoxide. The 
reaction provided the required ester 4.19 in 72% yield after optimization of conditions. 
Subsequent saponification by 2 N sodium hydroxide and acidification afforded acid 
4.20 in 77% yield (Scheme 4-9).  
 
Scheme 4-9. Synthesis of acid 4.20 
 
 
Differing from the reaction in Scheme 4-3, azide 4.3 was firstly reduced to its 
corresponding amine 4.21 under the same conditions as before, which then underwent 
the amide coupling with acid 4.20 using the common coupling reagents EDCI/HOBt 
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to give 4.22 in 75% yield (Scheme 4-10). It is noteworthy that the free secondary 
alcohol of 4.20 is not affected during coupling. The hydrogenation of 4.22 using 
Lindlar catalyst in the presence of 1 equivalent of quinoline (suppressor of the Lindlar 
catalyst) gave the desired enamide 4.23a with the cis stereochemistry within an hour. 
The cis geometry of the double bond was confirmed by the presence of a coupling 
constant of 11.6 Hz typical of cis-olefinic protons. It was found that when reactions 
were carried out with less quinoline (e.g. ≤0.5 equiv) and longer reaction time, over-
reduced compound 4.23b was obtained as the main product. Both products (4.23a and 
4.23b) were subjected to base-catalysed ring closing transesterification to give 
compounds 4.24a and 4.24b. Both were treated with dilute HCl to deprotect the 
MOM groups to afford the final products 4.25a and 4.25b.  
 
Scheme 4-10. Synthesis of cis-enamide 4.25a and amide 4.25b.a  
 
a Reagents and conditions: (a) PPh3 (2 eq), H2O (4 eq), THF, rt, 24 h, 89%; (b) (S)-5-hydroxyhex-2-
ynoic acid, EDC.HCl (1.3 eq), HOBt (1.3 eq), iPr2NEt (3 eq), DMF, rt, 24 h, 75%; (c) H2, 5% 
Pd/CaCO3 (2 mol%, Pb posioned), quinoline (1.1 eq), EtOAc, rt, 30 min, 80%; (d) NaH (5 eq), 
THF/DMF, rt, 1.5 h, 35 - 75%; (e) 2N HCl, MeOH, 50 °C, 4 h, 67% - 83%. 
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The analogue 4.30 was designed to mimic LL-Z-1640-2 which has an olefin 
motif at the 1',2' position. Based on the same synthetic strategy described above, 1',2'-
unsaturated  analogue 4.30 was synthesized utilizing the unsaturated alcohol 4.11 
prepared previously (Scheme 4-11). In brief, the amine 4.26 was achieved by 
Mitsunobu substitution of the primary alcohol of 4.11 with an azide which was then 
reduced to amine without purification of the azide intermediate. Subsequent amide 
coupling followed by Lindlar hydrogenation afforded cis-olefin 4.28 efficiently. Ring-
closing reaction via transesterification followed by MOM deprotection gave the 
desired 1',2'-olefinic enamide 4.30.     
 
Scheme 4-11 Synthesis of cis-enamide 4.30.a 
 
 
a Reagents and conditions: (a) i) (PhO)2PON3 (1.7 eq), DIAD (1.7 eq), PPh3 (2 eq), THF, rt, 1 day; ii) 2. 
PPh3 (2 eq), H2O, THF, rt, 16 h, 30% in 2 steps; (b) 4.20, EDC (1.3 eq), HOBt (1.3 eq), iPr2NEt (3 eq), 
DMF, rt, 1 day, 31%; (c) H2, 5% Pd/CaCO3 (2 mol%, Pb posioned), quinoline (1 eq), EtOAc/MeOH, 
80%; (d) NaH (5 eq), THF/DMF, 0 - 10 °C, 4 h, 52%; (e) 2N HCl, MeOH, 50 °C, 4 h, 93%. 
 
4.2.3.3 X-ray structures of compounds 4.25a and 4.30 
 The structures of cis-enamide 4.25a and 1',2'-olefinic cis-enamide 4.30 were 
further determined by the analysis of their X-ray crystal structures (Figure 4-6a, b). 
Superimposition of the two crystal structures showed that their geometries are very 
similar, with only a slight twist between the 1',2'-single bond of 4.25a and the 1',2'-
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double bond of 4.30 (Figure 4-6c). In general, the C1' and C10' of the macrocycle are 
located at the same plane of the resorcyclic ring (Figure 4-6d), whereas the other 
portion of the macrocylic ring (i.e., C2' to C9') bends down to a nearly 90 degree 
angle. The C10'-methyl faces up as the S configuration, and the 7',8'-olefinic bond is 
shown as the cis configuration as expected. 
 










4.2.4 Synthesis of N-acetylated enamide analogues  
 During the course of preliminary structure-activity relationship studies, it was 
envisioned that N-acylation of an enamide would increase the electrophilicity of 
enamide thereby enhancing its potency as a covalent inhibitor. To prepare N-acyl 
(a) ORTEP structure of 4.25a (b) ORTEP structure of 4.30 
(c) Superimposition of 4.25a and 4.30 - 1 (d) Superimposition of 4.25a and 4.30 - 2 
   Chapter 4   
81 
 
enamides, the 2-phenolic group of 4.24a was firstly protected as its MOM ether (4.31) 
in 93% yield (Scheme 4-12).  
 




a Reagents and conditions: (a) MOM-Cl (1.5 eq), NaH (4 eq), THF, 0 °C, 1.5 h, 93%; (b) LDA (2.5 eq), 
Ac2O (2 eq), -78 °C, 1 h, 59%; (c) 1M TFA, DCM, rt, 1 h, 70%;  (d) BCl3 (0.16M), -10 - 0 °C, 2 h. 
 
Table 4-2. Screening of conditions for the N-acetylation of 4.31. 
Entry  Conditions  Result  
1  NaH , AcCl, 0 ºC  to rt, 16 h  Unknown by-product (polar )  
2  NaHMDS (4 eq) , AcCl, 0 ºC  to rt, 16 h  
Mixture of same unknown and starting 
material 4.31.  
3  tBuOK, AcCl, 0 ºC  to rt, 16 h  No reaction, 4.31 was recovered  
4  MgBr2.OEt2, Et3N, Ac2O, rt, 6 h  
No reaction after 3 h, then add more reagents 
to give MOM-deprotected product  
5  LDA (8 eq), Ac2O (8 eq), -78 ºC, 30 min  
4.32 obtained in 49% yield, with by-product 
4.32a in 16%.  
6 LDA (2.5 eq), Ac2O (2 eq), -78 ºC, 30 min 
4.32 obtained in 59%, with by-product 4.32a 
in 9%. 
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 Several conditions for N-acetylation on 4.31 (Table 4-2) were attempted, but 
only the conditions using LDA as base and acetic anhydride as the acetylating reagent 
provided the desired N-acetyl compound (Entry 5, 6). Optimized conditions by adding 
LDA and acetic anhydride portionwise at -78 °C  provided the best yield of 4.32 in 59% 
yield with a by-product 4.32a obtained in 9% yield due to acylation at the α-carbon of 
the acetyl group (Entry 6). The bis-MOM deprotection of 4.32 was attempted under 
several conditions. When the reactions were carried out in MeOH in the presence of 
either TFA or dilute HCl, the by-products 4.36 and 4.37 were obtained but no desired 
product 4.34 was detected. However, when 4.32 was treated with 1M TFA in dry 
DCM for a short period of time (30 min), selective deprotection of MOM group at the 
C-2 position occurred, providing the mono-MOM product 4.33 in 70% yield. 
Compound 4.33 has the desired N-acetyl functionality as well as the 2-phenol motif 
for the SAR study, and therefore is a potential compound to be tested for MNK 
inhibition. In order to obtain desired compound 4.34, alternative deprotection 
conditions was sought. When a strong Lewis acid BCl3 was used as the deprotection 
reagent, a 3:5 mixture of N-acetyl cis- and trans-enamide (4.34) and (4.35) was 
obtained, most likely caused by the acid-catalyzed isomerization of the cis-enamide. 
This mixture was separated by preparative HPLC to afford pure 4.34 and 4.35 for 
biological studies. 
4.2.5 Synthesis of 4-methoxy enamide analogues 4.45 and 4.48. 
To expand the diversity of compounds for biological studies, analogues 4.45 
and 4.48 were obtained to mimic the 4-methoxy resorcylic ring of L-783,277 
(Scheme 4-13). Starting from 4-methoxy phenol 4.38, compound 4.45 was 
synthesized in seven linear steps based on the same method established before 
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(Schemes 4-3 and 4-11). The synthesis of N-acetyl analogue 4.48 was then 
accomplished in three more steps from 4.45 using the method established previously 
(see Scheme 4-12). The final deprotection of the MOM group at C-2 was easily 
achieved using TFA.  
 
Scheme 4-13 Synthesis of 4-methoxy enamides 4.45 and 4.48 
 
a Reagents and conditions: (a) Tf2O (1.2 eq), pyridine (4 eq), DCM, 0 °C ~rt, 3 h, 91%; (b) i) 4-buten-
1-ol , Pd2(dba)3 (4mol%), iPr2NEt, DMF, 90 °C, 2 h; ii) 10% Pd/C, H2, EtOAc, rt, 16 h; iii) NaBH4 (5 
eq), MeOH, rt, 1 h, 91% in 3 steps; (c) (PhO)2PON3 (1.7 eq), DIAD (1.7 eq), PPh3 (2 eq), THF, rt, 18 h, 
60%; (d) PPh3 (2 eq), H2O, THF, rt, 18 h, 80%; (e) 4.20, EDC (1.3 eq), HOBt (1.3 eq), iPr2NEt (3 eq), 
DMF, rt, 1 day, 63%; (f) H2, 5% Pd/CaCO3 (2 mol%, Pb posioned), quinoline (1.1 eq), EtOAc, 30 min, 
76%; (g) NaH (5 eq), THF/DMF, 0 °C to rt, 5 h, 51%; (h) MOM-Cl (1.5 eq), NaH (4 eq), THF, 0 -
10 °C, 3 h, 94%; (i) LDA (3 eq), Ac2O (2.5 eq), -78 °C, 40 min, 25%; (j) 1M TFA, DCM, rt, 3 h, 38%. 
 
4.2.6 Synthesis of 3'-hydroxy enamide RAL 4.62 and 4.64 
 To further extend analogue diversity, RAL analogues bearing a 3'-hydroxy 
substitution on the macrocycle (4.62 and 4.64) were also synthesized. It was 
hypothesized that this hydroxyl group would mimic one of the hydroxyl group present 
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in the natural product L-783277 or LL-1460-2, and may enhance the binding affinity 
to the kinase. The synthesis of such analogues required the preparation of the key 
intermediate 4.54.  
 The synthesis of 4.54 began with the commercially available diacetonide 
protected D-mannitol (4.49) (Scheme 4-14), which underwent oxidative cleavage to 
give the D-glyceraldehyde acetonide (4.50).146 Subsequent Wittig reaction following 
literature procedures147 gave the olefin 4.51 which was used in the next step without 
purification. After deprotection of acetonide group using TFA, the diol 4.52 was re-
protected as its bis-TBS ether 4.53 in a 58% overall yield in three steps. The TBS 
group on the primary alcohol of 4.53 was then selectively removed using pyridinium 
tribromide148 to give the desired compound 4.54 in 43% yield.  
 
Scheme 4-14. Synthesis of intermediate compound 4.54a  
 
a Reagents and conditions: (a) NaIO4, DCM, Sat NaHCO3, rt, 2 h, 89%; (b) MeP+Ph3Br-, n-BuLi, THF, 
-78 °C to rt, 20 h; (c) TFA (4 eq), MeOH/H2O, rt, 2 h; (d) TBSCl (3 eq), imidazole (5 eq), DCM, 0 °C 
to rt, 16 h, 58% in 3 steps; (e) pyridiumn tribromide, MeOH/DCM, 0 °C-rt, 4 h, 43%. 
 
 The Heck reaction of the O-TBS protected butene 4.54 with triflate 4.1 was 
initially carried out at 100 °C to give only 29% yield of the desired product 4.55. The 
low yield was likely due to the volatility of the alkene 4.54 under open-heating 
conditions. The reaction was then carried out in a sealed tube, which improved the 
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yield to 38% after further optimization of conditions by changing the base from 
bicyclohexylmethylamine to diisopropylethylamine (Scheme 4-15). Although the 
improvement of yield was not significant, the starting materials could be recovered 
and re-used, and sufficient 4.55 was obtained for subsequent synthesis. The remaining 
steps to complete the syntheses of compounds 4.62 and 4.64 were carried out in a 
similar fashion as before. Interestingly, under the same conditions for the deprotection 
of bis-MOM using BCl3, only the cis 3'-hydroxy enamide 4.64 was isolated.  
 
Scheme 4-15. Synthesis of 3'-hydroxy enamides 4.62 and 4.64a 
 
a Reagents and conditions: (a) 4.54, Pd2(dba)3 (4mol%), Cy2NMe, DMF, 100 °C, 15 h, sealed tube, 
38%; (b) (PhO)2PON3 (1.7 eq), DIAD (1.7 eq), PPh3 (2 eq), THF, rt, 18 h, 68%; (c) PPh3 (2 eq), H2O, 
THF, rt, 18 h, 85%; (d) 4.20, EDC (1.3 eq), HOBt (1.3 eq), iPr2NEt (3 eq), DMF, rt, 1 day, 73%; (e) H2, 
5% Pd/CaCO3 (2 mol%, Pb posioned), quinoline (1.1 eq), EtOAc, 90 min, rt, quant yield; (f) NaH (5 
eq), THF/DMF, 0 -10 °C, 53%; (g) MOM-Cl (1.7 eq), NaH (4 eq), THF, 0 °C - rt, 2 h, 80%; (h) LDA 
(3 eq), Ac2O (2.5 eq), -78 ºC, 90 min, 49%; (i) 2N HCl, MeOH, 50 °C, 4 h, quant yield; (j) BCl3 (0.1M), 
-10 - 0 °C, 1 h, then TBAF, THF, rt, 2 h, 30%. 
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4.3 NMR studies of covalent interaction using cysteamine as a model compound 
In parallel to the synthesis work, the covalent binding ability of the 
synthesized enamide compounds were assessed by 1H NMR spectroscopy using 
cysteamine as a model compound to mimic the cysteine residues in the kinase.149 This 
approach monitors the disappearance of the characteristic olefinic protons by 1H 
NMR spectroscopy and enables rapid assessment of potential compounds as covalent 
kinase inhibitors. The natural product L-783,277 which is known as a covalent protein 
kinase inhibitor was used as positive control. When it was treated with cysteamine in 
DMSO-d6, rapid disappearance of the 7', 8' olefinic protons was observed within 5 
min (Figure 4-7a), indicating the formation of a covalent adduct. The synthetic 
analogue possessing a trans-enamide (i.e. 4.7), however, did not react with 
cysteamine in DMSO-d6, as there was no discernible changes observed in the 
1H 
NMR spectra even after 24 hours (Figure 4-7b). It was reasoned that a trans-enamide 
may not be reactive enough as a Michael acceptor to cysteamine. However, the cis-
enamide 4.25a did not react with cysteamine either (Figure 4-7c), suggesting that a 
cyclic enamide, regardless of olefin geometry, is not sufficiently reactive as a Michael 
acceptor. This is in contrast to the reported acyclic covalent kinase inhibitors having 
acrylamides as covalent traps.93 At this point, it was considered that by acylating the 
amide nitrogen, the electrophilicity of the enamide could be increased. Indeed, when 
acylated cis-enamide 4.33 was treated with cysteamine in DMSO-d6, rapid adduct 
formation (within 5 min) was observed by 1H NMR analysis (Figure 4-7d), 
characterized by the disappearance of the 7', 8' olefinic protons. Similar reactivity was 
also observed for both cis- and trans- N-acetyl enamides 4.34 and 4.35 (Figure S1a 
and S1b in Appendix), suggesting they could be cysteine covalent modifiers. The 
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enhanced reactivity of N-acyl enamides indicated that the electronic properties and the 
reactivity of enamides can indeed be tuned by introducing an electron-withdrawing 
group such as an acyl group onto the enamide nitrogen. 
It is noteworthy that all of the NMR analyses were carried out before the 
biological testing. In the following kinase inhibition study (Section 3.4), it was found 
that most compounds that can bond covalently with cysteamine (e.g., 4.33, 4.34), also 
display potent kinase inhibitory activities. The only exception is that observed for the 
trans-enamide 4.35, which showed lower kinase inhibitory activity than its cis isomer.  
 
Figure 4-7. 1H-NMR studies for the reactions of cysteamine with trans-enamide 4.7, 
cis-enamide 4.25a and N-acetyl enamide 4.33: No change was observed in 1H NMR 
spectra of 4.7 and 4.25a after 24 hours, whilst the 7', 8' olefinic protons of 4.33 and L-
783,277 disappeared after 5 min and not restored after 2 h, indicating the covalent 









d6  L-783,277 + cysteamine, after 5min  
L-783,277 + cysteamine, after 2 h 







4.4 Kinase inhibitory activities of enamide RAL analogues against MNK1/2  
The preliminary NMR studies suggested that N-acyl enamides could be 
promising covalent kinase inhibitors. The kinase inhibitory activities (IC50 values) of 
4.7  + cysteamine, after 2 h 
b). 
4.7  in DMSO-d
6 
 
4.7  + cysteamine, after 24 h 
4.33 + cysteamine, after 5min  
4.33 + cysteamine, after 2 h  
4.25a  + cysteamine, after 2 h 
4.25a  + cysteamine, after 24 h  
c). 





4.33 in DMSO-d6  
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the synthesized enamide RAL analogues (Figure 4-8) was determined against 
MNK1/2 in the IMAP enzymatic assay. In agreement with the NMR results, the N-H 
containing enamides 4.7, 4.8 and 4.25a were essentially inactive (IC50 >40 µM) 
against both MNK1 and MNK2 although the 1',2'-olefin analogue 4.30 has slightly 
improved activity (27.6 µM) against MNK2. In contrast, the N-acetyl compound 4.33 
showed remarkable improvement of its potency with IC50 value of 6.1 µM against 
MNK2 (Table 4-3). The drastic increase in potency is most likely due to a covalent 
modification of the protein as observed in the 1H-NMR studies (see Section 4.3) 
which was further confirmed by protein mass spectrometry analysis (see Section 4.6).  
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Table 4-3. IC50 values (µM) of synthetic enamide RAL analogues against MNK1 and 
MNK2.a,b,c  
Kinase 4.25a 4.30 4.33 4.34 4.35 4.48 4.64 
MNK2 41.7±1.2 27.6±11.7 6.1±1.4 1.3±0.1 34.0±3.5 4.1±0.1 34.7±3.5 
MNK1 >50 >50 15.9±3.5 8.9d >50 11.6±0.3 >50 
a All other compounds in Figure 4-8 have IC50 values > 50 µM against both MNK1 and 2.  
b Measurements were carried out in duplicate unless otherwise stated.  
c L-783,277: IC50 0.061±0.005 µM (MNK2) and 0.325±0.109 µM (MNK1). 
d Run once. 
 
The fully deprotected compound (4.34) showed further improvement in 
potency with IC50 values of 1.3 M and 8.9 M for MNK 2 and MNK1 respectively 
(Table 4-3), suggesting a positive interaction of the 4-hydroxy of 4.34 with the 
binding site. The trans- analogue 4.35, however displayed a much lower potency of 
ca 30 fold (for MNK2). Although both NMR (see supporting information) and protein 
mass analysis of trans-isomer 4.35 indicated it is a covalent modifier, the much 
weaker potency suggested its conformation is unfavorable for binding to the kinase. 
Here it should be noted that NMR study using cysteamine is not a direct tool to reflect 
the covalent binding ability in the protein. The significant difference in biological 
activities between the cis- and trans-isomers of a RAL compound has also been 
reported previously.65, 66 This difference indicates that the potency of a covalent 
inhibitor is governed by both its covalent binding ability and stereochemical 
interactions at the binding site. Methylation of the 4-phenol group (compound 4.48) to 
mimic the resorcylic portion of the natural products did not show further improvement 
in potency. Instead, its activity is marginally reduced as compared to 4.34 (IC50 4.1 
M vs 1.3 M against MNK2).  
To further improve the potency of enamide RAL, a 3'(S)-hydroxy group was 
introduced onto the macrocyclic ring to mimic the natural product (e.g. L-783,277 and 
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LL-Z1640-2). Compounds 4.62 and 4.64 were synthesized for this purpose. Upon 
testing, the presence of the 3'(S)-hydroxy group did not improve activity, but instead, 
resulted in significant reduction of activity when comparing 4.62 with 4.30 (IC50 >50 
µM vs 27.6 µM), and 4.64 with 4.34 (IC50 34.7 µM vs 1.3 µM). This result suggests 
that the 3'(S)-hydroxy group occupies an undesirable position in the binding site of the 
enzyme. A docking study for 4.64 carried out subsequently showed that the 3'(S)-
hydroxy group may clash with the phenol ring of the F159 residue located in the 
upper hydrophobic portion of the binding site (see Section 4.8). In addition, protein 
mass analysis of 4.64 showed that it does not form covalent adduct with MNK1/2 
proteins (see Section 4.6).  
The positive control L-783,277 remains the most potent inhibitor with an IC50 
value of 0.179 µM for MNK2 and 0.256 µM for MNK1. In general, all the test 
compounds showed more potent inhibitory activities against MNK2 than MNK1. This 
is also reflected in the MNK1/2 activities of aigialomycin D as discussed in Chapter 3. 
The different levels of MNK1/2 inhibition by the RAL compounds could be explained 
by their structural differences.110, 116 Although there is about 80% sequence alignment 
between MNK1 and MNK2, it has been shown that the N-terminal lobe of MNK2 tilts 
by approximately 10 degrees as compared to MNK1, making the kinase binding 
pocket slightly more open to accommodate ATP or a small molecule inhibitor.110 
Such structural differences could lead to their different levels of inhibition by small 
molecule inhibitors.  
4.5 In vitro studies on Ser209 phosphorylation of eIF4E by MNK1/2  
As noted in Chapter 3, MNK1/2 are known to phosphorylate serine 209 of 
eIF4E, which is a key component of the eIF4F complex that promotes translation 
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initiation in mammalian cells.112, 117 It was found that Ser209 phosphorylation of 
eIF4E is not essential for the activity of eIF4E in normal cells but is required in cancer 
cells. Therefore inhibition of Ser209 phosphorylation of eIF4E by MNK1/2 is 
believed to be one of the methods to target cancers.122  
Here, the enamide RAL analogues were assessed for their in vitro inhibition of 
phosphorylation of eIF4E in HeLa cells. This assay was initially conducted at the 
concentration of 10 µM of inhibitors. From this study, compounds 4.34 and 4.48 were 
identified as the most potent compounds with 90.4% and 79.4% inhibition 
respectively (Table 4-4), in good agreement with the results from the enzymatic assay 
on MNK2. The IC50 values of these two compounds were further determined on 
eIF4E phosphorylation and were shown to be 1.6 µM and 4.7 µM respectively. These 
results confirmed that the target inhibition by 4.34 and 4.48 was effective in both 
biochemical and cellular assays.  
Table 4-4. Percentage inhibition (10 µM) and IC50 values for the phosphorylation of 
Ser209 on eIF4E in HeLa cells. 
Compoundsa 4.25a 4.33 4.34 4.35 4.48 4.64 
% Inhibition 
at 10 µM 
3.4 44.6 90.4 28.8 79.4 51.2 
IC50 (µM) NDb ND 1.6 ND 4.7 ND 
a Other synthetic compounds have no inhibition at 10 µM. b Not determined. 
 
4.6 Protein mass spectrometric analysis for the study of covalent modification of 
MNK1/2 
In order to confirm the covalent binding of the active enamides to the target 
kinases, protein mass spectrometry studies were carried out. This was investigated by 
incubating MNK1 or MNK2 respectively with the enamides followed by protein mass 
spectrometric analysis. MNK2 and MNK1 have mass peaks at 35888.83 and 34701.87 
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respectively. As shown in Figure 4-9 (a, b), when the reference natural product L-
783,277 was incubated with MNK2 and MNK2 individually, the peaks of the 
protein/ligand adducts were both observed at 36253.27 and 35066.33 respectively. 
Similar protein/ligand adducts were also detected for N-acetyl enamide 4.33, with 
peaks of MNK2/ligand adducts at 36296.31 and MNK1/ligand adduct at 35106.85 
respectively (Figure 4-9 c, d). The results confirmed that indeed L-783,277 and the 
N-acetyl enamides (4.33 – 4.35) covalently react with MNK1 and MNK2. On the 
contrary, the free N-H containing enamides (4.8, 4.25a) did not form detectable 
adducts, in agreement with both NMR studies (Section 4.3) and bioassay results 
(Section 4.4). This finding further confirmed that unlike those known acyclic 
acrylamide-based covalent inhibitors, the cyclic N-H enamides do not possess 
covalent binding abilities towards MNK1/2 kinases.  
It is interesting to note that unlike 4.34, 3'-hydroxy enamide 4.64 does not 
react covalently with MNK1/2 despite the presence of the N-acetyl group. This is in 
consistent with the bioassay result that 4.64 has much lower inhibitory activity than 
4.34 (IC50 34.7 µM vs 1.3 µM).  
 
Figure 4-9. Mass spectra of MNK1/2 incubated with L-783,277 and 4.33 showing 
covalent adduct formation. 
 












(MNK1) 35106.85 (MNK1 + 4.33) 
36296.31 (MNK2 + 4.33) (MNK2 ) 
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4.7 Time-dependent kinase inhibition assay 
The irreversibility of MNK2 inhibition by compounds 4.34 and 4.48 was 
further verified in a time-dependent assay (Figure 4-10). The compounds were pre-
incubated with MNK2 at two concentrations and the kinase activities were monitored 
at different time points. The results showed that both 4.34 and 4.48 (each at two 
concentrations) reduced the MNK2 activity linearly (expressed as the fluorescence 
polarization reading) as incubation time increased (5, 10, 20 and 40 min.). This is a 
known characteristic of irreversible inhibition.150  
 








4.8 Kinase profiling of compound 4.48 
In order to explore other potential kinases as targets in the cells, kinase 
profiling for N-acetyl enamide 4.48 was performed. Fifty kinases were screened (see 
full list of percentage inhibition in Appendix Table-4 and selectivity score in 
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hypothemycin that have conserved cysteine residues next to DFG motifs. Targets of 
aigialomycin D (identified also by kinase profiling as stated in Chapter 2) are also 
included in the profiling. It is interesting to find that besides MNK2 which is inhibited 
at 28% of DMSO control (the results are comparable to our test results with IC50 at 
4.1 M), four other kinases (FLT3, KIT, PDGFR-β, MEK4) and their mutants are 
inhibited with higher potency (Table 4-5 and Figure 4-11), with all of them falling 
into the category of targets of cis-enone RAL. Selected targets were further assessed 
for their Kd values (Table 4-5). In particular, FLT3 and its mutants (ITD, D835H), 
KIT and its mutant (V559D) which are all targets of AML (acute myeloid leukemia), 
are inhibited at nanomolar to sub-micromolar range (Kd 0.7 – 2.0 µM). Other tyrosine 
kinases like PDGFR-β and MEK4, which are the downstream signaling kinases of 
FLT3/KIT, are also inhibited at 1.6 and 2.4 µM respectively. Compound 4.48 also 
showed good selectivity. Of 50 kinases tested, 15 kinases were inhibited below 35% 
of negative control and 6 kinases were inhibited below 10% of control, and their 
selectivity scores are 0.23 and 0.11 respectively (Figure 4-11).    
These results showed that enamide RAL 4.48 potently inhibits some kinases 
within the group of cis-enone RAL targets, notably the kinases involved in leukemic 
diseases, with good selectivity.     
 
Table 4-5. Selected kinases with inhibition ≤ 35% control by 4.48a and their Kd 
values 




KIT  KIT 
(V559D) 
MEK4 PDGFR-β MNK2 
%Controla 1.8 15 9.4 18 7 8.1 6.4 28 
Kd (M) 0.7 0.44 1.6 nt
b 2.0 2.4 1.6 ntb 
a Determined at 10 µM with DMSO as a negative control. A lower value indicates a stronger inhibition. b Indicate 
“not tested, IC50 = 4.1 M”. 
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Figure 4-11. Kinase treespot of 4.48 showing the distribution of kinases inhibited 




4.9 Cancer cell anti-proliferative activities 
 Four of the most potent N-acetyl enamides were tested for their anti-
proliferative activities in four cancer cell lines, benchmarked to the natural product L-
783,277 (Table 4-6). The results showed these RAL enamide analogues are selective 
for cancer cell lines and 4.48 is most effective for MDAMB435s (human breast 
cancer) (GI50: 8.5 µM), comparable to the natural product L-783,277 (GI50: 7.5 µM). 
4-O-Methylated analogue (4.48) is more active than the 4-phenol compound (4.34). 
Apart from MDAMB435s, some of the compounds also showed moderate activities 
against K562 and HeLa cell lines but are all largely inactive against the lung cancer 
cell line A549 including the natural product L-783,277. It is encouraging that 
although our synthetic analogues are weaker in the kinase inhibition assay (e.g. 
against MNK2) when compared to L-783,277 (Table 4-3), they have similar levels of 
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In addition, it is interesting to note that unlike the kinase inhibitory studies (Section 
4.6), both the cis and trans N-acetyl enamides (4.34 and 4.48) are active at the cellular 
level although 4.48 is slightly less potent in MDAMB435s and K562 cells. This is 
again in agreement with the reported cytotoxicity of natural cis/trans-enone RALs for 
which the cis and trans isomers show similar cellular activities.151 
 
Table 4-6. GI50 (µM) for anti-proliferative activities of RAL enamides against 
several cancer cell lines.a  
Cell line 4.33 4.34 4.35 4.48 L-783,277 
MDAMB435s 
(breast cancer) 
12.8±1.3 18.5±0.4 25.0±1.5 8.5±1.1 7.5b 
HeLa  
(cervical cancer) 
>50 >50 35.1±0.1 38.8±1.2 40.7±0.7 
K562 (leukemia) 31.4±0.3 19.5±0.1 29.5±0.2 10.1±0.01 ntc 
A549 (lung cancer) >50 >50 >50 >50 >50 
a Measurements were carried out in duplicate unless otherwise stated. b Run once only. c Not tested. 
 
4.10 Summary 
In summary, we have developed a group of novel resorcylic acid enamide 
analogues as covalent MNK1/2 kinase inhibitors by incorporating the privileged RAL 
scaffold and the acrylamide motif as a Michael acceptor to cysteine residues in 
protein kinases. It is significant to find that unlike those well-known acyclic 
acrylamide-based covalent inhibitors, the macrocyclic enamides with free N-H, are 
not sufficient Michael acceptors for covalent binding. However, by tuning the 
reactivity of the enamide by N-acylation, the covalent binding ability to MNK2 was 
successfully gained. This led to the discovery of RAL-based enamides 4.34 and 4.48 
that show highly promising inhibitory activities against MNK1/2 as covalent 
inhibitors. In the context of this study, we have also demonstrated that 1H NMR 
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spectroscopy is a convenient and effective tool for the screening of the covalent 
binding reactivity of the enamide using cysteamine as a mimic of the key cysteine 
residue in the enzyme while mass spectrometry analysis serves to confirm covalent 
modification of the kinases. More importantly, these easily accessible novel RAL 
analogues are as potent as the natural product L-783,277 in the growth inhibition of 
cancer cell lines. In short, the strategy of incorporating an enamide motif into a 
macrocyclic structure and tuning its activity electronically has the potential to be 
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Chapter Five De Novo design, synthesis and biological evaluation of covalent FLT3 
inhibitors based on a resorcylic acid core  
5.1 Overview of FLT3 kinase and its inhibitors 
5.1.1 FMS-like tyrosine kinase 3 (FLT3)  
FMS-like tyrosine kinase 3 (FLT3), also termed fetal liver kinase-2 (FLK-2) 
or stem cell kinase-1 (STK-1), is a member of the type III/PDGFR subfamily of 
receptor tyrosine kinases (RTKs) consisting of PDGFR-α/β, FMS, and KIT. FLT3 is 
primarily expressed in hematopoietic progenitor cells152, 153 and mainly found in 
lymphohematopoietic organs such as the liver, spleen, thymus and placenta.154  
FLT3 protein contains 993 amino acids and is visualized as a doublet band on 
electrophoretic gels, consisting of a mature (glycosylated) form and an immature 
form.155 Structurally, FLT3 is composed of four domains, including an 
immunoglobulin-like extracellular ligand-binding domain, a transmembrane domain, 
a juxtamembrane domain, and a highly conserved intracellular kinase domain (Figure 
5-1). The kinase domain is interrupted by a short hydrophilic insert sequence.104, 156 
The juxtamembrane domain is capable of negatively regulating the tyrosine kinase 
activity, and mutations within this region can disrupt its negative regulatory functions. 
The major mutation of FLT3, called internal tandem duplication (ITD), occurs in this 
juxtamembrane domain. 
The activation of FLT3 in normal function relies on a FLT3 ligand (FL).157 In 
unstimulated state, FLT3 receptor exists as an unphosphorylated monomer with an 
inactive kinase moiety. Upon interaction with FLT ligand, the receptor undergoes a 
conformational change in its activation loop, allowing ATP to access its active site. 
Phosphorylation of monomer FLT3 results in receptor-receptor dimerization, which 
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act as the prelude to the activation of the tyrosine kinase enzyme, leading to 
phosphorylation of various sites in the intracellular domain156 (Figure 5-1). The 
activated FLT3 receptor recruits a number of proteins in the cytoplasm to form a 
complex of protein-protein interactions in the intracellular domain. SHC proteins, 
GRB2, GRB2-associated binder 2 (GAB2), SHIP, CBL, and CBLB (CBLB-related 
protein) are a few of the many adaptor proteins that interact with the activated FLT3 
receptor.158-160 As each protein binds to the complex, it becomes activated in turn, 
resulting in a cascade of phosphorylation reactions that culminates in activation of a 
number of secondary mediators, including MAP kinase, STAT, and AKT/PI3 kinase 
signal transduction pathways. Once activated, these activated mediators are 
chaperoned to the nuclear interphase by HSP90, in which the message is translocated 
to the nucleus. In the nucleus, these transcriptional mediators trigger a series of events 
culminating in regulation of cell differentiation, proliferation, apoptosis, and cell 
survival (Figure 5-1).156 
Figure 5-1. FLT3 signal transduction pathway156 
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Activation of FLT3 by FLT3 ligand is believed to play a critical role in 
governing normal hematopoiesis and cellular growth by regulating of a number of 
cellular processes (e.g., phospholipid metabolism, transcription, proliferation, and 
apoptosis).161 The majority of B-cell acute lymphocytic leukemia (ALL) and acute 
myeloid leukemia (AML) (>90%) express FLT3 at various levels.152 Other 
hematopoietic malignancies, including myelodysplasia (MDS), chronic myeloid 
leukemia (CML), T-cell ALL, and chronic lymphocyctic leukemia (CLL), also 
express FLT3 receptors although less frequently.  
Mutations leading to the constitutive activation of FLT3 receptor have been 
identified as the most frequent genetic disorder in AML.157 Studies in genomic 
alterations in FLT3 gene identified two distinct mutations - internal tandem 
duplication of the juxtamembrane domain (FLT3-ITD) and point amino acid 
mutations in the activation loop of the tyrosine kinase domain of the FLT3 (FLT3-
ALM or FLT3-TKD). FLT3-ITD mutation was first reported in 1996 in a polymerase 
chain reaction (PCR) screen of AML patients,162 and later on was identified in a high 
proportion of AML patients. These mutations are the result of a segmental duplication 
of a fragment within the juxtamembrane domain (JM) coding region (encoded by 
exons 14 and 15) of FLT3. Clinical studies have identified the FLT3-ITD mutation in 
15%–35% of AML cases in different ages of patients, representing highest frequency 
in FLT3 related AML cases. Such mutation also occur in CML (5–10%) and MDS 
(5–10%) patients.156 The ITD insertion generally occurs near the JM hinge region and 
may change the JM orientation thereby preventing autoinhibition of catalytic activity 
and disrupting its negative regulatory function, leading to constitutive tyrosine kinase 
activation.157 
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A second type of mutation of FLT3 is the activation loop mutation (ALM) 
located in the tyrosine kinase domain, mostly occurring at residue D835. The most 
prevalent mutation is D835Y, and others include D835V, D835H, D835E, and 
D835N.163 Mutations in other residues of the kinase domain have also been 
discovered, such as I836L+D, Y842C, N841I, N841Y, and I836D.105 These point 
mutations in the kinase domain are thought to induce a conformational change leading 
to the exposure of the kinase domain and uncontrolled activation.103 Although the 
constitutive receptor activation and ligand-independent proliferation caused by FLT3-
ALMs are similar to that of FLT3/ITD, they are believed to promote activation of 
different downstream effectors,164 and give rise to different biological responses.165 
FLT3-ALMs have been found in malignant cells from patients with AML (5–10%), 
CML (1%), ALL (1–3%), and MDS (2–5%).156  
5.1.2 Reported FLT3 inhibitors 
Due to the wide expression of FLT3 and its mutants in hematopoietic 
malignancies, and the implication of its roles in multiple tumorigenic pathways, FLT3 
is believed to be an effective candidate for targeted therapy particularly in the 
treatment of AML which has attracted intensive drug discovery efforts in recent 
years.104, 105, 156, 166, 167. Many FLT3 inhibitors have been reported in the literature, 
with at least ten of them being advanced to clinical trials by 2012 (Figure 5-2).168-171 
Representative examples of these clinical trial inhibitors include: CEP-701 
(Cephalon), which was identified via screening of chemical libraries for small 
molecules that inhibit FLT3;105, 172 MLN518 (CT53518-Millenium Pharmaceuticals), 
a piperazinyl quinazoline compound which is specific to the inhibition of PDGFR, c-
Kit and FLT3;105 PKC412 (Novartis Pharma AG), a staurosporine derivative 
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originally evaluated as a protein kinase C inhibitor105, 173 and later found to be a multi-
targeting kinase inhibitor including inhibition of both FLT3-ITD and FLT3-
D835Y;174-176 SU11248 (or Sunitinib, Pfizer, Inc.), which was originally developed as 
a VEGF receptor inhibitor, but was later shown to be active against the PDGF 
receptor as well as KIT and FLT3;105, 177, 178 and AC220 (or Quizartinib), which is 
probably the most potent and specific inhibitor of FLT3 currently in development for 
the treatment of AML.179, 180  
However, most of the above mentioned clinical candidates were not initially 
designed to target FLT3 and their resistance in AML patients have been observed.96, 
181 Moreover, many of these drug candidates are not sufficiently effective for the 
monotherapy of leukemia diseases.168, 182 Hence, the discovery and clinical 
development of novel FLT3 inhibitors with improved pharmacological properties and 
specificity, especially against the mutant enzymes, is still in great demand.  
 
Figure 5-2. FLT3 inhibitors in clinical trials 
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By virtue of recent advances in structural biology and computer-aided 
approach, more FLT3 inhibitors are currently under development. A notable example 
is VX-322, a recently developed dual FLT3/c-KIT inhibitor for the treatment of AML 
by Vertex Pharmaceuticals.168, 169 The diaminotriazole scaffold of VX-322 was 
discovered through screening of a library of compounds in Vertex, and was rapidly 
optimized with the help of molecular modelling to give VX-322 as a potent dual 
inhibitor of both FLT3 and c-KIT. VX-322 was cytotoxic against both FLT3 and c-
KIT expressing cell lines, but has no effect on cells that do not express FLT3/c-KIT 
kinases, thereby showing specificity. The dual inhibition function of VX-322 was 
proven to be more efficacious against primary AML blast cells in patient. Another 
typical example of using a rational design approach in developing FLT3 inhibitors 
was reported by Yang and co-workers.170, 183 Starting with a quinazoline core structure, 
a highly potent FLT3 inhibitor was developed using a restricted de novo design 
strategy, wherein the researcher examined the binding modes of all the known 4-
anilinoquinazoline-type inhibitor-kinase complexes available and identified their 
common features. Subsequent SAR studies in cell assays gave rise to a FLT3 inhibitor 
with good selectivity and potency both in vitro and in vivo.183 A third example is the 
development of SB1518 (Pacritinib) as a dual JAK2/FLT3 inhibitors for the treatment 
of myelofibrosis and lymphoma by a Singapore company S*Bio.171 The inventors 
developed this macrocyclic compound by connecting the two ends of a commonly 
used pyrimidine-based motif to circumvent the crowded patent issue, and this 
conformationally constrained macrocycle was able to interact with the active site 
residues of the target enzymes that are not easily approached with an acyclic structure.  
Apart from the above mentioned heterocyclic FLT3 inhibitors (Figure 5-2), 
cis-enone RAL natural products were also reported to be FLT3 inhibitors. For 
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example, hypothemycin has an inhibition constant (Ki) in the low nanomolar range for 
FLT3 and four other homologous kinases including MEK1, MEK2, FLT1, and 
KDR.43 As mentioned above, such RAL-based inhibitors are capable of forming 
covalent bonds with cysteine residues (corresponding to Cys166 in ERK2) adjacent to 
the conserved DFG motif within the ATP binding site of kinases. The unique 
structural features make RAL an attractive scaffold for the exploration as FLT3 
inhibitors.  
5.2 Hypothesis and objective 
From the kinase screening studies with our previously synthesized enamide 
RAL analogue 4.51 (refer to Chapter 4), it was found that this compound inhibits not 
only MNK1/2 but also FLT3 (IC50 = 0.7 µM). The latter kinase target is also inhibited 
by L-783,277 and hypothemycin (Figure 5-3).43, 67, 86 This observation evoked our 
interest in the context of developing simplified RAL derivatives as FLT3 kinase 
inhibitors for novel lead discovery and SAR studies. 
Figure 5-3. RALs containing a cis-enone Michael acceptor  
 
As mentioned above, cis-enone RALs inhibit a subset of kinases including 
FLT3 through covalent modification of a suitably positioned cysteine residue. It was 
rationalised that a resorcylic acid derivative bearing a ring-opened electrophilic trap 
linked via a spacer to C-6 of the resorcylic ring could similarly serve as a Michael 
acceptor to the desired cysteine residue of FLT3. This scaffold, when incorporated 
with a variety of substituents via the ester bond at C-1 position and at the C-4 position, 
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may provide FLT3 inhibitors with covalent binding ability. The objective of this work 
is to design and synthesize a series of simplified acyclic derivatives of RAL 
containing different types of Michael acceptors (e.g., acrylamide, vinylsulfonamide 
and maleimide) as potential covalent traps of cysteine at the binding site of FLT3. The 
potency and selectivity of the synthesized compounds towards FLT3 and its mutants 
(FLT3-D835Y, FLT3-ITD) will be evaluated at both protein and cellular levels. 
5.3 Design of covalent FLT3 inhibitors based on a β-resorcylic acid core 
Our strategy in the design of covalent FLT3 inhibitors is based on the β-
resorcylic acid core structure (Figure 5-4) in which the salicylic acid moiety is known 
to be critical in anchoring the ligand via H-bonding to the hinge region of the ATP 
binding site in structurally similar kinases, e.g., ERK2.60, 68, 86 A hydrophobic 
fragment (R2) would be linked to the core via an ester bond to enable interaction with 
the hydrophobic pocket II.30 A second fragment (R1) at position-4 of the phenyl ring 
would serve as a tunable group for improving the physicochemical properties. Most 
importantly, an electrophilic Michael acceptor (R3) would be linked via a spacer to 
position-6 of the core structure to enable covalent modification of the cysteine residue 
in the active site. Three types of covalent modifiers, i.e. acrylamide, vinylsulfonamide 
and maleimide, will be incorporated. Among these Michael acceptors, 
vinylsulfonamide and maleimide have not been widely explored as electrophilic 
warheads for cysteine residues. 
Figure 5-4. General structure of designed ring-opened RAL derivatives as FLT3 
inhibitors 
 




In order to carry out the docking study of ATP-competitive FLT3 inhibitors, 
an active form (or DFG-in form) FLT3 structure is needed so that the ATP binding 
pocket is accessible for docking.183 However, the only existing crystal structure of 
FLT3 (pdb ID: 1rjb) is in an inactive form without any complexed small molecule 
ligand. From inspection of the crystal structure, it was found that the ATP binding 
pocket is partially blocked by the activation loop residues including the DFG motif. 
To confirm this, the FLT3 structure was superimposed with ERK2-hypothemycin 
wherein ERK2 was then removed but hypothemycin is remained. Indeed, the 
superimposed hypothemycin is found to clash with the phenyl ring of F830 of FLT3 
(Figure 5-5a), suggesting a blockage of the FLT3 binding site. Therefore the building 
of an active-form homolog of FLT3 is required for docking studies. We next modelled 
the native FLT3 structure (1rjb) and built a FLT3 homolog based on the structure of 
KIT-ADP complex (pdb ID: 1pkg) using a template-based modelling approach using 
ICM software. KIT and FLT3 belong to the same family of Class-III receptor tyrosine 
kinase, and their structures, particularly the binding sites, are closely related. The 
resulting homolog model of FLT3 has a more open activation loop (Figure 5-5b), 
enabling the access of ligands for binding. Worthy to mention is that the location of 
the target cysteine residue (C828 in 1rjb or C179 in the homolog FLT3) for covalent 
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binding does not change much. In Section 5.6, the docking study of compound 5.42 
will be discussed.  
Figure 5-5. (a) Native FLT3 structure (pdb ID: 1rjb, ribbon) embedded with 
hypothemycin (yellow-red color stick). The phenyl ring of F830 (grey color stick) is 
clashed with hypothemycin. (b) Ribbon structure of FLT3 homolog embedded with 
hypothemycin. The activation loop (in red color) is flipped away from the binding 
pocket. 
 
5.4 Chemistry – synthesis of compounds 
The ring-opened RAL analogues for SAR study can be classified into two 
categories i.e. acrylamides/vinylsulfonamides and maleimide derivatives. The general 
route for the synthesis of acrylamides and vinylsulfonamides is outlined in Scheme 5-
1 and Scheme 5-2. This route took advantage of the starting material 4.4 synthesized 
previously (see Chapter 4). Compounds 5.2 – 5.4 were prepared from 4.4 by 
deprotection of the MOM group in TFA/DCM followed by substitution with the 
corresponding alcohols under Mitsunobu conditions (Scheme 5-1a). The triflates 5.2 
– 5.4 then underwent Heck reaction with Boc-protected allylamine using Pd2(dba)3 as 
the catalyst to provide E-olefins 5.6 – 5.9 (Scheme 5-2), which were then subjected to 
transesterification with various alcohols using sodium hydride as a base to provide the 
corresponding ester intermediates. The N-Boc protecting group on these esters was 
then deprotected to afford the free amines 5.10 – 5.17 in good yields. These amines 
(a) (b) 
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were next coupled with acryloyl chloride, crotonyl chloride, or 2-
chloroethanesulfonyl chloride respectively under basic conditions, or with (E)-4-
(diethylamino)but-2-enoic acid (5.18) via amide coupling to provide a series of ring-
opened RAL analogues (5.19 – 5.35) bearing substituted acrylamide or 
vinylsulfonamide Michael acceptors (Scheme 5-2). The acid 5.18 was prepared from 
trans-methyl 4-bromo-2-butenoate by alkylation with diethylamine followed by 
saponification (Scheme 1b). The vinylsulfonamide 5.25 containing a 1',2'-single bond 
was prepared from its amine precursor 5.16 (see Scheme 5-4) which was obtained 
from hydrogenation of the intermediate 5.8 followed by transesterification and N-Boc 
deprotection. 
        Scheme 5-1a. Synthesis of triflates 5.2 to 5.4a 
 
a Reagents and conditions: (a) TFA, DCM, rt, 8 h, 95%; (b) alcohol, DIAD, PPh3, THF, rt, 24 h, 56 - 
93%. 
 
     Scheme 5-1b. Synthesis of (E)-4-(diethylamino)but-2-enoic acid 
 
Scheme 5-2. Synthesis of substituted acrylamides and vinylsulfonamidesa 





 Reagents and conditions: (a) BocNHCH2CH=CH2, Pd2(dba)3 (5 mol%), iPr2NEt, DMF, 110 ◦C, 24-36 
h, 15 - 38%; (b) alcohol, NaH, THF, 0 °C, 1 h; (c) TFA, DCM, reflux, 3 h, 54 - 85% in 2 steps; (d) acid 
chlorides or 2-chloroethanesulfonyl chloride, Et3N, DCM or DMF/DCM, 0 °C, 1 h; or: acid 5.18, 
EDC.HCl, HOBt, iPr2NEt, DMF, rt, 24 h, 34 - 61%. 
 
The synthesis of the maleimides was more challenging than anticipated. Initial 
attempts to install the maleimide functionality by a Mitsunobu displacement of the 
alcohol precursor 5.36 with free maleimide gave very low yield (<10%) of the desired 
product 5.37 (Scheme 5-3). Additionally, subsequent transesterification to install the 
R2 group was unsuccessful. We then investigated an alternative route in which 
substituted maleimides were prepared by cyclisation of a maleic monoamide (Scheme 
5-4),184 which proved to be successful. For example, maleic acid monoamides 5.39 (a-
f) were obtained by ring-opening amidation of maleic anhydride with amines (5.10, 
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5.12-5.16). The monoamide intermediates were then subjected to ring-closing 
dehydration in refluxing acetic anhydride to provide the maleimides 5.40 (a-f), 
accompanied by O-acetylation of the 2-phenolic group. Attempted deprotection of the 
O-acetyl group of 5.40a under basic conditions (e.g. aqueous NaHCO3 in MeOH) was 
unsuccessful due to incompatibility of the maleimide functionality under basic 
conditions. After screening a number of conditions, p-TsOH/SiO2 in heated toluene 
(80 °C) was found to be the best conditions and provided the deprotected products 
(5.41 – 5.46) in good yields (Scheme 5-4). Accordingly, the 1',2'-single bonded 
maleimide 5.47 and 5.48 were prepared similarly from its corresponding amine 5.47' 
and 5.48'.    
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Scheme 5-4. Synthesis of maleimidesa  
 
a Reagents and conditions: (a) maleic anhydride, THF, rt, 1 h; (b) Ac2O, NaOAc, 80 °C, 1-3 h, 21- 28% 
two steps; (c) p-TsOH, SiO2, toluene, 80 °C, 3 h, 56 - 78% 
 
In summary, based on two general synthetic routes, 26 ring-opened resorcylic 
acid derivatives that included 9 maleimides, 6 vinylsulfonamides and 11 acrylamides 
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Figure 5-6. Structures of synthesized ring-opened resorcylic acid derivatives 
 
5.5 Structure-activity relationship (SAR) study of kinase inhibition 
With the focused compound library in hand, the kinase binding activities of 
the compounds were investigated by measuring their IC50 values using a 
LanthaScreen™ Eu kinase binding assay (Figure 5-7). The assay is based on the 
binding and displacement of Alexa Fluor® 647-labeled, ATP-competitive kinase 
inhibitor (or kinase tracer) to the kinase of interest (Figure 5-7). Binding of the tracer 
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to the kinase is detected using a Eu (europium)-labeled antibody. Simultaneous 
binding of both the tracer and antibody to the kinase results in a high degree of FRET 
(fluorescence resonance energy transfer) from the Eu donor fluorophore to the Alexa 
Fluor® 647 acceptor fluorophore on the kinase tracer. Binding of an inhibitor to the 
kinase competes for binding with the tracer, resulting in a loss of FRET.185 
 
Figure 5-7.  Schematic representation of LanthaScreen® Eu kinase binding assay.185 
 
The kinase binding activities of these compounds were assessed on FLT3, its 
mutants FLT3-D835Y and FLT3-ITD. Of the 26 synthetic compounds, 17 compounds 
were found to be active (IC50 < 30 µM) against at least one of the FLT3 proteins 
(Table 5-1). Of these, all the maleimide analogues were active inhibitors of both 
FLT3 and FLT3-D835Y kinases, whilst only some of the vinylsulfonamides and 
acrylamides were active. 15 selected compounds that include all the maleimides, 
active vinylsulfonamides against FLT3, and some substituted acrylamides were 
further tested in FLT3-ITD assay. The dose-response curves of the FLT3 inhibitors 
with IC50 values ≤ 10 uM are shown in Figure 5-8. 
 
 








IC50 ± SD (µM) 
FLT3-D835Yb 
IC50 ± SD (µM) 
FLT3-ITDc 
IC50 (µM) 
5.19 >30 >30 8.31 
5.20 9.61 ± 2.18 2.81 ± 0.99 0.50 
5.21 16.22 ± 5.92 10.52 ± 4.44 ntd 
5.22 >30 15.90 ± 4.51 nt 
5.23 >30 >30 1.11 
5.24 10.82 ± 2.35 12.03 ± 2.70 2.25 
5.25 >30 18.59 ± 8.30 4.23 
5.30 >30 14.15 ± 0.80 nt 
5.40a 3.37 ± 0.27 3.61 ± 0.12 21.80 
5.41 0.54 ± 0.09 1.34 ± 0.072 9.79 
5.42 0.15 ± 0.099 0.94 ± 0.062 0.98 
5.43 1.90 ± 0.18 1.74 ± 0.74 >30 
5.44 1.64 ± 0.36 0.95 ± 0.26 >30 
5.45 2.69 ± 0.32 2.10 ± 0.81 >30 
5.46 3.01 ± 0.36 5.20 ± 2.04 >30 
5.47 0.43 ± 0.081 3.03 ± 0.10 13.18 
5.48 0.58 ± 0.070 0.81 ± 0.10 8.87 
L-783,277 0.062 ± 0.013 0.011 ± 0.001 0.036 
a Compounds that are active (IC50 < 30 µM) in at least one of the FLT3 isoforms are listed here, 
other compounds (5.26 – 5.29, 5.31 – 5.35) are inactive (IC50 ≥ 30 µM); b Measured in triplicate 
with standard derivation (SD); c Measured once using an alternative assay; d nt = not tested. 
 
Figure 5-8. Dose-response curves of FLT3 inhibitors with IC50 values ≤ 10 µM 
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With the data in hand, the structure-activity relationship (SAR) among 
different functional groups (R1, R2, R3 and the linker) of the synthetic resorcylic esters 
(Figure 5-4) was examined. Among all the Michael acceptors (MAs), the maleimides 
showed highest potency in inhibition of FLT3 and FLT3-D835Y, outperforming other 
MAs such as acrylamide and vinylsulfonamides (Table 5-1, 5.41 vs 5.24, 5.31 and 
5.32; 5.42 vs 5.20 and 5.21; 5.48 vs 5.25; 5.43 – 5.30 vs 5.26 – 5.29), with 5.42 being 
the most potent inhibitor in the upper nanomolar range (IC50 0.15 µM for FLT3, 0.94 
µM for FLT3-D835Y). Considering the effect of varying the R2 substituents, the 
isopropyl group appeared to be the best among the R2 groups tested (5.41 vs 5.43, 
5.45, 20 except 5.44; 5.24 vs 5.26 – 5.29). The free phenolic group at C-2 plays a 
crucial role in enhancing the binding affinity to all FLT3 kinases (5.40a vs 5.41) with 
up to 6 fold increase for FLT3. This is most likely due to the formation of H-bond 
with the hinge region residue as demonstrated in cis-enone RAL natural products.60, 68, 
86 For the R1 substituents, the 3-morpholinopropyl group was the most effective in 
enhancing potency over other R1 groups within the same class of analogues (e.g. 5.42 
vs 5.41; 5.20 vs 5.19 and 5.31; 5.21 vs 5.32 and 24). When comparing the activities of 
compounds having an olefin linker (e.g. 5.41) to those bearing a saturated alkyl linker 
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(5.47), the difference is only marginal, except for 5.41 which is 2-3 fold more potent 
than 5.47 for FLT3-D835Y.  
Regarding the selectivity among FLT3 and its mutants, it was observed that all 
of the maleimides bearing an isopropyl group at R2 (Table 5-1, e.g. 5.41 – 5.48) are 
more potent inhibitors of wild-type (wt) FLT3 than its mutants (ca 2 – 8 fold than 
FLT3-D835Y and 6 – 30 fold than FLT3-ITD), whilst maleimides with bulkier R2 
groups (e.g. 5.43 – 20) have comparable inhibition potency towards wt-FLT3 and 
FLT3-D835Y, but all are inactive (IC50 > 30 µM) in FLT3-ITD assays. In contrast, the 
acrylamides (e.g. 5.20, 5.21 and 5.23) and vinylsulfonamides (5.24, 5.25) are 
generally more potent against mutant kinases (FLT3-D835Y and FLT3-ITD) than wt-
FLT3 (e.g. > 5 fold for ITD) (Table 5-1). Natural product L-783,277, which serves as 
a positive reference, is the most potent inhibitor (with IC50 values at low nanomolar 
range) for all three kinases assayed.  
From the observations above, several points are noted regarding the inhibitory 
activities of the resorcylic esters (Figure 5-9). Firstly, the presence of a free C-2 
phenolic group is critical for the inhibitory activity, consistent with the biological 
activities of other reported RAL compounds, as this functionality is known to anchor 
at the hinge region via H-bonding with the active site residues of the kinases.60, 68, 86 
Secondly, a smaller hydrophobic ester group such as isopropyl is preferred for better 
activity. Thirdly, a more hydrophilic substituent at the R1 position (such as 3-
morpholinyl) appears to enhance binding affinity. Lastly, among the three types of 
Michael acceptors, the maleimide is the best electrophilic warhead for cysteine 
binding and the most favourable as a covalent inhibitor against FLT3 and its D835Y 
mutant. The vinylsulfonamide however, appears to be a more potent group for the 
inhibition of FLT3-ITD. Other Michael acceptors, such as acrylamides (5.31, 5.34), 
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crotonamides (5.21, 5.32, 5.33) and 4-(diethylamino)but-2-enamide (5.35), are 
essentially inactive against FLT3 proteins. The covalent binding abilities of selected 
compounds were then assessed by NMR and kinetic binding assay (see Section 5.7 
and 5.8). 
 
Figure 5-9. Summary of structure-activity relationship in the inhibition of FLT3 
kinases at protein level 
 
 
5.6 Computational docking study of maleimide 5.42 
Based on the homolog model of  FLT3 described in Section 5.3, the most 
potent compound, i.e. maleimide 5.42, was choosen for docking studies. Based on the 
approach described previously in Chapters 2 and 4 using ICM software, the docking 
experiment was carried out to analyse the binding mode.   
As shown in Figure 5-10a, 5.42 adopts a docking pose similar to 
hypothemycin wherein the resorcylic ring is located in the hinge region and the 
maleimide moiety sits in a similar position as the C-5' to C-7' of hypothemycin. Two 
potential H-bond interactions between the resorcylic ester with the hinge region 
Isopropyl > 3-methyl-2-butanol  
and other bulky groups 
H-bond is 
crucial 
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residues could help anchor the molecule in the ATP binding site (Figure 5-10b). In 
particular, the H-bonds could form between the hydroxy of C-2 phenol with backbone 
nitrogen of C117 (2.9 Å), and the protonated N-H of morpholine group with carboxyl 
C=O of Leu45 (2.9 Å). The reactive double bond of maleimide is in close vicinity to 
C179 (3.8 Å), making the covalent binding interaction (Michael addition) between the 
cysteine SH and the Michael acceptor possible. The covalent binding interaction of 
5.42 with FLT3 kinase is further confirmed by kinetic binding studies (see Section 
5.8).    
Figure 5-10. (a) Docked 5.42 (yellow-red color stick) overlapped with hypothemycin 
(cyan) in the binding pocket of homolog FLT3. (b) Predicted binding interactions of 







3.8 Å   
(a). 
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5.7 Evaluation of covalent binding using NMR spectroscopy 
Based on the previously described  proton NMR spectroscopic method  for the 
evaluation of covalent binding abilities of Michael acceptors (Chapter 4 section 4.3), 
the covalent binding ability of compounds 5.20, 5.24 and 5.41 representing the three 
different Michael acceptors (acrylamide, vinylsulfonamide and maleimide 
respectively) were tested with both cysteamine and L-glutathione (GSH) as cysteine 
mimics. When 5.41 and 5.24 were treated with cysteamine respectively in DMSO-d6, 
rapid disappearance of the characteristic olefinic protons of each compound (within 
10 min) were observed (Figure 5-11), suggesting that covalent bonds were rapidly 
formed with cysteamine. In contrast, 5.20 showed lower reactivity towards 
cysteamine as its olefinic protons only completely disappeared after 300 min. When 
L-glutathione was employed, however, only 5.41 reacted with it, and the covalent 
reaction was only completed after 30 minutes, demonstrating there is a reactivity 
difference when L-glutathione is used instead of cysteamine. The other two 
compounds, 5.20 and 5.24 did not react with L-glutathione even after 24 hours. These 
results confirmed that the maleimides are stronger Michael acceptors than the 
acrylamides or vinylsulfonamides in terms of reactivity towards cysteine residues in 
kinases. This is in agreement with the results obtained from the kinetic studies with 
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Figure 5-11. 1H-NMR studies for reactions of cysteamine/or L-glutathione with 











5.20 + cysteamine, 300 min 
5.20 in DMSO-d6 
5.20 + cysteamine, 10 min 
5.20 + cysteamine, 100 min 
5.41 + cysteamine, 300 min 
5.41 in DMSO-d6 
5.41 + cysteamine, 10 min 






5.8 Kinetic off rate (koff) determination for assessment of covalent binding to FLT3 
One of the properties of an irreversible inhibitor is its long residence time 
within the binding site of the target protein leading to a prolonged duration of drug 
action. A covalent inhibitor can be either irreversible or reversible, depending on the 
electrophilicity of the Michael acceptor, the proximity to cysteine residue, and the 
overall conformation and orientation of the inhibitor within the particular 
surroundings.93, 140 To evaluate the irreversibility of the resorcylic esters as FLT3 
5.41 + GSH, 30 min 
5.41 in DMSO-d6 
5.41 + GSH, 10 min 
5.24 + cysteamine, 300 min 
5.24 in DMSO-d6 
5.24 + cysteamine, 10 min 
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inhibitors, the binding kinetics of representative analogues and their dissociation rates 
(koff) with FLT3 kinase were determined. Current methods for the measurement of 
dissociation/association rates of enzyme inhibition include surface plasmon resonance 
(SPR) or classic enzyme kinetics experiments. While SPR yields highly quantitative 
data, costly instrumentation is required and the procedure utilise covalent conjugation 
of either protein targets or bait ligand to surfaces. The classical enzymatic methods 
are well established but are fairly tedious. For our studies, we used a simple protocol 
based on the same kinase binding assay from Invitrogen for measuring the off rate 
(koff).
186 
Figure 5-12. Basic steps in an off-rate experiment using the LanthaScreen® Eu 




This experiment as illustrated in Figure 5-12 is carried out by first incubating 
the kinase with a saturating amount of inhibitor. This kinase/inhibitor complex is then 
diluted with a saturated concentration of the tracer. Following dilution, samples are 
read for the absorption/emission signals of the complex in different time intervals to 
monitor the change in signal over time. As the inhibitor dissociates and the tracer 
associates, the TR-FRET signal increases.186 
Time = 0 Time = 1 Time = 2 
Inhibitor Kinase:Eu-Ab Kinase:Eu-Ab:Inhibitor complex 
Kinase:Eu-Ab:Tracer 
Tracer 
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Four compounds, namely acrylamide 5.20, vinylsulfonamide 5.24 and 
maleimides 5.41 and 5.42, were chosen for this study. L-783,277 was used as the 
positive control whilst Sunitinib, a potent (IC50 = 4.4 nM) reversible kinase inhibitor 
of FLT3 was used as the negative control. As shown in Figure 5-13, compounds 5.20, 
5.24 as well as Sunitinib exhibited typical curves with varied dissociation rates koff 
and binding half-lives t1/2 (Table 5-2), suggesting that they are actually reversible 
FLT3 inhibitors. In contrast, maleimides 5.41 and 5.42 as well as L-783,277 showed 
no dissociation from the kinase as demonstrated in their flat and non-altered signals 
within a test period (≥ 200 min), strongly suggesting that they formed covalent and 
irreversible bonds with FLT3.   
The studies above demonstrated that although acrylamide and substituted 
acrylamide moieties are well-known Michael acceptors present in reported 
irreversible kinase inhibitors,38, 93 they do not form covalent bond with the cysteine 
residue of FLT3 in our case. This is also reflected in the NMR study with GSH above. 
However, maleimide, which is more electrophilic, is a Michael acceptor of FLT3 as 
demonstrated for compounds 5.41 and 5.42, which exhibit potent inhibition of FLT3 
with IC50 values in the nanomolar range. 
 
Figure 5-13. Off-rate (koff) measurement of compounds on FLT3: As shown for 
reversible inhibitor (5.20, 5.24 and Sunitinib), the TR-FRET signal increases over 
time as the inhibitor dissociates and the fluorescent tracer binds, koff and t1/2 are given. 
For irreversible inhibitor (5.41, 5.42 and L-783,277), however, the signal has no 
change along the measured times as it irreversibly binds to kinase, the koff is 
essentially zero. 
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Table 5-2. Off-rates and half-life times of reversible FLT3 inhibitors 
 Sunitinib 5.20 5.24 
Apparent koff (min-1) 0.0613 0.103 0.118 
t1/2 (min) 11.3 6.8 5.9 
 
5.9 Cell anti-proliferative activity studies in cancer cell lines 
The anti-proliferative activities of the resorcylic esters were further tested in 
five cell lines including MV-4-11 (a AML cell line with FLT-ITD mutant and wt-
FLT3), THP-1 (cells derived from patients with acute monocytic leukemia with wild-
type FLT3), K-562 (a CML cell line harbouring BCR/ABL but has no FLT3 kinases), 
HL-60 (Human promyelocytic leukemia cells which do not express FLT3)187 and 
Hek-293T (human embryonic kidney cells used for general toxicity study). All of the 
synthetic compounds were initially tested in MV-4-11 and THP-1 cells, each at 5 M 
and 10 M respectively. The hit compounds that have higher than 50% inhibition of 
cell growth at 10 M were further assayed to measure their IC50 values. The activities 
of these hit compounds were also tested in three additional cell lines (K-562, HL-60 
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and Hek-293T) and their growth inhibition were determined at 5 µM (Table 5-3). The 
results showed that for the two FLT3-related cell lines (Table 5-3), most compounds 
that are active against at least one of the FLT3 isoforms in the binding assay are also 
active in the MV-4-11 cells (IC50 values: 1.01 µM to 7.73 µM) with the exception of 
5.21, 5.22 and 5.30. In comparison, fewer compounds are active in THP-1 (IC50 
values: 5.43 µM to 7.97 µM). The active compounds include all the maleimides 5.40a, 
5.41 – 5.48 and vinylsulfonamides 5.24 – 5.29. Interestingly, the maleimides seem to 
be more selective to MV-4-11 that carries FLT3-ITD mutant than THP-1 that carries 
wild-type FLT3 (with 1 – 8 fold higher potency) (Figure 5-14a), whilst most of the 
vinylsulfonamides have similar activities in both cell lines except for 5.24 (Figure 5-
14b), including the four compounds (5.26 – 5.29) that showed no activity (>30 µM) in 
protein assays. On the other hand, the cellular activities of substituted acrylamides 
depend on other functional groups besides the Michael acceptors. For instance, out of 
the four free terminal acrylamides (5.19, 5.20, 5.31 and 5.34), only the two with 
extended substitution at R1 position (fluorobenzyl ether 5.19 and morpholine 5.20) are 
active in MV-4-11. Furthermore, only one 4-(diethylamino)but-2-enamide 5 is active 
in MV-4-11. This compound also bears a fluorobenzyl substituent. Other 4-
(diethylamino)but-2-enamides (5.22 and 5.35), all three crotonamides (5.21, 5.32, 
5.33), and the negative control compound 5.30 (non-Michael acceptor) are all inactive 
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Figure 5-14. Comparison of cellular activities of maleimides and vinylsulfonamides 
between MV4-11 and THP-1 cell lines 
 
 
The cellular specificity and toxicity of the above mentioned active compounds 
among all five tested cell lines were assessed by comparing the percentage inhibition 
of compounds in each cell line at 5 µM (Table 5-3). Firstly, the resorcylic esters 
generally showed lower toxicity (all <50% and mostly <30% of percentage inhibitions) 
against Hek-293T cells as compared to L-783,277 (74.6%). In terms of the specificity 
of the four cancer cell lines, it was apparent that almost all maleimides (except 5.43) 
are most active ones in MV-4-11, as well as show high potency against K-562 and 
HL-60 (mostly >70%), indicating that they could be non-specific inhibitors of cancer 
cells. Compound 5.43 is of particular interest as it was the only compound that 
displayed specificity against the cell line bearing the FLT3-ITD mutation but has 
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much lower activity in K-562 and HL-60 cells. This specificity could be due to the 
presence of the bulkier bromophenyl substituent within 5.43 which could block its 
covalent binding to improperly positioned cysteine residue of other protein targets. In 
contrast, some of the active vinylsulfonamides, e.g, 5.20, 5.23 and 5.24, although 
slightly less potent in MV-4-11 than maleimides, are more specific to MV-4-11 
(all >50%, mostly >70%) than the other three cell lines including THP-1 (generally 
<50% and mostly <30%). Most interestingly in the biochemical assay, compounds 
5.20, 5.23 and 5.24 are also more potent inhibitors of FLT3-ITD mutant whilst they 
are generally inactive or only moderately active in wt-FLT3 (Table 5-1). These 
compounds also showed no or very low activity in non-FLT3 related cells (K562 and 
HL-60). As such, they are most likely to be target specific inhibitors against mutant 
FLT3-ITD kinase and hence are better anti-proliferative agents of MV-4-11 cells. 
Table 5-3. Cell anti-proliferative activities of test compounds.a 
Compd MV4-11 THP-1 MV4-11 THP-1 K562 HL60 Hek293T 
 IC50 (µM)b IC50 (µM) b  
% Growth 
Inhibition  
at 5 µM 
% Growth 
Inhibition  
at 5 µM 
% Growth 
Inhibition  
at 5 µM 
% Growth 
Inhibition  




at 5 µM 
5.19 4.45 >10 61.8 23.2 18.5 12.2 25.8 
5.20 3.74 20.7 73.9 9.1 23.0 8.1 26.5 
5.23 4.04 >10 84.9 25.7 49.8 36.8 28.5 
5.24 4.66 14.7 72.3 19.9 36.2 16.6 0.1 
5.25 7.61 >10 20.4 0.0 13.8 2.0 28.4 
5.26 6.06 6.24 61.0 31.2 38.4 8.1 0.0 
5.27 5.14 6.55 70.5 41.7 52.0 10.9 0.0 
5.28 5.86 7.88 56.4 26.5 27.4 7.5 31.2 
5.29 7.73 >10 9.6 5.6 16.7 9.5 22.5 
5.40a 2.15 10.4 99.8 3.3 99.2 87.9 47.4 
5.41 1.73 7.32 99.8 41.8 95.7 65.7 8.0 
5.47 1.57 6.74 99.8 98.8 98.9 67.9 13.4 
5.42 1.89 7.88 99.8 62.5 95.9 89.1 38.8 
5.48 3.51 5.43 99.8 81.5 99.3 98.9 13.3 
5.43 1.01 7.97 97.9 0.0 28.7 36.7 20.1 
5.44 1.46 7.34 99.7 0.0 96.4 82.2 37.9 
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5.45 1.97 7.71 99.8 5.9 85.1 71.0 6.9 
5.46 3.38 >10 99.0 0.0 74.9 56.0 0.0 
L-
783,277 
0.010 1.18 99.7 81.5 69.7 86.0 74.6 
a Compounds active in MV-4-11 (IC50 ≤10 µM) are listed here. Other compounds (5.21, 5.22, 5.30 – 5.35) have 
IC50 > 10 µM in MV-4-11. b Tested once. 
5.10 Summary 
In summary, based on a β-resorcylic acid core, we have designed and 
synthesized a focused library of simplified resorcylic esters bearing various 
substitutions and three types of Michael acceptors (acrylamide, vinylsulfonamide and 
maleimide) as FLT3 kinase inhibitors. The covalent binding abilities of representative 
compounds were evaluated using NMR spectroscopy and off-rate measurements. In 
vitro cell anti-proliferative activities of these RAL derivatives on related hematologic 
cell lines were also investigated. Most of the maleimides showed potent binding 
activities in FLT3 proteins but lack specificity at cellular levels which could be 
attributed to the high reactivity of the maleimide Michael acceptor. However, unlike 
other maleimides, 5.43 indeed showed some specificity in MV-4-11 cell harbouring 
FLT3-ITD, which could be due to the presence of a bulkier bromophenyl substituent. 
In comparison, the acrylamides 5.20, 5.23 and vinylsulfonamide 5.24 were 
more target specific inhibitors of FLT3-ITD vs wt-FLT3 and inhibited the cell 
proliferation of MV-4-11, while their activities in non-FLT3 related cell lines were 
considerably lower. Thus they could be potential lead compounds for further 









Chapter Six Methods and experimental details 
6.1 General experimental details for chemistry 
Solvents (i.e., THF, dichloromethane, diethyl ether, toluene, acetonitrile and 
DMF) for moisture sensitive reactions were taken from a Glasscontour solvent 
purification system under nitrogen. Other anhydrous solvents were from commercial 
sources and used directly. 1H/13C NMR spectra were recorded in parts per million 
(ppm) at 400/100 MHz on a Bruker 400 UltraShield spectrometer operating at 400 
MHz and 100 MHz respectively. All the proton and carbon spectra were referenced to 
the respective residual solvent peaks (for 1H NMR, CDCl3: δ = 7.26; CD3OD: δ = 
3.31; DMSO-d6: δ = 2.50; acetone- d6: δ = 2.05; for 13C NMR, CDCl3: δ = 77.16; 
CD3OD = 49.00; DMSO-d6: δ = 39.52; acetone- d6: δ = 29.84). The following 
abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet and br = broad. High resolution mass spectra were obtained 
using an Agilent 6210 time-of-flight LC/MS spectrometer. Preparative HPLC was 
carried out using either a Waters preparative LC-MS system combining 2545 binary 
gradient module, with a 2545 SFO, 2767 sample manager and 2996 detector, or 
Aglient 1260 infinity series. Analytical HPLC traces were obtained from Aglient 1260 
infinity analytical system with a binary pump.  Analytical thin layer chromatography 
(TLC) separations were performed on Merck’s silica gel 60 F254-precoated aluminum 
sheets. Flash column chromatography purification was carried out either manually 
using Silica Gel 60 (spherical, 40-100 µm) or by using a Biotage SP1 purification 
system by gradient elution with a mixed solvent of ethyl acetate in petroleum ether 
(b.p. 60-80 °C). 




6.2 Experimental details for Chapter 2 
6.2.1 Synthetic procedures and data characterization of aigialomycin D and its 
macrocylic analogues 
6.2.1.1 Synthesis of aigialomycin D (2.1) and 2. 14 - 2. 16  
Compound 2.1 and 2.16 were prepared from commercial available (R)-4-
penten-2-ol, 2.2.15 was prepared from 3-buten-1-ol and 2.14 from (S)-4-penten-2-ol. 
The general procedures for the total synthesis were exemplified in the synthesis of 
analogue 2.14 as below. 
 
2,4-Bis(methoxymethoxy)-6-methylbenzoic acid (2.6) 
To a suspension of 60% NaH (3.69 g, 92.20 mmol) in anhydrous 
THF (150 mL) was added 2,4-dihydroxy-6-methylbenzoic acid 
(3.10 g, 18.44 mmol) slowly at 0 °C and the mixture was stirred for 10 min then 
MOM-Cl (90% purity) (6.22 mL, 73.76 mmol) was added slowly via syringe. The 
mixture was stirred for another 3 hours upon slowly warmed to room temperature, 
quenched by addition of cold water, diluted and extracted with EtOAc (150 mL x 3), 
washed with brine, dried over MgSO4 and concentrated to give a crude product which 
was purified by column chromatography (0-30% EtOAc in hexane) to afford a fully 
protected intermediate product. The purified intermediate (2.77 g, 9.22 mmol) was 
dissolved and refluxed in a mixture of acetonitrile (5 mL), water (5 mL) and 4N 
NaOH (8 mL) for 24 hours, cooled down. The mixture was neutralized by addition of 
6 N HCl slowly, the mixture was extracted with EtOAc (100 mL x 3). The combined 
organic phases were washed with water (100 mL x 2), dried (MgSO4) and filtered, the 




solvent was evaporated under reduced pressure to give the product 2.6 as colorless 
gum (2.21 g, 47% in two steps). The data of NMR and MS (ESI) match the literature 
results.79 
(3R,6R)-2,2-Dimethyldihydrofuro[3,4-d][1,3]dioxol-4(3H)-one (2.17) 
The mixture of D-(-)-erythronolactone (2.5) (3.60 g, 30.51 mmol), 2,2-
dimethoxypropane (25 mL), p-TsOH (30 mg, 0.6 mol%) in acetone (30 
mL) was stirred at room temperature for 16 hours. The solvent was 
removed under reduced pressure, water was added. The mixture was extracted with 
Et2O (100 mL x 3) and washed with brine and dried over MgSO4. The crude product 
was concentrated under reduced pressure and re-crystallized from ether to give 
desired product 2.17 as white solid (4.54 g, 94%). The data of NMR and MS (ESI) 
match the literature results.79 
(3R,6R)-2,2-Dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (2.18) 
To a solution of 2.17 (4.80 g, 30.38 mmol) in DCM (100 mL) was added 
DIABL-H (1M in cyclohexane, 50 mL) dropwise at -78 °C under argon. 
The mixture was stirred for 3 hours at -78 °C, quenched by addition of MeOH (~3 
mL), warmed to room temperature and solvents were then removed under reduced 
pressure. The mixture was acidified by addition of dilute H2SO4 to pH ~4 to dissolve 
formed gel. Water and EtOAc were added, the organic mixture was extracted with 
EtOAc (100 mL x 3), washed with brine, dried (MgSO4) and concentrated under 
reduced pressure. The crude product was purified by silica gel column 
chromatography by gradient elution with 0-50% EtOAc in petroleum ether to afford 








To a solution of 2.18 (2.70 g, 16.88 mmol) in DCM (120 mL) 
were added ethyl (triphenylphosphoranylidene)acetate (7.66 
g, 21.99 mmol) and benzoic acid (0.06 g, 0.49 mmol). The solution was refluxed for 
16 hour. The solvent was evaporated and the residue was triturated with 30% ether in 
hexane (80 mL x 3). The combined extracts were evaporated and the residue was 
purified by column chromatography on silica gel by gradient elution with 0-60% Et2O 
in petroleum ether to give the isomeric mixture as olefin product (2.19). The product 
was re-dissolved in EtOAc (80 mL), degassed with nitrogen, 10% Pd/C (448 mg, 2.5 
mol%) was then added. The mixture was degassed again with hydrogen gas and 
stirred under hydrogen gas at room temperature for 16 hours. The mixture was filtered 
through Celite, and the filtrate was evaporated under reduced pressure to give 2.20 
(3.13 g, 80% in two steps) as colorless oil. The data of NMR and MS (ESI) match the 
literature results.79 
Ethyl 3-((4S,5S)-5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl)propanoate (2.21) 
To a stirred suspension of PCC (5.81 g, 26.94 mmol), sodium 
acetate (276 mg, 3.37 mmol, 25 mol%) and 4 Å molecular 
sieves (3 g) in DCM (150 mL) was added 2.20 (3.13 g, 13.47 
mmol) in DCM (10 mL) dropwise. The suspension was stirred at room temperature 
for 3 hours. The solvent was removed under reduced pressure and the residue was 




purified through a silica gel column eluted with diethyl ether to provide the aldehyde 
2.21 (2.30 g, 74%) as colorless oil. The data of NMR and MS (ESI) match the 
literature results.79 
Ethyl 3-((4S,5R)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl)propanoate (2.22) 
To a suspension of tBuOK (4.38 g, 39.12 mmol) in THF (120 mL) 
was added methyl(triphenyl)-phosphonium bromide (20.96 g, 
58.68 mmol) portionwise at 0 °C under argon. The mixture was 
stirred at 0 °C to room temperature for 2 hours. The resulting supernatant was 
transferred to the solution of aldehyde 2.21 (4.50 g, 19.56 mmol) in THF (80 mL) via 
cannular at 0 °C and stirred for another 1 hour upon warmed to room temperature. 
The reaction was then quenched by addition of saturated NH4Cl, and diluted with 
water. The mixture was extracted with Et2O (150 mL x 3), washed with brine and 
dried over MgSO4. The crude product was concentrated in vacuum and purified by 
flash column chromatography by gradient elution with 0-20% Et2O in petroleum ether 
to afford olefin 2.22 (3.22 g,  72%) as a colorless oil. The data of NMR and MS (ESI) 
match the literature results.79 
3-((4S,5R)-2,2-Dimethyl-5-vinyl-1,3-dioxolan-4-yl)-N-
methoxy-N-methylpropanamide (2.4) 
To a suspension of methoxymethylamine hydrochloride (1.50 g, 
15.38 mmol) in THF (60 mL) was added a solution of CyMgCl in THF (15.4 mL of 
2.0 M solution, 30.80 mmol) at -20 °C under argon. The mixture was stirred for 20 
min, then ester 2.22 (1.40 g, 6.14 mmol) in THF (10 mL) was added slowly via 
syringe and stirred for another one and half hour at -20 °C. The reaction was then 




quenched by addition of saturated NH4Cl, and diluted with water. The mixture was 
extracted with Et2O (80 mL x 3), washed with brine and dried over MgSO4. The crude 
product was concentrated in vacuum and purified by flash column chromatography by 
gradient elution with 0-100% Et2O in petroleum ether to afford the Weinreb amide 2.4 
(1.36 g,  91%) as a colorless oil. The data of NMR and MS (ESI) match the literature 
results.79 
(R)-Pent-4-en-2-yl 2,4-bis(methoxymethoxy)-6-methylbenzoate (2.8b) 
To a solution of 2.6 (2.21 g, 8.62 mmol), (S)-pent-4-en-2-
ol 4 (1.33 mL, 12.93 mmol) and triphenylphosphine 
(4.99 g, 18.96 mmol) in anhydrous THF (100 mL) was 
added DIAD (3.39 mL, 17.24 mmol) dropwise at room temperature. After stirring for 
2 days under argon, the solvent was removed under reduced pressure. The residue was 
purified by flash column chromatography by gradient elution with 0-35% EtOAc in 
petroleum ether to afford the title compound 2.8b (1.96 g, 70%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3) δ 6.66 (d, J = 2.0 Hz, 1H), 6.54 (d, J = 2.0 Hz, 1H), 5.91 – 
5.78 (m, 1H), 5.28 – 5.20 (m, 1H), 5.14 (s, 4H), 5.15 – 5.06 (m, 2H), 3.46 (s, 6H), 
2.55 – 2.33 (m, 2H), 2.29 (s, 3H), 1.34 (d, J = 6.3 Hz, 3H). ESI-MS m/z 347.3 
[M+Na]+, 100%. 
2.10b: 
To a solution of 2.8b (1.43 g, 4.41 mmol) in THF (30 mL) 
was added dropwise the freshly prepared  LDA solution 
(1M in THF, 7.9 mL), the mixture was stirred at -78 °C 
for 20 min, then amide 2.4 (1.07 g, 4.40 mmol) in THF 




(10 mL) was added slowly to above solution -78 °C. The resulting mixture was stirred 
for 40 min at -78 °C then quenched by addition of aqueous NH4Cl solution. Upon 
warming to room temperature, the mixture was extracted with Et2O (50 mL x 3) and 
washed with brine and dried over MgSO4, filtered and evaporated to afford the crude 
product, which was purified by flash column chromatography by gradient elution with 
0-80% Et2O in petroleum ether to afford the title compound 2.10b (1.15 g, 52%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.76 (d, J = 2.2 Hz, 1H), 6.52 (d, J = 2.2 
Hz, 1H), 5.90 – 5.72 (m, 2H), 5.33 – 5.05 (m, 5H), 5.15 (s, 4H), 4.51 – 4.46 (m, 1H), 
4.14 – 4.07 (m, 1H), 3.73 (d, J = 16.3 Hz, 1H), 3.70 (d, J = 16.3 Hz, 1H), 3.47 (s, 3H), 
3.46 (s, 3H), 2.68 – 2.31 (m, 4H), 1.72 – 1.64 (m, 2H), 1.45 (s, 3H), 1.33 (s, 3H), 1.31 
(d, J = 6.3 Hz, 3H). ESI-MS m/z 529.5 [M+Na]+, 85%. 
2.11b: 
To a solution of 2.10b (1.12 g, 2.21 mmol) in anhydrous 
1,2-dichloroethane (400 mL) was added Hoveyda-
Grubbs II catalyst (0.069 g, 0.11 mmol, 5 mol %). The 
solution was refluxed for 2 hours, cooled to room 
temperature, the solvent was removed under reduced pressure. The residue was 
purified by flash column chromatography by gradient elution with 0-70% Et2O in 
petroleum ether to afford the title compound 2.11b (754 mg, 71%) as a colorless gum. 
1H NMR (400 MHz, CDCl3) δ 6.73 (d, J = 2.2 Hz, 1H), 6.53 (d, J = 2.2 Hz, 1H), 5.90 
– 5.81 (m, 1H), 5.51 (dd, J = 15.6, 6.3 Hz, 1H), 5.37 – 5.28 (m, 1H), 5.16 – 5.08 (m, 
4H), 4.52 (t, J = 6.5 Hz, 1H), 4.14 – 4.08 (m, 1H), 3.91 (d, J = 15.0 Hz, 1H), 3.46 (s, 
3H), 3.43 (s, 3H), 3.40 (d, J = 15.0 Hz, 1H, overlapped), 2.57 – 2.46 (m, 2H), 2.41 – 
2.23 (m, 2H), 1.94 – 1.69 (m, 2H), 1.46 (s, 3H), 1.40 (d, J = 6.3 Hz, 3H), 1.31 (s, 3H). 




13C NMR (100 MHz, CDCl3) δ 207.0, 167.3, 159.0, 156.2, 134.2, 129.0, 128.7, 118.9, 
110.7, 108.0, 102.4, 94.8, 94.3, 77.9, 76.8, 71.3, 56.3, 56.2, 47.1, 38.2, 37.6, 27.7, 
25.2, 24.9, 20.1. ESI-MS m/z 479.5 [M+H]+, 18%; 501.4 [M+Na]+, 30%. 
 
2.13b: 
To a solution of 2.11b (750 mg, 1.57 mmol) in 
methanol (40 mL) and THF (10 mL) was added NaBH4 
(296 mg, 7.85 mmol) at 0 °C. The reaction was stirred 
for 30 min at 0 °C then quenched by addition of 
saturated aq. NH4Cl. The organic phase was extracted with EtOAc (50 mL x 3), 
washed with brine, dried with MgSO4 and concentrated under reduced pressure. The 
crude product was purified by silica gel column chromatography by gradient elution 
with 0-60% EtOAc in petroleum ether to afford alcohol 2.12b (557 mg, 74%) as a 
mixture of epimers (ratio 1:1 by 1H NMR). The epimers 2.12b (278 mg, 0.58 mmol) 
was re-dissolved in dry DCM (15 mL), Et3N (0.4 mL, 2.9 mmol) and DMAP (10 mg, 
0.080 mmol) were then added at room temperature under argon. To this mixture was 
added methanesulfonyl chloride (0.091 mL, 1.16 mmol) dropwise at 0 °C. The 
reaction mixture was warmed to room temperature and stirred for 2 hours. The solvent 
was removed under reduced pressure, and the crude mesylate was re-dissolved in 
toluene (15 mL) and DBU (0.87 mL, 5.79 mmol) was added. The mixture was heated 
to reflux for 4 hours, cooled down. Toluene was removed under reduce pressure and 
the organic phase was extracted with EtOAc (50 mL x 3), washed with brine, dried 
over MgSO4, filtered and evaporated under reduced pressure. The crude product was 




purified by flash column chromatography by gradient elution with 0-30% EtOAc in 
petroleum ether to afford the product 2.13b (179 mg, 50% in two steps) as a colorless 
gum. 1H NMR (400 MHz, CDCl3) δ 6.70 (d, J = 2.2 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 
6.43 (d, J = 15.8 Hz, 1H), 6.09 (dd, J = 15.8, 6.2 Hz, 1H), 5.90 – 5.81 (m, 1H), 5.67 
(dd, J = 15.7, 8.0 Hz, 1H), 5.24 – 5.16 (m, 1H), 5.18 – 5.11 (m, 4H), 4.60 – 4.52 (m, 
1H), 4.15 (dd, J = 12.8, 5.7 Hz, 1H), 3.46 (s, 3H), 3.45 (s, 3H), 2.67 – 2.58 (m, 1H), 
2.46 – 2.29 (m, 2H), 2.11 – 2.00 (m, 1H), 1.85 – 1.78 (m, 2H), 1.48 (s, 3H), 1.41 (d, J 
= 6.4 Hz, 3H), 1.35 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.2, 158.8, 155.4, 137.6, 
132.8, 130.3, 128.9, 128.2, 117.5, 107.8, 106.5, 102.6, 94.8, 94.4, 79.6, 78.1, 72.2, 
56.2, 56.1, 37.5, 28.4, 28.2, 28.1, 25.6, 20.2. ESI-MS m/z 463.4 [M+H]+, 97%; 485.4 
[M+Na]+, 100%. 
10'-epi-Aigialomycin D (2.14) 
To a solution of 2.13b (190 mg, 0.41 mmol) in methanol (6 
mL) was added 2 N HCl (1.5 mL), the mixture was stirred at 
40 °C for 6 hours, then cooled to room temperature. The 
mixture was neutralized using 2N NaOH. Methanol was removed under reduced 
pressure, the organic phase was extracted with EtOAc (40 mL x 3), washed with brine, 
dried (MgSO4) and concentrated under reduced pressure. The crude product was 
purified by silica gel column chromatography by gradient elution with 0-80% EtOAc 
in petroleum ether to afford final product 2.14 (85 mg, 62%) as a white solid. 1H 
NMR (400 MHz, acetone-d6) δ 6.95 (d, J = 15.5 Hz, 1H), 6.48 (d, J = 2.4 Hz, 1H), 
6.27 (d, J = 2.4 Hz, 1H), 6.02 – 5.90 (m, 2H), 5.79 (dddd, J = 15.6, 7.8, 1.8, 1.0 Hz, 
1H), 5.35 (d, J = 6.4 Hz, 1H), 4.31 (dd, J = 7.7, 1.9 Hz, 1H), 3.74 – 3.68 (m, 1H), 2.72 
– 2.63 (m, 1H), 2.54 – 2.45 (m, 1H), 2.34 – 2.16 (m, 2H), 1.87 – 1.68 (m, 2H), 1.44 (d, 




J = 6.4 Hz, 3H). 13C NMR (100 MHz, acetone-d6) δ 172.1, 165.4, 163.1, 144.0, 133.7, 
133.0, 131.7, 126.7, 108.0, 105.1, 102.5, 76.5, 73.7, 72.7, 37.6, 32.1, 28.7, 18.9. 
HRMS (ESI-TOF) m/z calcd for C18H21O6 [M-H]
- 333.1344, found 333.1351. 
N-Methoxy-N-methylhept-6-enamide (2.9) 
The Weinreb amide 2.9 was prepared from ethyl 6-heptenoate 
following the same procedure to prepare 2.4. Colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 5.88 – 5.75 (m, 1H), 5.05 – 4.92 (m, 2H), 3.68 (s, 3H), 3.18 (s, 3H), 2.43 (t, 
J = 7.4 Hz, 2H), 2.12 - 2.05 (m, 2H), 1.71 – 1.60 (m, 2H), 1.50 – 1.39 (m, 2H). ESI-
MS m/z 171.99 [M+H]+, 100%; 193.99 [M+Na]+, 25%. 
Aigialomycin D79 and its analogues 2.15 and 2.16 were synthesized according to the 
same procedure in the total synthesis of analogue 2.14 described above. 
2.15:  
White solid. 1H NMR (400 MHz, acetone-d6) δ 11.70 (s, 1H), 
9.24 (s, 1H), 7.06 (d, J = 15.6 Hz, 1H), 6.52 (d, J = 2.4 Hz, 
1H), 6.28 (d, J = 2.4 Hz, 1H), 6.02 (dt, J = 15.6, 6.1 Hz, 1H), 
5.87 – 5.71 (m, 2H), 4.58 (ddd, J = 11.4, 8.1, 3.5 Hz, 1H), 
4.39 – 4.29 (m, 2H), 3.81 (br d, J = 3.8 Hz, 1H), 3.66 - 3.57 (m, 1H), 3.59 (br d, J = 
5.7 Hz, 1H), 2.58 - 2.51 (m, 2H), 2.35 – 2.24 (m, 2H), 2.07 - 1.97 (m, 1H), 1.68 – 
1.57 (m, 1H). 13C NMR (100 MHz, methanol-d4) δ 173.0, 165.7, 163.7, 144.5, 133.9, 
133.2, 131.9, 129.5, 108.3, 104.6, 102.6, 77.3, 74.1, 65.8, 32.6, 29.8, 28.8. HRMS 
(ESI-TOF) m/z calcd for C17H19O6 [M-H]
- 319.1187, found 319.1196. 
 





White solid. 1H NMR (400 MHz, CDCl3) δ 11.88 (s, 1H), 7.13 
(br d, J = 15.0 Hz, 1H), 6.46 (d, J = 2.5 Hz, 1H), 6.32 (d, J = 2.5 
Hz, 1H), 6.02 (dt, J = 15.0, 5.0 Hz, 1H), 5.75 (br s, 1H), 5.59 – 
5.54 (m, 2H), 5.48 – 5.40 (m, 1H), 2.57 – 2.49 (m, 1H), 2.38 – 2.08 (m, 4H), 1.95 – 
1.85 (m, 1H), 1.80 - 1.69 (m, 1H), 1.61 – 1.48 (m, 2H), 1.39 (d, J = 7.0 Hz, 3H), 1.45 
– 1.33 (m, 1H, hidden). 13C NMR (100 MHz, CDCl3) δ 171.4, 164.8, 160.2, 143.9, 
134.4, 133.3, 129.9, 124.9, 107.1, 104.6, 102.0, 72.1, 37.5, 31.8, 30.2, 25.7, 25.6, 18.7. 
HRMS (ESI-TOF) m/z calcd for C18H21O4 [M-H]
- 301.1445, found 301.1444. HPLC 
purification: XTerra RP18, 1950 mm column, tR = 19.2 min, flow rate: 8 mL/min, 
MeCN in H2O: 20% (2 min), 20%-80% (20 min), 80% (10 min). 
6.2.1.2 Synthesis of analogues 2.23 – 2.27 and 2.34 – 2.36 
For general procedure for global deprotection of MOM and acetonide groups, see 
synthesis of 2.23.  
For general procedure for reduction of C-2' ketone of macrocyle, see synthesis of 2.25.  
For general procedure for hydrogenation of 1',2' and/or 7',8' double bonds, see 
synthesis of 2.24. For general procedure for mesylation and elimination (as for 2.28, 
2.29 and 2.30), see synthesis of 2.14 above.  
For general procedure for methylation using trimethylsilydiazomethane/methanol, see 
synthesis of 2.35 and 2.36. 
 
 





To a solution of 2.11a (25 mg, 0.052 mmol) in methanol 
(800 L) was added 2 N HCl (200 L), the mixture was 
stirred at 40 °C for 6 hours, then cooled to room 
temperature. Methanol was removed under reduced pressure, and EtOAc (3 mL) and 
H2O (2 mL) were added. The product was extracted with EtOAc (3 mL x 3), washed 
with brine, dried (MgSO4) and concentrated under reduced pressure. The crude 
product was purified by silica gel column chromatography by gradient elution with 0-
70% EtOAc in petroleum ether to afford ketone 2.23 (16 mg, 90%) as a white solid. 
1H NMR (400 MHz, acetone-d6) δ 11.79 (s, 1H, OH), 6.31 (d, J = 2.5 Hz, 1H), 6.25 
(d, J = 2.5 Hz, 1H), 5.70 (ddd, J = 15.6, 7.0, 1.6 Hz, 1H), 5.59 (dd, J = 15.6, 4.4 Hz, 
1H), 5.28 (m, 1H), 4.37 (d, J = 17.3 Hz, 1H), 4.19 (m, 1H), 3.84 (ddd, J = 9.3, 3.6, 2.0 
Hz, 2H), 3.59 (d, J = 17.3 Hz, 1H), 2.82 – 2.72 (m, 1H), 2.60–2.53 (m, 1H), 2.49 – 
2.35 (m, 2H), 2.00–1.90 (m, 1H), 1.73 – 1.60 (m, 1H), 1.37 (d, J = 6.4 Hz, 3H); 13C 
NMR (100 MHz, acetone-d6) δ 207.3, 172.0, 166.4, 163.2, 140.8, 134.5, 125.2, 113.5, 
102.7, 75.9, 73.3, 72.9, 50.6, 38.5, 38.1, 25.7, 19.2 (one quaternary carbon not 
detected); HRMS (ESI-TOF) m/z calcd for C18H21O7 [M-H]
- 349.1293, found 
349.1294. 
2.24:  
To a degassed solution of 2.23 (18.3 mg, 0.052 mmol) 
in ethanol (1 mL) was added 10% Pd/C (10 mg), the 
mixture was degassed and refilled with hydrogen thrice 
and then stirred under hydrogen atmosphere at room 




temperature for 20 hours. Upon completion of the reaction, the mixture was filtered 
through Celite and concentrated, purified by silica gel column chromatography by 
gradient elution with 0-50% EtOAc in petroleum ether to afford 2.24 (10.6 mg, 58%) 
as a white solid. 1H NMR (400 MHz, acetone-d6) δ 11.83 (s, 1H, OH), 6.31 (d, J = 2.5 
Hz, 1H), 6.22 (d, J = 2.5 Hz, 1H), 5.08 – 4.99 (m, 1H), 4.69 (d, J = 17.8 Hz, 1H), 3.95 
– 3.89 (m, 1H), 3.77 (d, J = 17.8 Hz, 1H), 3.72 – 3.65 (m, 1H), 2.84 – 2.61 (m, 2H), 
2.00 – 1.91 (m, 1H), 1.86 – 1.62 (m, 4H), 1.52 – 1.30 (m, 2H), 1.32 (d, J = 6.2 Hz, 
3H), 1.22 – 1.12 (m, 1H). 13C NMR (100 MHz, acetone-d6) δ 207.7, 163.1, 140.7, 
113.8, 102.7, 74.8, 74.3, 70.0, 50.1, 38.6, 36.6, 34.2, 25.5, 21.9, 20.8 (three quaternary 




To a solution of 2.11a (20 mg, 0.042 mmol) in methanol 
(1mL) was added NaBH4 (8 mg, 0.21 mmol) at 0 °C. The 
reaction was stirred for 30 min at 0 °C then quenched by 
addition of saturated aq. NH4Cl (1 mL). The product was 
extracted with EtOAc (3 mL x 3), washed with brine, dried (MgSO4) and 
concentrated under reduced pressure. The crude product was purified by silica gel 
column chromatography by gradient elution with 0-50% EtOAc in petroleum ether to 
afford the crude alcohol 2.12a which was then treated with 2 N HCl in MeOH 
similarly for the preparation of 2.23 to give 2.25 as a white solid (12 mg, 72%) after 
purification. 1H NMR (400 MHz, acetone-d6) δ 6.31 (br s, 1H), 6.26 (d, J = 2.1 Hz, 
1H), 5.74 (dt, J = 15.5, 7.0 Hz, 1H), 5.61 (dd, J = 15.5, 6.8 Hz, 1H), 4.63– 4.54 (m, 
1H), 3.97 – 3.92 (m, 1H), 3.79 – 3.72 (m, 1H), 3.55 – 3.48 (m, 1H), 2.98 (dd, J = 16.4, 




3.4 Hz, 1H), 2.87 (dd, J = 16.4, 11.2 Hz, 1H), 2.22 - 2.13 (m, 2H), 2.02 – 1.98 (m, 
1H), 1.89 – 1.78 (m, 2H), 1.56 – 1.45 (m, 1H), 1.12 (d, J = 6.2 Hz, 3H); 13C NMR 
(100 MHz, acetone-d6) δ 165.1, 143.3, 133.4, 130.0, 107.5, 101.9, 80.5, 76.5, 74.9, 
67.4, 43.3, 33.6, 32.2, 28.8, 23.4. (three quaternary carbons not detected); HRMS 
(ESI-TOF) m/z calcd for C18H23O7 [M-H]
- 351.1449, found 351.1454. 
2.26:  
2.26 (6 mg, 85%) was similarly prepared from 2.25 (7 mg, 
19.90 mol) by hydrogenation as described for 2.24. 1H 
NMR (400 MHz, methanol-d4) δ (phenol OH exchanged), 
6.23 (br s, 1H), 6.20 (d, J = 2.2 Hz, 1H), 4.60 – 4.50 (m, 1H), 3.78 – 3.70 (m, 1H), 
3.43 – 3.37 (m, 2H), 2.97 – 2.80 (m, 2H), 2.05 – 1.27 (m, 9H), 1.16 (d, J = 6.2 Hz, 
3H), 0.93 – 0.86 (m, 1H); 13C NMR (100 MHz, methanol-d4) δ 166.3, 165.6, 160.3, 
143.6, 107.9, 102.1, 81.3, 75.8, 75.7, 68.5, 40.2, 34.0, 33.8, 32.5, 29.2, 23.5, 23.2. 
(one quaternary carbon not detected); HRMS (ESI-TOF) m/z calcd for C18H25O7 [M-
H]- 353.1606, found 353.1606. 
2.27:  
To compound 2.23 (15 mg, 0.043 mmol) in anhydrous 
dioxane (1 mL) was added NaOAc (24.6 mg, 0.30 mmol) 
and then hydroxylamine hydrochloride (14.9 mg, 0.21 
mmol). The mixture was stirred at 100 °C for 3 hours, then cooled to room 
temperature. The solid was removed by filtration and to the filtrate was added water 
and EtOAc. The mixture was extracted with EtOAc (3 mL x 3) and concentrated 
under reduced pressure. The crude product was purified by silica gel column 




chromatography by gradient elution with 0-80% EtOAc in petroleum ether to afford 
the desired oxime product quantitatively. 2.27 was obtained as a mixture of cis- and 
trans- isomers in a ratio of 5:7, labeled as minor and major in 1H NMR assignment). 
1H NMR (400 MHz, acetone-d6) δ (phenol OH exchanged), 6.29 – 6.25 (m, 2H, Ar-
Hs, cis & trans), 5.86 - 5.52 (m, 2H, H-7’ & 8’, cis & trans), 5.37 – 5.30 (m, 1H, H-
10’, cis & trans), 4.23 (d, J = 16.4 Hz, 1H, H-1’a, major), 4.16 - 4.13 (m, 1H, H-6’, 
major), 4.09 – 4.05 (m, 1H, H-6’, minor), 3.94 (d, J = 16.4 Hz, 1H, H-1’a, minor), 
3.75 (d, J = 16.4 Hz, 1H, H-1’b, major), 3.63 (d, J = 16.4 Hz, 1H, H-1’b, minor), 3.57 
– 3.53 (m, 1H, H-5’, minor), 3.50 – 3.46 (m, 1H, H-5’, major), 2.70 – 2.62 (m, 1H, cis 
& trans), 2.46 – 1.80 (m, 5H, cis & trans), 1.45 (d, J = 6.4 Hz, 3H, CH3, minor), 1.44 
(d, J = 6.4 Hz, 3H, CH3, major); HRMS (ESI-TOF) m/z calcd for C18H22NO7 [M-H]
- 
364.1402, found 364.1406. 
 
2.34:  
2.34 was obtained by treating aigialomycin D (2.1) (2.0 
mg, 0.0060 mmol) with dimethyl sulfate (2 L) and 
K2CO3 (5 mg) in acetone (300 L) at room temperature 
for 1 hour. Purification of crude product by silica gel column chromatography (0-30% 
acetone in petro-ether) afforded 2.34 (2.1 mg, 94%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 11.73 (br s, 1H), 6.91 (d, J = 15.3 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 
6.31 (d, J = 2.5 Hz, 1H), 5.97 - 5.79 (m, 2H), 5.73 (dd, J = 15.3, 6.4 Hz, 1H), 5.33 (m, 
1H), 4.66 (t, J = 6.0 Hz, 1H), 4.19 - 4.15 (m, 1H), 2.69 – 2.61 (m, 1H), 2.55 -2.45 (m, 
1H), 2.32 – 2.20 (m, 1H), 2.10 – 1.99 (m, 1H), 1.85 – 1.76 (m, 2H), 1.50 (s, 3H), 1.45 




(d, J = 6.2 Hz, 3H), 1.37 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.3, 164.9, 160.5, 
143.5, 132.2, 130.3, 128.3, 127.9, 107.9, 107.6, 104.4, 102.2, 78.6, 77.2, 72.1, 38.2, 
30.4, 29.1, 28.1, 25.7, 19.1; HRMS (ESI-TOF) m/z calcd for C21H25O6 [M-H]
- 
373.1657, found 373.1670. 
2.35 & 2.36:  
To 2.1 (9 mg, 0.027 mmol) in a mixed solvent of MeOH/MeCN (2:3, 500 L) was 
added iPr2NEt (0.1 M in MeCN, 540 L) and then trimethylsilyldiazomethane (0.4 M 
in MeCN, 185 L) at room temperature. The mixture was stirred at room temperature 
for 18 hours and worked up as usual by the addition of saturated aq. NH4Cl, extracted 
with EtOAc, and concentrated under reduced pressure. The crude product was 
purified by HPLC (C18 column, 1950 mm, 20% (3 min), 20% - 70% (22 min) 
acetonitrile in water, flow rate: 10 mL/min) to give 2.35 (2.2 mg, tR 14.8 min) and 
2.36 (2.6 mg, tR 13.2 min) with combined 52% yield as white solids.  
 
2.35: 1H NMR (400 MHz, acetone-d6) δ 11.7 (br s, 1H), 
7.16 (dt, J = 15.9, 1.7 Hz, 1H), 6.58 (d, J = 2.6Hz, 1H), 
6.36 (d, J = 2.6 Hz, 1H), 6.17 (dt, J = 15.9, 5.5 Hz, 1H), 
5.88 (dt, J = 15.9, 7.4 Hz, 1H), 5.69 (br dd, J = 15.9, 5.1 Hz, 1H), 5.47 – 5.42 (m, 1H), 
4.35 (br d, J = 4.3 Hz), 3.85 (s, 3H), 3.65-3.60 (m, 1H), 2.61 – 2.54 (m, 1H), 2.48 – 
2.32 (m, 3H), 1.64 – 1.55 (m, 1H), 1.40 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, 
acetone-d6) δ 164.9, 143.9, 135.8, 134.1, 130.5, 129.8, 129.0, 126.1, 125.4, 106.9, 
100.6, 76.5, 73.19, 73.16, 55.8, 38.0, 28.5, 28.0, 19.1; HRMS (ESI-TOF) m/z calcd 
for C19H23O6 [M-H]
- 347.1500, found 347.1503. 




2.36: 1H NMR (400 MHz, acetone-d6) δ 6.68 (d, J = 2.1 
Hz, 1H), 6.46 (d, J = 2.1 Hz, 1H), 6.40 (dt, J = 16.3, 4.5 
Hz, 1H), 6.29 (dt, J = 16.3, 2.0 Hz, 1H), 5.76 (m, 1H), 
5.63 (ddd, J = 15.7, 7.0, 1.7 Hz, 1H), 5.38 (m, 1H), 4.28 
(br d, J = 6.9 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.59 (br d, J = 9.4 Hz, 1H), 2.53 – 
2.18 (m, 4H), 1.90 – 1.80 (m, 1H), 1.69 - 1.60 (m, 1H), 1.30 (d, J = 6.4 Hz, 3H); 13C 
NMR (100 MHz, acetone-d6) δ 168.1, 162.1, 158.6, 137.6, 134.1, 132.9, 129.8, 126.9, 
125.8, 101.4, 98.1, 77.3, 74.0, 71.1, 56.3, 55.8, 40.4, 27.1, 26.7, 21.5; HRMS (ESI-
TOF) m/z calcd for C20H25O6 [M-H]
- 361.1657, found 361.1655. 
6.2.1.3 Synthesis of 2.28 and 2.33 
 
2.28 was synthesized from 2.11a in a sequence of reduction (NaBH4), hydrogenation 
(H2/Pd/C), elimination and global deprotection (2 N HCl) following the general 
procedures described previously. 
2.28:  
White solid. 1H NMR (400 MHz, acetone- d6) δ 11.77 (s, 
1H), 7.20 (d, J = 15.7 Hz, 2H), 6.46 (d, J = 2.5 Hz, 2H), 
6.30 (d, J = 2.5 Hz, 2H), 5.97 (ddd, J = 15.7, 8.2, 4.9 Hz, 
1H), 5.04 - 4.96 (m, 1H), 3.81 - 3.73 (m, 2H), 3.47 (br s, 1H), 2.47 – 2.26 (m, 2H), 
1.88 – 1.48 (m, 7H), 1.43 – 1.31 (m, 1H, hidden), 1.40 (d, J = 6.1 Hz, 3H). 13C NMR 
(100 MHz, methanol-d4) δ 172.8, 165.6, 163.6, 144.8, 134.3, 133.3, 109.4, 105.1, 
102.8, 75.5, 75.1, 70.5, 37.2, 34.7, 29.9, 29.9, 22.0, 20.8. HRMS (ESI-TOF) m/z calcd 
for C18H23O6 [M-H]
- 335.1500, found 335.1492. HPLC purification: XTerra RP18 




column, 19  50 mm, tR = 15.8 min, flow rate: 8 mL/min, MeCN in H2O: 20% (2 min), 
20% - 50% (30 min), 50% - 80% (5 min).  
2.33: 
2.33 was obtained as a white solid in 40% yield by 
hydrogenation reaction of 2.1. 1H NMR (400 MHz, 
acetone- d6) δ 11.70 (br s, 1H), 6.32 (d, J = 2.5 Hz, 1H), 
6.22 (d, J = 2.5 Hz, 1H), 5.13 – 5.04 (m,1H), 3.82 – 3.75 
(m, 2H), 3.49 (td, J = 12.1, 3.9 Hz, 1H), 2.33 (td, J = 12.1, 4.4 Hz, 1H), 1.90 - 1.77 (m, 
3H), 1.75 – 1.33 (m, 9H), 1.32 (d, J = 6.2 Hz, 3H). 13C NMR (100 MHz, acetone- d6) 
δ 163.5, 149.2, 111.8, 101.8, 74.5, 74.0, 69.3, 37.2, 36.5, 34.5, 32.8, 28.2, 26.5, 21.6, 
21.0 (one quaternary C not detected). HRMS (ESI-TOF) m/z calcd for C18H25O6 [M-
H]- 337.1657, found 337.1669. 
6.2.1.4 Synthesis of 2.29 and 2.30 
To 2.31 (12 mg, 0.026 mmol) in MeOH (800 L) was added trifluoroacetic acid 
solution (1 M in MeOH, 200 L). The mixture was stirred at room temperature for 3 
hours and quenched by saturated NaHCO3. The mixture was extracted with EtOAc (2 
mL  3), washed with brine and dried over MgSO4. The crude product was 
concentrated under reduced pressure and purified by flash column chromatography by 
gradient elution with 0-50% Et2O in petroleum ether to afford pure intermediate 2.32 
(9.5 mg, 96%) as white solid. 2.32 was then treated with TMSCHN2/MeOH, followed 
by deprotection of MOM at C-4 to afford 2.29, which was then purified by HPLC: 
XTerra RP18 column, 1950 mm, tR = 15.9 min, flow rate: 8 mL/min, MeCN in H2O: 
20% (2 min), 20% - 50% (30 min), 50% - 80% (5 min).  





White solid. 1H NMR (400 MHz, acetone-d6) δ 6.58 (d, J = 
2.0 Hz, 1H), 6.38 (d, J = 2.0 Hz, 1H), 6.35 – 6.23 (m, 2H), 
5.76 (ddd, J = 15.5, 9.1, 3.5 Hz, 1H), 5.62 (ddd, J = 15.5, 
6.8, 1.6 Hz, 1H), 5.41 – 5.32 (m, 1H), 4.27 (br d, J = 7.0 
Hz, 1H), 3.75 (s, 3H), 3.58 (br d, J = 9.4 Hz, 1H), 2.51 – 2.29 (m, 3H), 2.25 – 2.16 (m, 
1H), 1.88 – 1.79 (m, 1H), 1.69 – 1.59 (m, 1H), 1.30 (d, J = 6.4 Hz, 3H). HRMS (ESI-
TOF) m/z calcd for C19H23O6 [M-H]
- 347.1500, found 347.1502. 
2.30 was prepared from 2.11a in a sequence of reduction (NaBH4), hydrogenation 
(H2/Pd/C), elimination (MsCl, then DBU), followed by same procedure for the 
preparation of 2.29.  
2.30:  
White solid. 1H NMR (400 MHz, acetone-d6) δ 6.52 (d, J 
= 2.0 Hz, 1H), 6.48 (d, J = 16.1 Hz, 1H), 6.40 (d, J = 2.0 
Hz, 1H), 6.17 (ddd, J = 16.1, 7.1, 4.9 Hz, 1H), 5.20 – 5.10 
(m, 1H), 3.75 (s, 3H), 3.77 – 3.72 (m, 1H, hidden), 3.71 – 
3.65 (m, 1H), 2.50 – 2.38 (m, 1H), 2.30 –2.19 (m, 1H), 1.83 – 1.73 (m, 1H), 1.71 – 
1.44 (m, 5H), 1.43 – 1.24 (m, 2H), 1.27 (s, 3H). 13C NMR (100 MHz, acetone d6) δ 
168.2, 159.9, 158.8, 138.4, 134.6, 127.4, 116.8, 105.0, 98.7, 74.1, 72.1, 70.6, 56.2, 
37.1, 33.7, 27.8, 27.3, 22.1, 20.8. HRMS (ESI-TOF) m/z calcd for C19H25O6 [M-H]
- 
349.1657, found 349.1660. HPLC purification: Xterra RP18 column, 1950 mm, tR = 
16.5 min, flow rate: 8 mL/min, MeCN in H2O: 20% (2 min), 20% - 50% (30 min), 50% 
- 80% (5 min). 




6.2.2 IMAP enzymatic assay for kinase inhibition study 
6.2.2.1 Determination of IC50 against CDK2 using IMAP assay 
The IMAP 800-tp FP assay kit and FAM-Histone H1-derived peptide (5-
FAM-GGGPATPKKAKKL-COOH) were purchased from Molecular Devices. 
CDK2/cyclin A active enzyme was purchased from Millipore. ATP and 384-well 
Corning black plat bottom plate were purchased from Sigma-Aldrich. Tecan Infinite 
M1000 plate reader was used to measure the fluorescent polarization operated using i-
controlTM software. The readings were taken with 470 ± 5 nm as excitation 
wavelength and 530 ± 5 nm as emission wavelength. The G factor for the fluorescent 
polarization was calibrated based on the preset of 60 mP for control well, which was 
determined to be 1.132. The enzyme was firstly calibrated from the sigmoidal curve 
(plotted using GraphPad Prism 5.0) and its EC70 was determined and used as the 
enzyme concentration for the inhibition experiments. In a typical percentage 
inhibition (at 10 µM of drug) experiment, 5 µl of drug solution (40 µM in 4% v/v 
DMSO in 1buffer), 5 µl of enzyme solution (at EC70), 5 µl of 120 M ATP, 5 µl of 
400 nM peptide substrate were added in each well (4 duplicates) of 384-well plate in 
sequence, pipette mixed and incubated at room temperature for 1 hour. The control 
well replaces the enzyme solution and drug solution with 10 µl of 1IMAP buffer 
(with 1 mM DTT), and the vehicle control only replaces the enzyme solution with 5 
µl of same IMAP buffer. All of the above dilutions were performed using 1IMAP 
reaction buffer with 1mM DTT, and discarded after one day, the drug stock solution 
was 10 mM in DMSO. After 1h incubation, the 1 optimal binding solution 
(1binding buffer containing 1/400 binding reagent) was added, mixed well, and 
incubated at room temperature for another 30 min for the binding reaction to complete. 




Both incubations were covered with aluminum foil to avoid light. The plate was then 
read with 30 flashes. The IC50 measurements were performed by the same protocol, 
eight concentrations of each test compound was analyzed using GraphPad Prism 5.0 
software.  The data was fit into the dose-response inhibition curve using the non-
linear regression as the fit method under “Log (inhibitor) vs response with variable 
slope”. The IC50 value was auto-determined as the concentration that gives half of 
maximum response.  
The following equation is used for the calculation of percentage inhibition:  
Percentage Inhibition = (FPvehicle – FPdrug)/(FPvehicle – FPcontrol) * 100 
 
6.2.2.2 Determination of IC50 against MNK2 using IMAP assay 
2.0 μl of 5.0 μM activated MNK2 (prepared in-house), 2.0 μl of compound at 
10X concentrations, 12.0 μl of buffer B (20 mM HEPES/KOH pH 7.4, 10 mM 
MgCl2, 0.5 mM DTT) were added to a 384-well plate and incubated at 30
oC for 1 
hour. 2.0 μl of 1.0 μM FAM labeled JH3 peptide and 2.0 μl of 200 μM ATP were then 
added to each well and the plate was incubated at 30oC for another 2 hours. The final 
concentration of MNK2, JH3 peptide, ATP and compound in 20 μl of assay volume is 
0.25 μM, 100 nM, 20 μM, and 1X respectively. The reaction was terminated with 60 
μl of IMAP optimal binding solution. After 1 hour incubation at room temperature, 
fluorescence polarization was measured by the Safire2 microplate reader.  




6.2.3 Computational docking studies 
Docking studies were carried out using ICM-VLS (Molsoft LLC, La Jolla) on 
a dual-quadcore MacPro. The CDK2-cyclin A crystal structure (PDB: 1E9H) 
containing the ligand indurubicin-5-sulfate was obtained from the RCSB Protein Data 
Bank. The receptor was prepared by first deleting all the water molecules and ligands 
from the protein structure, then adding in all nonpolar hydrogens. All amine-
containing residues were protonated except histidines, and all carboxylic acid residues 
were converted to carboxylate. The receptor maps were then generated using the exact 
vw method (Lennard-Jones 12-6) with the following terms selected: Van der Waals, 
1-4 Van der Waals, hydrogen bonding, electrostatics, torsion energy, proton vw grid 
energy, heavy atoms vw grid energy, hydrogen bonding grid energy, surface grid 
energy and atomic properties field grid energy. 
  The ligands were prepared by drawing the 2D structures in ChemBioDraw 
Ultra 12 (Cambridgesoft, UK) and saving the structures in SDF format. The library of 
compounds was then imported into ICM-VLS, which automatically generated the 3D 
conformers and assigned MMFF charges to the structures. The docking parameters 
were set to allow for ring flexibility of the macrocycles. The thoroughness level was 
set to 5 for all docking runs. The results were then sorted according to the ICM score. 
Refinements were carried out on the top 5 docking results using the ICM 
Refinement option. The resulting individual protein conformations were setup as 
receptors, and their corresponding ligands were rescored without further docking to 
obtain the refined ICM score. Refinement also gave a list of the H-bonding 
interactions between the ligand and protein and the atomic distances.  




6.2.4 Kinase profiling of aigialomycin D 
Kinase profiling of our synthetic aigialomycin D was carried out by 
DiscoveRx, KINOMEscan™. It is based on a competition binding assay that 
quantitatively measures the ability of a compound to compete with an immobilized, 
active-site directed ligand. The assay is performed by combining three components: 
DNA-tagged kinase; immobilized ligand; and a test compound. The ability of the test 
compound to compete with the immobilized ligand is measured via quantitative PCR 
of the DNA tag.  
6.3 Experimental details for Chapter 3 
6.3.1 Synthesis of ring-opened analogues of aigialomycin D          
Preparation of 3.8 and 3.9:  
To the suspension of NaH (6 mg) in anhydrous THF (0.5 mL) was added the (S)-4-
penten-2-ol (0.5M in THF, 150 µL, 0.075 mmol) at 0 °C and stirred for 10 min, 
followed by the addition of a solution of compound 3.5 (25 mg, 0.050 mmol) in THF 
(0.5 mL) slowly. The mixture was stirred for 1 hour 0 °C and then quenched by 
addition of a few drops of saturated NH4Cl. The organic phase was extracted with 
EtOAc (3 x 2 mL), washed with brine, dried over MgSO4 and concentrated to give a 
crude product which was purified by column chromatography (0-25% EtOAc in 
petroleum ether) to afford compound (3.7) (15.5 mg, 60%) as a colorless gum. Then 
To a solution of compound 3.7 (11 mg, 0.019 mmol) in THF (0.5 mL) was added 
tetra-n-butylammonium fluoride (1M in THF, 40 µL). The mixture was stirred at 
room temperature for 1 hour, then concentrated and purified by column 




chromatography (50% EtOAc in petroleum ether) to afford compound 3.8 (7  mg, 
95%) as a colorless gum. 
 
Compound 3.8 1H NMR (400 MHz, CDCl3) δ 11.74 (s, 1H, OH), 6.80 (d, J = 11.5 Hz, 
1H), 6.39 (d, J = 2.6 Hz, 1H), 6.29 (d, J = 2.1 Hz, 1H), 5.87 – 5.77 (m, 1H), 5.63 – 
5.57 (m, 1H), 5.26 – 5.17 (m, 1H), 5.16 – 5.08 (m, 2H), 4.24 – 4.11 (m, 2H), 3.81 (s, 
3H), 3.52 – 3.48 (m, 2H), 2.50 – 2.29 (m, 4H), 1.44 (s, 3H, CH3), 1.36 (s, 3H, CH3), 
1.33 (d, J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 170.5, 165.3, 163.7, 
141.1, 133.5, 133.3, 124.6, 118.1, 110.6, 108.3, 104.6, 99.8, 77.8, 76.6, 72.0, 61.6, 
55.4, 40.2, 28.3, 28.0, 25.4, 19.5. HRMS (ESI-TOF) m/z calcd for C22H29O7 [M-H]
- 
405.1919, found 405.1907. 
The preparation of 3.10 was carried out similarly from 3.6 following the procedure for 
the preparation of 3.8.  
3.10: colorless gum. 1H NMR (400 MHz, CDCl3) δ 11.85 (s, 1H, OH), 6.34 (d, J = 
2.6 Hz, 1H), 6.27 (d, J = 2.6 Hz, 1H), 5.86 – 5.75 (m, 1H), 5.34 – 5.27 (m, 1H), 5.18 
– 5.04 (m, 2H), 4.17 – 4.10 (m, 2H), 3.79 (s, 6H), 3.60 (t, J = 5.5 Hz, 2H), 3.09 – 3.02 
(m, 1H), 2.82 – 2.73 (m, 1H), 2.56 – 2.37 (m, 2H), 1.88 – 1.80 (m, 2H), 1.65 – 1.50 
(m, 2H), 1.45 (s, 3H, CH3), 1.39 (d, J = 6.3 Hz, 3H, CH3), 1.34 (s, 3H, CH3). 
13C 
NMR (100 MHz, CDCl3) δ 170.9, 165.8, 163.9, 147.0, 133.3, 118.3, 110.8, 108.1, 




104.9, 99.0, 77.9, 76.9, 71.8, 61.9, 55.3, 40.2, 36.7, 29.1, 28.9, 28.2, 25.4, 19.5. 
HRMS (ESI-TOF) m/z calcd for C22H31O7 [M-H]
- 407.2075, found 407.2068. 
Synthesis of Compound 3.9 and 3.11 
3.9:  
To a solution of 3.7 (12 mg, 0.023 mmol) in MeOH 
(400 µL) was added 2N HCl (100 µL). The mixture 
was stirred at room temperature for 3 hours. Saturated NaHCO3 solution was added to 
above mixture dropwise to adjust pH to ~ 6-7, the mixture was then diluted with 
EtOAc and water, extracted with more EtOAc (2 mL x 3), washed with brine, dried 
over MgSO4, concentrated, and then subjected to column chromotography (50-100% 
EtOAc in petroleum ether) to afford compound (3.9) (6.8 mg, 81%) as a colorless 
gum. 1H NMR (400 MHz, acetone-d6) δ 11.66 (s, 1H, OH), 6.81 (d, J = 11.6 Hz, 1H), 
6.46 (d, J = 2.4 Hz, 1H), 6.38 (d, J = 2.4 Hz, 1H), 5.96 – 5.77 (m, 2H), 5.25 - 5.19 (m, 
1H), 5.18 – 5.06 (m, 2H), 3.84 (s, 3H, OCH3), 3.75 - 3.44 (m, 7H, including OHs), 
2.56 – 2.42 (m, 3H), 2.36 – 2.27 (m, 1H), 1.35 (d, J = 6.3 Hz, 3H, CH3). 13C NMR 
(100 MHz, acetone-d6) δ 171.6, 165.9, 164.8, 143.0, 135.0, 132.9, 127.9, 118.2, 110.9, 
105.6, 100.7, 75.1, 73.7, 72.9, 64.6, 55.9, 40.8, 33.2, 19.7. HRMS (ESI-TOF) m/z 
calcd for C19H25O7 [M-H]
- 365.1606, found 365.1610. 
 
Compound 3.11 was prepared similarly from 3.7 as 
colorless gum (8.2 mg, 73%). 1H NMR (400 MHz, 
acetone-d6) δ 11.74 (s, 1H, OH), 6.38 (d, J = 2.6 Hz, 
1H), 6.32 (d, J = 2.6 Hz, 1H), 5.95 - 5.83 (m, 1H), 5.34 - 5.28 (m, 1H), 5.20 – 5.07 (m, 




2H), 3.82 (s, 3H, OCH3), 3.75 – 3.55 (m, 6H, include OHs), 3.47 - 3.42 (m, 1H), 3.05 
- 2.85 (m, 2H), 2.63 – 2.45 (m, 2H), 1.95 - 1.74 (m, 2H), 1.68 – 1.45 (m, 2H), 1.42 (d, 
J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, acetone-d6) δ 171.9, 166.4, 165.0, 148.9, 
134.9, 118.3, 111.1, 105.9, 99.8, 75.5, 73.7, 72.7, 64.9, 55.8, 40.8, 37.5, 34.3, 29.2, 
19.7. HRMS (ESI-TOF) m/z calcd for C19H27O7 [M-H]
- 367.1762, found 367.1764. 
 
Compound 3.12 (5.4 mg) was prepared from 2.9 (10 
mg) similarly by trans-esterification and deprotection of 
OTBS in 66% yield as colorless gum. 1H NMR (400 
MHz, CDCl3) δ 11.68 (s, 1H, OH), 7.08 (d, J = 15.5 Hz, 1H), 6.45 (d, J = 2.5 Hz, 1H), 
6.39 (d, J = 2.5 Hz, 1H), 5.93 – 5.77 (m, 2H), 5.31 – 5.23 (m, 1H), 5.18 – 5.10 (m, 
2H), 4.34 – 4.28 (m, 1H), 4.24 – 4.19 (m, 1H), 3.82 (s, 3H, OCH3), 3.69 (t, J = 5.9 Hz, 
2H), 2.60 – 2.40 (m, 4H), 1.50 (s, 3H), 1.38 (s, 3H), 1.37 (d, J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 170.6, 165.0, 164.0, 143.0, 133.9, 133.4, 127.4, 118.3, 
108.5, 108.3, 104.1, 99.9, 77.8, 76.5, 71.9, 61.7, 55.4, 40.2, 32.9, 28.1, 25.4, 19.6. 
HRMS (ESI-TOF) m/z calcd for C22H29O7 [M-H]
- 405.1919, found 405.1911. 
 
Synthesis of Compound 3.17 
5,7-Dihydroxy-2,2-dimethyl-4H-1,3-benzodioxin-4-one (3.15) 
To a solution of 2,4,6-trihydroxybenzoic acid monohydrate (94% 
purity, 1.0 g, 5.00 mmol) in acetone (10 mL) was added TFA (4 mL) 
and TFAA (2.5 mL) slowly at 0 °C.  The mixture was warmed to 
room temperature and stirred for 15 hours after which it was refluxed for another 6 




hours, cooled to room temperature. The solution mixture was concentrated under 
reduced pressure and then diluted with EtOAc and water. Saturated sodium 
bicarbonate was added slowly to above mixture under stirring to adjust the aqueous 
pH to 5~6. The organic layer was extracted with EtOAc (30 mL x 3), washed with 
brine, dried over MgSO4 and concentrated to give a brown solid which after 
precipitation from DCM gave a white solid. The solid was filtered off as pure product 
3.15. The solution was concentrated and purified by column chromatography (0-50% 
EtOAc in petroleum ether) to afford the title compound (3.15) as yellowish to white 
powder. The combined yield of 3.15 was 63% (657 mg). The data of NMR and MS 
(ESI) match the literature results.188 
5-Hydroxy-7-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
(3.16)  
To a stirred solution of 3.15 (420 mg, 2.00 mmol) in 
anhydrous THF (20 mL) was added triethylamine (556 µL, 
4.00 mmol) at 0 °C and the mixture was stirred for 20 min then 
MOMCl (228 µL, 2.40 mmol) was added portion-wise over 2 hours. The mixture was 
stirred for another 3 hours upon slowly warmed to room temperature, quenched by 
addition of sat. NH4Cl, diluted with water and extracted with EtOAc (30 mL x 3), 
washed with brine, dried over MgSO4 and concentrated to give a crude product which 
was purified by column chromatography (0-25% EtOAc in hexane) to afford the title 
compound (3.16) (459 mg, 90%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 6.28 
(d, J = 2.2 Hz, 1H), 6.13 (d, J = 2.2 Hz, 1H), 5.17 (s, 2H), 3.47 (s, 3H, OCH3), 1.73 (s, 
6H, CH3x2). 
13C NMR (100 MHz, CDCl3) δ 165.3, 165.2, 162.9, 156.9, 107.0, 98.0, 
95.9, 94.1, 93.8, 56.5, 25.7 (2C); ESI-MS m/z 253 [M-H]-. 





The solution of compound 2.52 (254 mg, 1.00 mmol), 
N-(hydroxypropyl)phthalimide (226 mg, 1.10 mmol) 
and triphenylphosphine (393 mg, 1.50 mmol) in THF 
(10 mL) was degassed and refilled with argon, DIAD 
(256 µL, 1.30 mmol) was then added via syringe. The mixture was stirred for 2 hours, 
THF was then removed under reduced pressure. The crude product was purified by 
silica gel column chromotography (0-50% EtOAc in petroleum ether) to afford 
compound (2.53) (410 mg, 93%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.81 
(dd, J = 5.4, 3.0 Hz, 1H), 7.69 (dd, J = 5.5, 3.0 Hz, 1H), 6.20 ( br s, 2H), 5.16 (s, 2H), 
4.09 (t, J = 6.2 Hz, 2H), 3.97 (t, J = 6.6 Hz, 2H), 3.47 (s, 3H), 2.30 – 2.22 (m, 2H), 
1.66 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 176.2, 168.4, 163.8, 162.0, 159.1, 157.7, 
133.9 (2C), 132.2, 123.2 (2C), 105.0, 97.7, 96.0, 95.7, 94.2, 66.9, 56.5, 35.3, 28.3, 
25.6 (2C), 20.7. ESI-MS m/z 442 [M+H]+, 464 [M+Na]+. 
General procedure for the preparation of 3.19a, b and 3.21, 3.23  
3.23:  
To the suspension of NaH (60%, 20 mg, 0.50 mmol) in THF 
(1 mL) was added the solution of alcohol (18 µL, 0.13 mmol) 
in THF (0.5 mL) at 0 °C. The mixture was stirred at 0 °C for 
15 min then the solution of compound 3.17 in THF (0.5 mL) 
was added slowly. The mixture was then warmed to room temperature and continued 
stirring for 16 hours, then quenched with saturated NH4Cl, diluted with EtOAc (3 mL) 
and H2O (2 mL). The organic phase was extracted with EtOAc (3 mL x 3), washed 




with brine, dried (MgSO4) and concentrated under reduced pressure. The crude 
product was purified by silica gel column chromatography (0-40% EtOAc in 
petroleum ether) to afford compound 3.21 (31 mg, 61%) as a white solid. To a 
solution of 3.23 (24 mg, 0.046 mmol) in MeOH (800 µL) and DCM (400 µL) was 
added 2N HCl (200 µL). The mixture was stirred at 45 °C for 16 hours. Saturated 
NaHCO3 solution was added to above mixture dropwise to adjust pH to ~ 6-7, the 
mixture was then diluted with EtOAc and water, extracted with more EtOAc (3 mL x 
3), washed with brine, dried over MgSO4, concentrated, and then subjected to column 
chromotography (0-30% EtOAc in petroleum ether) to afford compound 3.23 (16 mg, 
74%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 12.02 (s, 1H, OH), 7.85 (dd, J = 
5.4, 3.0 Hz, 2H), 7.72 (dd, J = 5.4, 3.0 Hz, 2H), 7.44 – 7.40 (m, 2H), 7.33 (t, J = 7.5 
Hz, 2H), 7.27 – 7.22 (m, 2H), 6.40 (br s, 1H), 6.03 (d, J = 2.2 Hz, 1H), 5.93 (d, J = 
2.2 Hz, 1H), 5.90 (t, J = 6.9 Hz, 1H), 4.00 (t, J = 6.5 Hz, 2H), 3.90 (td, J = 6.6, 1.3 Hz, 
2H), 2.27 - 2.20 (m, 2H), 2.13 - 2.07 (m, 1H), 2.02 – 1.92 (m, 1H), 0.97 (t, J = 7.4 Hz, 
3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 170.7, 168.6 (2C), 165.7, 162.1, 162.0, 
140.6, 134.2 (2C), 131.9 (2C), 128.4 (2C), 127.8, 126.6 (2C), 123.4 (2C), 97.0, 96.4, 
92.5, 78.6, 66.6, 35.2, 29.5, 28.6, 10.2. HRMS (ESI-TOF) m/z calcd for C27H24NO7 
[M-H]- 474.1553, found 474.1542. 
Compound 3.21 was prepared similarly from 3.17 and the 
corresponding alcohol according the procedure to prepare 
3.23. Colorless gum, 1H NMR (400 MHz, CDCl3) δ 11.98 (s, 
1H, OH), 7.83 (dd, J = 5.4, 3.0 Hz, 2H), 7.71 (dd, J = 5.4, 
3.0 Hz, 2H), 6.04 (d, J = 2.2 Hz, 1H), 5.91 (d, J = 2.2 Hz, 1H), 5.63 (br s, 1H), 4.79 - 
4.67 (m, 2H), 4.00 (t, J = 6.1 Hz, 2H), 3.91 (t, J = 6.9 Hz, 2H), 2.42 – 2.15 (m, 6H), 




2.07 (br s, 1H), 1.24 (s, 3H, CH3), 1.19 (d, J = 8.6 Hz, 1H), 0.78 (s, 3H, CH3). 
13C 
NMR (100 MHz, CDCl3) δ 171.0, 168.5 (2C), 165.4, 161.9, 161.9, 142.9, 134.1 (2C), 
132.0 (2C), 123.3 (2C), 121.2, 97.0, 96.4, 92.4, 67.3, 66.5, 43.5, 40.7, 38.1, 35.4, 31.5, 
31.2, 28.4, 26.1, 20.9. HRMS (ESI-TOF) m/z calcd for C28H28NO7 [M-H]
- 490.1866, 
found 490.1854. 
Compound 3.19a was prepared similarly as a white solid 
in two steps from 3.17 and (S)-pent-4-en-2-ol (8%). 1H 
NMR (400 MHz, acetone-d6) δ 12.02 (s, 1H, OH), 7.87 - 
7.82 (m, 4H), 6.00 (d, J = 2.3 Hz, 1H), 5.99 (d, J = 2.3 
Hz, 1H), 5.95 - 5.84 (m, 1H), 5.28 - 5.20 (m, 1H), 5.18 – 5.13 (m, 1H), 5.07 – 5.03 (m, 
1H), 4.08 - 4.03 (m, 2H), 3.94 (t, J = 6.9 Hz, 2H), 2.63 – 2.44 (m, 2H), 2.26 - 2.19 (m, 
2H), 1.39 (d, J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, acetone-d6) δ 171.9, 168.9 
(2C), 166.6, 164.7, 163.2, 135.2, 135.0 (2C), 133.3 (2C), 123.7 (2C), 117.9, 96.9, 96.6, 
93.3, 72.0, 67.3, 40.9, 36.1, 29.2, 19.9. HRMS (ESI-TOF) m/z calcd for C23H22NO7 
[M-H]- 424.1402, found 424.1409. 
Compound 3.19b was prepared similarly as a white solid in 
two steps 3.17 and (R)-pent-4-en-2-ol (12%). 1H NMR (400 
MHz, acetone-d6) δ 12.02 (s, 1H, OH), 7.88 – 7.82 (m, 4H), 
6.00 (d, J = 2.3 Hz, 1H), 5.99 (d, J = 2.3 Hz, 1H), 5.95 – 5.84 
(m, 1H), 5.28 - 5.20 (m, 1H), 5.18 – 5.12 (m, 1H), 5.08 – 5.03 (m, 1H), 4.08 - 4.02 (m, 
2H), 3.94 (t, J = 6.8 Hz, 2H), 2.64 – 2.44 (m, 2H), 2.26 - 2.18 (m, 2H), 1.40 (d, J = 
6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, acetone-d6) δ 171.9, 168.9 (2C), 166.6, 164.6, 
163.2, 135.2, 135.0 (2C), 133.3 (2C), 123.7 (2C), 117.9, 96.9, 96.6, 93.3, 72.0, 67.3, 




40.9, 36.1, 29.2, 19.9. HRMS (ESI-TOF) m/z calcd for C23H22NO7 [M-H]
- 424.1396, 
found 424.1389. 
Synthesis of compounds 3.25 – 3.28  
To a solution of allylamine (1M in THF, 300 µL) in THF (2 mL) was added LiHMDS 
°C under argon, the mixture was stirred at 0 °C for 20 min 
followed by the addition of  the solution of compound 3.17 (88 mg, 0.20 mmol) in 
THF (1 mL) slowly via syringe. The mixture was slowly warmed to room temperature 
and stirred for 8 hours. The reaction was quenched by the addition of saturated NH4Cl, 
diluted with EtOAc and water, then extracted with EtOAc (5 mL x 3), washed with 
brine, dried (MgSO4) and concentrated under reduced pressure. The crude product 
was purified by preparative HPLC [Gemini C18 column, 10x100 mm, 5 mL/min, 
acetonitrile/H2O, 20% (2 min) – 20% to 80% (25 min) – 80% (10 min)] to afford 
three main products (3.25, 3.26 and 3.27) as well as recovered starting material 3.17. 
 
Compound 3.25: tR = 13.3 min. White solid. 
1H 
NMR (400 MHz, CDCl3) δ 8.03 (br s, 1H, NH), 
7.73 – 7.69 (m, 1H), 7.46 - 7.42 (m, 3H), 6.23 
(d, J = 2.2 Hz, 1H), 6.21 (d, J = 2.2 Hz, 1H), 
5.93 - 5.83 (m, 1H), 5.24 (dd, J = 17.2, 1.5 Hz, 1H), 5.17 (s, 2H), 5.12 (dd, J = 10.3, 
1.5 Hz, 1H), 4.15 (t, J = 5.6 Hz, 2H), 4.01 - 3.97 (m, 2H), 3.73 - 3.62 (m, 2H), 3.48 (s, 
3H), 2.19 – 2.12 (m, 2H), 1.61 (s, 6H). ESI-MS m/z 499 [M+H]+, 521 [M+Na]+. 
 




Compound 3.26: tR = 14.7 min. White solid. 
1H 
NMR (400 MHz, CDCl3) δ 14.13 (s, 1H, OH), 
8.38 (br s, 1H, NH), 7.68 – 7.66 (m, 1H), 7.54 – 
7.47 (m, 3H), 7.13 (br s, 1H, NH), 6.42 (br s, 1H, 
NH), 6.28 (d, J = 2.3 Hz, 1H), 6.10 (d, J = 2.3 Hz, 1H), 6.00 – 5.82 (m, 2H), 5.29 – 
5.22 (m, 2H), 5.19 – 5.14 (m, 2H), 5.15 (s, 2H), 4.19 (t, J = 6.2 Hz, 2H), 4.05 (t, J = 
5.6 Hz, 2H), 4.00 (t, J = 5.6 Hz, 2H), 3.57 (q, J = 6.6 Hz, 2H), 3.46 (s, 3H, OCH3), 
2.16 – 2.09 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 169.9, 169.6, 169.0, 166.1, 161.2, 
159.0, 134.6, 134.5, 134.3, 133.3, 130.5, 130.4, 129.0, 127.8, 117.0, 116.4, 98.7, 97.6, 
94.1, 92.0, 66.5, 56.3, 42.5, 41.7, 36.8, 29.1. ESI-MS m/z 496 [M-H]-, 498 [M+H]+, 
520 [M+Na]+.                      
 
Compound 3.27: tR = 20.4 min.
 White solid. 1H NMR 
(400 MHz, CDCl3) δ 14.15 (s, 1H, OH), 8.40 (br s, 1H, 
NH), 7.85 (dd, J = 5.5, 3.0 Hz, 2H), 7.74 (dd, J = 5.5, 
3.0 Hz, 2H), 6.28 (d, J = 2.3 Hz, 1H), 6.04 (d, J = 2.3 Hz, 1H), 6.02 – 5.95 (m, 1H), 
5.28 (dd, J = 17.1, 1.5 Hz, 1H), 5.18 – 5.14 (m, 2H), 5.15 (s, 2H), 4.14 (q, J = 5.9 Hz, 
4H), 3.87 (t, J = 6.9 Hz, 2H), 3.46 (s, 3H), 2.25 – 2.18 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 169.9, 168.3, 166.1 (2C), 161.2, 158.8, 134.4, 134.2 (2C), 132.0 (2C), 123.4 
(2C), 116.2, 98.7, 97.7, 94.1, 91.9, 66.3, 56.3, 41.7, 34.8, 28.2. HRMS (ESI-TOF) m/z 
calcd for C23H23N2O7 [M-H]
- 439.1511, found 439.1524. 




Compound 3.28: To a solution of 3.27 (2.5 mg, 5.67 
µmol) in MeOH (300 µL) was added 2N HCl (100 µL). 
The mixture was stirred at 50 °C for 8 hours. Saturated 
NaHCO3 solution was added to above mixture 
dropwise to adjust pH to ~ 6 - 7, the mixture was then diluted with EtOAc and water, 
extracted with more EtOAc (1 mL x 3), washed with brine, dried over MgSO4, then 
concentrated, the crude product was purified by semi-preparative HPLC [tR = 24.9 
min, Gemini C18 column, 10x100 mm, 6 mL/min, acetonitrile/H2O, 20% (2 min) – 20% 
to 80% (35 min) – 80% (5 min)] to give 3.28 as white solid. 1H NMR (400 MHz, 
CDCl3) δ 14.21 (s, 1H, OH), 8.36 (br s, 1H, NH), 7.86 (dd, J = 5.5, 3.1 Hz, 2H), 7.74 
(dd, J = 5.5, 3.1 Hz, 2H), 6.04 (d, J = 2.3 Hz, 1H), 6.03 – 5.93 (m, 1H), 5.91 (d, J = 
2.3 Hz, 1H), 5.31 – 5.25 (m, 1H), 5.16 (dd, J = 10.2, 1.4 Hz, 1H), 4.15 – 4.09 (m, 4H), 
3.88 (t, J = 6.9 Hz, 2H), 2.25 – 2.18 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 169.9, 
168.3, 166.2, 164.3, 159.9, 159.4, 134.4, 134.2 (2C), 131.9, 123.4 (2C), 116.2, 97.7, 
91.1, 66.4, 41.9, 34.8, 28.2 (2 quaternary carbons missing). HRMS (ESI-TOF) m/z 
calcd for C21H19N2O6 [M-H]
- 395.1242, found 395.1249. 
6.4 Experimental details for Chapter 4 
6.4.1 Synthetic procedures and data characterization of enamide RAL analogues 
6.4.1.1 Synthesis of trans-enamide RALs 
7-(Methoxymethoxy)-2,2-dimethyl-4-oxo-4H-
benzo[d][1,3]dioxin-5-yl trifluoromethanesulfonate (4.1)  
To a stirred solution of 3.16 (1.85 g, 7.28 mmol) in anhydrous 
DCM (40 mL) was added anhydrous pyridine (1.77 mL, 21.84 mmol). After stirring 




at 0 °C for 15 min, trifluoromethane sulfonic anhydride (1.48 mL, 8.74 mmol) was 
added dropwise at 0 °C and the mixture was slowly warmed to room temperature and 
stirred for 3 hours, then quenched by addition of sat. NH4Cl. The DCM was removed 
under reduced pressure. The crude mixture was diluted with water and extracted with 
EtOAc (80 mL x 3), washed with brine, dried over MgSO4 and concentrated to give a 
crude product which was purified by column chromatography (0-30% EtOAc in 
petroleum ether) to afford the title compound (4.1) (2.19 g, 78%)  as a white solid. 1H 
NMR (400 MHz, CDCl3) δ 6.67 (d, J = 2.3 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.66 (s, 
1H), 5.22 (s, 2H), 3.50 (s, 3H), 1.74 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 163.2, 
158.6, 157.0, 149.8, 120.4, 106.6, 106.5, 103.7, 94.7, 56.8, 25.6. ESI-MS m/z 387 
[M+H]+, 409 [M+Na]+. 
5-(4-Hydroxybutyl)-7-(methoxymethoxy)-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-
one (4.2)  
To a solution of aryl triflate 4.1 (1.56 g, 4.05 mmol) and 
3-buten-1-ol (624 µL, 7.29 mmol) in DMF (20 mL) was 
added Pd2(dba)3 (147 mg, 4 mol%) and then 
diisopropylethylamine (1.42 mL). The mixture was degassed under reduced pressure 
and refilled with argon (repeat 3 times), stirred at 90 °C (equipped with a condenser) 
for 2 hours before being cooled to ambient temperature. The palladium precipitate 
was filtered off through Celite and the solvent was removed under reduced pressure. 
The crude intermediate was re-dissolved in EtOAc (20 mL) and 10% Pd/C (66 mg, 10 
mol%) was then added. The mixture was stirred under H2 atomosphere (balloon) at 
room temperature for 16 hours. The Pd/C catalyst was removed by filtration and 




EtOAc evaporated under reduced pressure. The crude product was purified by column 
chromotography on silica gel (0-50% EtOAc in petroleum ether) to afford the title 
compound (4.2) (colorless gum, 898 mg, 71%) and an aldehyde product (280 mg). 
The aldehyde (280 mg, 0.91 mmol) was dissolved in MeOH and added portionwise 
NaBH4 (172 mg, 4.55 mmol) at 0 °C. The mixture was stirred under argon for 1 hour, 
and quenched with saturated NH4Cl, diluted with EtOAc and water, extracted with 
more EtOAc (15 mL x 3), washed with brine, dried over MgSO4, concentrated, and 
then subjected to column chromotography (0-50% EtOAc in petroleum ether) to 
afford second batch of compound (4.2) (279 mg). The combined yield of 4.2 was 90%. 
1H NMR (400 MHz, CDCl3) δ 6.57 (d, J = 2.4 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 5.18 
(s, 2H), 3.71 (t, J = 6.0 Hz, 2H), 3.47 (s, 3H, OCH3), 3.03 (t, J = 7.8 Hz, 2H), 1.68 (s, 
6H, CH3x2 ), 1.70 - 1.64 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ 162.6, 160.3, 159.0, 
150.0, 113.5, 105.6, 105.0, 101.8, 94.1, 62.0, 56.4, 34.0, 32.2, 26.9, 25.6 (2C). ESI-
MS m/z 311 [M+H]+, 643 [2M+Na]+. 
(E)-5-(4-Hydroxybut-1-en-1-yl)-7-(methoxymethoxy)-2,2-dimethyl-4H-
benzo[d][1,3]dioxin-4-one (4.11)  
4.11 was prepared by Heck coupling following the first 
step in the preparation of 4.2. The product was purified 
by repeated silica gel column chromotography. 1H NMR 
(400 MHz, CDCl3) δ 7.43 (d, J = 15.8 Hz, 1H), 6.83 (d, J = 2.4 Hz, 1H), 6.52 (d, J = 
2.4 Hz, 1H), 6.14 (dt, J = 15.8, 7.1 Hz, 1H), 5.21 (s, 2H), 3.79 (t, J = 6.1 Hz, 2H), 
3.49 (s, 3H, OCH3), 2.56 - 2.49 (m, 2H), 1.70 (s, 6H, CH3x2). ESI-MS m/z 309 
[M+H]+. 





one (4.3)  
To a solution of compound 4.2 (2.03 g, 6.55 mmol) and 
triphenylphosphine (3.44 g, 13.10 mmol) in THF (50 mL) 
was added diphenylphosphoryl azide (2.39 mL, 11.13 
mmol) and then DIAD (2.19 mL, 11.13 mmol) under argon. The mixture was stirred 
at room temperature for 18 hours, THF was then removed under reduced pressure. 
The crude gum was triturated by vigorous stirring in 1:1 ether-petroleum ether (three 
times) to remove the PPh3O precipitates. The combined organic solution was then 
concentrated and then subjected to silica gel column chromatography (0-30% EtOAc 
in petroleum ether) to afford compound 4.3 (1.79 g, 82%) as a colorless gum. 1H 
NMR (400 MHz, CDCl3) δ 6.57 (d, J = 2.4 Hz, 1H), 6.48 (d, J = 2.4 Hz, 1H), 5.19 (s, 
2H), 3.49 (s, 3H, OCH3), 3.31 (t, J = 6.4 Hz, 2H), 3.07 (t, J = 7.2 Hz, 2H), 1.69 (s, 6H, 
CH3x2), 1.73 - 1.66 (m, 4H, overlapped). 
13C NMR (100 MHz, CDCl3) δ 162.5, 160.0, 
159.0, 149.3, 113.5, 105.7, 105.0, 101.9, 94.1, 56.5, 51.3, 34.1, 28.8, 28.0, 25.7. 
(S)-Pent-4-en-2-yl 2-(4-azidobutyl)-6-hydroxy-4-(methoxymethoxy)benzoate (4.4)  
To a suspension of 60% NaH in mineral oil (112 mg, 4.66 
mmol) in anhydrous THF (4 mL) was added the (S)-4-
penten-2-ol (90 µL, 0.87 mmol) at 0 °C and stirred for 10 
min, followed by the addition of a solution of compound 4.3 (195 mg, 0.58 mmol) in 
THF (1 mL). The mixture was stirred for 2 hours at 0 °C and then quenched by 
addition of saturated NH4Cl until the mixture was neutral. The organic phase was 
extracted with Et2O (20 mL x 3), washed with brine, dried over MgSO4 and 
concentrated to give a crude product which was purified by column chromatography 




(0-30% EtOAc in petroleum ether) to afford compound (4.4) (163 mg, 77%) as a 
colorless gum. 1H NMR (400 MHz, CDCl3) δ 11.70 (s, 1H, OH), 6.51 (d, J = 2.5 Hz, 
1H), 6.37 (d, J = 2.5 Hz, 1H), 5.87 - 5.75 (m, 1H), 5.36 - 5.28 (m, 1H), 5.17 (s, 2H), 
5.15 – 5.10 (m, 2H), 3.47 (s, 3H, OCH3), 3.29 (br t, 2H), 3.02 – 2.79 (m, 2H), 2.56 - 
2.39 (m, 2H), 1.70 - 1.62 (m, 4H), 1.39 (d, J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, 
CDCl3) δ 170.7, 165.4, 161.4, 147.0, 133.2, 118.4, 111.4, 106.0, 101.9, 93.9, 71.8, 
56.3, 51.5, 40.2, 36.3, 29.0, 19.5 (2C). 
(S)-Pent-4-en-2-yl 2-(4-aminobutyl)-6-hydroxy-4-(methoxymethoxy)benzoate 
acetic acid salt (4.5) 
To a solution of compound 4.4 (34 mg, 0.10 mmol) 
in THF (1 mL) and H2O (10 µL) was added 
triphenylphosphine (52 mg, 0.20 mmol). The mixture 
was stirred at room temperature for 16 hours under argon. The solvent was then 
removed under reduced pressure. EtOAc (3 mL), H2O (2 mL) and acetic acid (to pH ~ 
4 - 5) was added until the solution reached ~pH 5. . Extraction was repeated for three 
times between the organic phase and aqueous phase, the aqueous phase was then 
concentrated and dried under reduced pressure to afford amine salt 4.5 (30 mg, 76%) 
as a colorless gum. 1H NMR (400 MHz, CD3OD) δ 6.45 (d, J = 2.5 Hz, 1H), 6.43 (d, 
J = 2.5 Hz, 1H), 5.92 – 5.82 (m, 1H), 5.34 - 5.28 (m, 1H), 5.18 (s, 2H), 5.18 (s, 2H), 
5.18 - 5.16 (m, 1H, overlapped), 5.14 – 5.08 (m, 1H), 3.44 (s, 1H, OCH3), 3.00 - 2.80 
(m, 4H), 2.56 – 2.43 (m, 2H), 1.91 (s, 3H, CH3), 1.73 – 1.63 (m, 4H), 1.39 (d, J = 6.3 
Hz, 3H, CH3). 





(methoxymethoxy)benzoate (4.6)  
To a solution of compound 4.5 (30 mg, 0.075 
mmol) in anhydrous DCM (2 mL) was added the 
triethylamine (31 µL, 0.23 mmol) and stirred for 
10 min at room temperature. The reaction mixture was cooled to -15 °C, followed by 
the addition of crotonyl chloride (9 µL, 0.09 mmol) dropwise. The mixture was stirred 
for 1 hour at -15 °C  and then quenched by addition of saturated NH4Cl. DCM was 
removed and EtOAc and water were added. The organic phase was extracted with 
EtOAc, washed with brine, dried over MgSO4 and concentrated to give a crude 
product which was purified by column chromatography on silica gel (0-80% EtOAc 
in petroleum ether) to afford compound (4.6) (24 mg, 78%) as white solid. 1H NMR 
(400 MHz, CDCl3) δ 11.64 (s, 1H, OH), 11.64 (s, 1H), 6.82 (dq, J = 13.7, 6.8 Hz, 1H), 
6.50 (d, J = 2.5 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 5.85 – 5.73 (m, 2H), 5.44 (br s, 1H, 
NH), 5.34 - 5.27 (m, 1H), 5.16 (s, 2H), 5.17 – 5.08 (m, 2H), 3.46 (s, 3H, OCH3), 3.36 
- 3.30 (m, 2H), 3.01 - 2.78 (m, 2H), 2.54 – 2.37 (m, 2H), 1.84 (dd, J = 6.8, 1.5 Hz, 3H, 
CH3), 1.63 – 1.54 (m, 4H), 1.37 (d, J = 6.3 Hz, 3H, CH3). 13C NMR (100 MHz, 
CDCl3) δ 170.6, 165.9, 165.3, 161.4, 147.3, 139.7, 133.2, 125.1, 118.4, 111.4, 106.0, 








Compound 4.16 was prepared by acylation of 
4.5 with methacryloyl chloride following the 
procedure to synthesize 4.6. 1H NMR (400 MHz, 
CDCl3) δ 11.62 (s, 1H, OH), 6.50 (d, J = 2.6 Hz, 
1H), 6.37 (d, J = 2.6 Hz, 1H), 5.85 - 5.75 (m, 2H), 5.65 (br s, 1H, NH), 5.35 – 5.24 (m, 
2H), 5.17 (s, 2H), 5.18 – 5.09 (m, 2H), 3.47 (s, 3H, OCH3), 3.37 - 3.32 (m, 2H), 3.02 
– 2.80 (m, 2H), 2.54 – 2.38 (m, 2H), 1.96 (br s, 3H, CH3), 1.65 - 1.57 (m, 4H), 1.38 (d, 
J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 170.6, 168.4, 165.2, 161.4, 
147.3, 140.3, 133.2, 119.1, 118.4, 111.5, 106.0, 101.9, 93.9, 71.8, 56.3, 40.2, 39.6, 
36.3, 29.6, 29.2, 19.5, 18.7. HRMS (ESI-TOF) m/z calc. for C22H30NO6 [M-H]
-: 
404.2079, found 404.2065. 
(S,E)-16-Hydroxy-14-(methoxymethoxy)-3-methyl-3,4,9,10,11,12-hexahydro-1H 
benzo[l][1,7]oxaazacyclotetradecine-1,7(8H)-dione (4.7) 
To a solution of 4.6 (50 mg, 0.12 mmol) in DCM (25 
mL) was added Grubbs II catalyst (21 mg, 20 mol%). 
The mixture was refluxed under argon atmosphere for 8 
hour, cooled to ambient temperature, the catalyst was 
filtered off through a pad of Celite, the filtrate was concentrated to give the crude 
product which was purified by column chromatography on silica gel (0-100% EtOAc 
in petroleum ether) to afford compound (4.7) (27 mg, 60%) as white solid. 1H NMR 
(400 MHz, CDCl3) δ 11.75 (s, 1H, OH), 6.97 - 6.88 (m, 1H), 6.57 (t, J = 6.0 Hz, 1H, 
NH), 6.49 (d, J = 2.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 6.04 (d, J = 15.2 Hz, 1H), 
5.46 - 5.37 (m, 1H), 5.16 (s, 2H), 3.46 (s, 3H, OCH3), 3.48 - 3.40 (m, 1H), 3.30 – 3.21 
(m, 1H), 3.11 – 3.02 (m, 1H), 2.75 – 2.66 (m, 2H), 2.58 - 2.49 (m, 1H), 1.72 – 1.57 (m, 




4H), 1.40 (d, J = 6.3 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 171.0, 165.6, 
165.5, 161.5, 147.7, 138.6, 127.4, 111.3, 105.9, 101.8, 93.9, 71.3, 56.3, 39.5, 38.2, 





To a solution of 4.7 (9 mg, 0.025 mmol) in methanol (1.2 mL) 
was added 2 N HCl (300 L). The mixture was stirred at 
50 °C for 8 hours, then cooled to ambient temperature. 
Methanol was removed under reduced pressure, and EtOAc 
(3 mL) and H2O (2 mL) were added. The product was extracted with EtOAc (3 mL x 
3), washed with brine, dried with MgSO4 and concentrated. The crude product was 
purified by column chromatography on silica gel (0-100% EtOAc in petroleum ether) 
to afford compound 4.8 quantitatively as a white solid. 1H NMR (400 MHz, acetone-
d6) δ 11.74 (s, 1H, OH), 9.21 (br s, 1H, OH), 7.69 (t, J = 5.6 Hz, 1H, NH), 6.90 - 6.80 
(m, 1H), 6.28 (d, J = 2.4 Hz, 1H), 6.22 (d, J = 2.4 Hz, 1H), 6.18 (d, J = 15.3 Hz, 1H), 
5.46 - 5.38 (m, 1H), 3.50 – 3.39 (m, 1H), 3.25 - 3.15 (m, 1H), 3.09 – 3.02 (m, 1H), 
2.75 - 2.55 (m, 3H), 1.73 – 1.54 (m, 4H), 1.40 (d, J = 6.3 Hz, 3H, CH3). 13C NMR 
(100 MHz, acetone-d6) δ 172.1, 166.6, 166.0, 163.3, 148.8, 138.7, 128.8, 111.8, 105.0, 
101.9, 72.2, 39.8, 38.7, 36.9, 30.8, 30.3, 19.9. HRMS (ESI-TOF) m/z calc. for 
C17H20NO5 [M-H]








Compound 4.17 was prepared by RCM reaction 
following the procedure to synthesize 4.7. 1H NMR (400 
MHz, CDCl3) δ 11.42 (s, 1H, OH), 6.51 (d, J = 2.5 Hz, 
1H), 6.39 (d, J = 2.5 Hz, 1H), 5.64 (br s, 1H, NH), 5.52 – 
5.46 (m, 1H), 5.32 – 5.24 (m, 1H), 5.17 (s, 2H), 3.80 – 3.72 (m, 1H), 3.47 (s, 3H, 
OCH3), 3.27 – 3.17 (m, 1H), 3.05 – 2.95 (m, 2H), 2.75 - 2.65 (m, 1H), 2.38 - 2.30 (m, 
1H), 1.90 (s, 3H, CH3), 1.83 – 1.57 (m, 4H), 1.41 (d, J = 6.3 Hz, 3H, CH3). 13C NMR 
(100 MHz, CDCl3) δ 170.9, 170.5, 165.1, 161.5, 147.0, 135.8, 127.7, 110.8, 106.3, 




Compound 4.18 was prepared by MOM deprotection of 4.17 
following the procedure to synthesize 4.8. 1H NMR (400 MHz, 
acetone-d6) δ 11.55 (s, 1H, OH), 9.09 (br s, 1H, OH), 7.20 (br 
s, 1H, NH), 6.28 (d, J = 2.5 Hz, 2H), 6.23 (d, J = 2.5 Hz, 2H), 5.53 – 5.46 (m, 1H), 
5.23 - 5.15 (m, 1H), 3.70 – 3.62 (m, 1H), 3.24 - 3.02 (m, 2H), 2.94 - 2.85 (m, 1H), 
2.62 – 2.53 (m, 1H), 2.34 - 2.26 (m, 1H), 1.86 (t, J = 1.6 Hz, 3H, CH3), 1.77 – 1.52 (m, 
4H), 1.40 (d, J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, acetone-d6) δ 172.3, 170.6, 
166.2, 148.8, 137.1, 127.7, 110.7, 105.6, 101.7, 73.8, 40.0, 37.1, 36.7, 29.2, 29.0, 21.3, 
20.8 (one carbon missing). 
 
6.4.1.2 Synthesis of cis-enamides RALs 






To a solution of compound 4.3 (738 mg, 2.20 mmol) in 
THF (40 mL) and H2O (0.4 mL) was added 
triphenylphosphine (1.15 g, 4.40 mmol). The mixture 
was stirred at room temperature for 24 hours under argon. The solvent was then 
removed under reduced pressure. The crude mixture was subjected to column 
chromatography on silica gel by 80-100% EtOAc firstly to elute PPh3/PPh3O, 
followed by 10-20% MeOH in DCM (with 0.1% Et3N) to afford compound 4.21 (606 
mg, 89%) as a colorless gum. 1H NMR (400 MHz, CDCl3) δ 6.57 (d, J = 2.4 Hz, 1H), 
6.47 (d, J = 2.4 Hz, 1H), 5.18 (s, 2H), 3.48 (s, 3H, OCH3), 3.08 – 3.02 (m, 2H), 2.74 (t, 
J = 6.7 Hz, 2H), 1.69 (s, 6H, CH3x2), 1.67 – 1.51 (m, 4H). 13C NMR (100 MHz, 
CDCl3) δ 162.4, 160.1, 158.9, 150.0, 113.5, 105.7, 104.9, 101.7, 94.1, 56.4, 41.7, 34.4, 
33.5, 28.1, 25.7 (2C). 
 
(S)-5-Hydroxy-N-(4-(7-(methoxymethoxy)-2,2-dimethyl-4-oxo-4H-benzo[ 
d][1,3]dioxin-5-yl)butyl)hex-2-ynamide (4.22)  
A mixture of compound 4.21 (520 mg, 1.68 mmol), 
(S)-5-hydroxyhex-2-ynoic acid (258 mg, 2.02 mmol), 
EDCI (419 mg, 2.18 mmol) and HOBt (295 mg, 2.18 
mmol) was dissolved in anhydrous DMF (25 mL), and stirred  at room temperature 
under argon for 24 hours. DMF was then removed under reduced pressure and the 
crude product was purified by column chromatography on silica gel (0-60% EtOAc in 
petroleum ether) to afford compound (4.22) (528 mg, 75%) as a colorless gum. 1H 




NMR (400 MHz, CDCl3) δ 6.64 (br s, 1H, NH), 6.56 (d, J = 2.4 Hz, 1H), 6.47 (d, J = 
2.4 Hz, 1H), 5.18 (s, 2H), 4.06 - 3.98 (m, 1H), 3.48 (s, 3H, OCH3), 3.40 - 3.34 (m, 
2H), 3.03 - 2.95 (m, 2H), 2.52 - 2.37 (m, 2H), 1.69 (s, 6H, CH3x2), 1.66 - 1.60 (m, 
4H), 1.28 (d, J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 162.7, 160.5, 
159.1, 153.5, 149.6, 113.7, 105.4, 105.1, 102.0, 94.1, 83.7, 77.6, 65.8, 56.5, 38.7, 33.9, 
29.2, 28.6, 28.0, 25.6, 22.5 (2C). ESI-MS m/z 420 [M+H]+, 839 [2M+H]+. 
 
(S,Z)-5-Hydroxy-N-(4-(7-(methoxymethoxy)-2,2-dimethyl-4-oxo-4H-
benzo[d][1,3]dioxin-5-yl)butyl)hex-2-enamide (4.23a)  
To a solution of compound 4.22 (388 mg, 
0.93 mmol) in EtOAc (20 mL) was added 
quinoline (131 mg, 1.02 mmol). The mixture 
was degassed under nitrogen gas, then added 
5% Pd/CaCO3 (lead poisoned) (46 mg, 2 mol% of Pd). The resulting mixture was 
degassed again under H2 gas, then stirred under H2 balloon at room temperature for 30 
min. The catalyst was filtered off through Celite and the solvent evaporated under 
reduced pressure. The crude product was purified by silica gel column 
chromatography (0-5% methanol in DCM) to give cis-olefin product 4.23a (313 mg, 
80%) as a colorless gum. 1H NMR (400 MHz, CDCl3) δ 6.80 (br s, 1H, NH), 6.57 (d, 
J = 2.3 Hz, 1H), 6.48 (d, J = 2.3 Hz, 1H), 6.16 – 6.07 (m, 1H), 6.01 (d, J = 11.6 Hz, 
1H), 5.19 (s, 2H), 4.02 – 3.93 (m, 1H), 3.49 (s, 3H, OCH3), 3.45 – 3.38 (m, 2H), 3.04 
– 2.97 (m, 2H), 2.75 – 2.57 (m, 2H), 1.70 (s, 6H, CH3x2), 1.68 – 1.61 (m, 4H), 1.25 (d, 
J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 167.0, 162.7, 160.5, 159.0, 




149.7, 139.6, 126.1, 113.7, 105.4, 105.1, 102.0, 94.1, 67.1, 56.5, 38.2, 37.8, 34.0, 28.7, 




To the suspension of 60% NaH in mineral oil (5 mg, 
0.083 mmol) in anhydrous THF (1 mL) was added a 
solution of 4.23a (7 mg, 0.017 mmol) in THF (0.5 
mL) at 0 °C and the mixture was stirred for 90 min upon warmed to room temperature, 
then quenched by addition of saturated NH4Cl. The organic phase was extracted with 
EtOAc (2 mL x 3), washed with brine, dried over MgSO4 and concentrated to give a 
crude product which was purified by column chromatography on silica gel (0-100% 
EtOAc in petroleum ether) to afford compound (4.24a) (4.5 mg, 75%) as white solid. 
1H NMR (400 MHz, CDCl3) δ 11.70 (s, 1H, OH), 6.50 (d, J = 2.5 Hz, 1H), 6.40 (d, J 
= 2.5 Hz, 1H), 5.99 (dd, J = 11.5, 1.7 Hz, 1H), 5.90 (dt, J = 11.4, 5.7 Hz, 1H), 5.54 
(br s, 1H, NH), 5.41 – 5.33 (m, 1H), 5.17 (s, 2H), 3.84 - 3.75 (m, 1H), 3.46 (s, 3H, 
OCH3), 3.50 - 3.39 (m, 1H), 3.30 - 3.22 (m, 1H), 2.98 – 2.86 (m, 1H), 2.78 - 2.70 (m, 
1H), 2.44 – 2.37 (m, 1H), 1.94 - 1.51 (m, 4H), 1.43 (d, J = 6.3 Hz, 3H, CH3). 13C 
NMR (100 MHz, acetone-d6) δ 172.2, 167.9, 166.0, 162.4, 148.4, 136.3, 128.4, 128.4, 
110.1, 101.9, 94.7, 73.2, 56.3, 40.7, 36.0 (2C), 28.1, 27.7, 21.1. ESI-MS m/z 362 [M-
H]-, 725 [2M-H]-. 
 
(S,Z)-14,16-Dihydroxy-3-methyl-3,4,9,10,11,12-hexahydro-1H-benzo[ 
l][1,7]oxaazacyclotetradecine-1,7(8H)-dione (4.25a)  




Compound 4.25a was prepared by MOM deprotection of 
4.24a following the procedures for the synthesis of 4.8. 1H 
NMR (400 MHz, CD3OD) δ 6.23 (d, J = 2.4 Hz, 1H), 6.14 
(d, J = 2.4 Hz, 1H), 6.03 (dd, J = 11.7, 1.5 Hz, 1H), 5.97 (ddd, J = 11.7, 10.3, 4.8 Hz, 
1H), 5.37 - 5.28 (m, 1H), 3.58 - 3.52 (m, 1H), 3.34 - 3.25 (m, 1H, overlapped), 3.18 – 
3.07 (m, 1H), 3.02 – 2.95 (m, 1H), 2.72 - 2.63 (m, 1H), 2.52 - 2.45 (m, 1H), 1.81 - 
1.55 (m, 4H), 1.40 (d, J = 6.3 Hz, 3H, CH3); 
13C NMR (100 MHz, CD3OD) δ 172.6, 
170.4, 165.9, 163.6, 148.3, 137.3, 127.7, 110.3, 106.3, 101.7, 73.0, 40.9, 36.7, 36.3, 
28.5 (2C), 21.0. HRMS (ESI-TOF) m/z calc. for C17H20NO5 [M-H]




Compound 4.25b was prepared from 3.23b following the 
procedure to synthesize 4.25a. 1H NMR (400 MHz, 
MeOD) δ 6.20 (d, J = 2.5 Hz, 1H), 6.16 (d, J = 2.5 Hz, 
1H), 5.25 – 5.16 (m, 1H), 3.60 (dt, J = 13.6, 3.6 Hz, 1H), 3.09 (td, J = 12.1, 4.2 Hz, 
1H), 2.82 – 2.73 (m, 1H), 2.47 - 2.37 (m, 2H), 2.02 – 1.94 (m, 1H), 1.87 - 1.66 (m, 
5H), 1.62 - 1.53 (m, 2H), 1.41 - 1.28 (m, 1H, overlapped), 1.34 (d, J = 6.2 Hz, 3H, 
CH3). 
13C NMR (100 MHz, MeOD) δ 176.8, 172.9, 166.5, 164.0, 149.2, 112.1, 105.4, 
102.1, 73.8, 39.9, 38.4, 37.1, 35.5, 31.3, 31.0, 25.8, 21.4. HRMS (ESI-TOF) m/z calc. 
for C17H20NO5 [M-H]
-: 320.1498, found 320.1500. 
(S,5Z,11E)-14,16-Dihydroxy-3-methyl-3,4,9,10-tetrahydro-1H- 
benzo[l][1,7]oxaazacyclotetradecine-1,7(8H)-dione (4.30)  




Compound 3.30 was prepared from 4.11 following the 
procedures for the synthesis of 3.25a. 1H NMR (400 MHz, 
acetone-d6) δ 12.05 (s, 1H, OH), 7.12 (dd, J = 15.3, 1.4 Hz, 
1H), 6.87 (br s, 1H, NH), 6.49 (d, J = 2.5 Hz, 1H), 6.30 (d, J = 2.5 Hz, 1H), 5.95 (dd, 
J = 11.5, 2.0 Hz, 1H), 5.86 – 5.77 (m, 2H), 5.33 - 5.24 (m, 1H), 3.73 - 3.62 (m, 2H), 
3.05 – 2.94 (m, 1H), 2.87 – 2.75 (m, 1H), 2.35 - 2.23 (m, 2H), 1.43 (d, J = 6.1 Hz, 3H, 
CH3). 
13C NMR (100 MHz, CD3OD) δ 171.5, 168.4, 165.2, 162.6, 143.4, 136.1, 134.1, 
130.1, 126.1, 107.9, 102.3, 101.6, 72.2, 38.2, 35.3, 31.9, 20.0. HRMS (ESI-TOF) m/z 
calc. for C17H18NO5 [M-H]
-: 316.1190, found 316.1200. 
 
6.4.1.3 Synthesis of N-acetylated enamides 
(S,Z)-14,16-Bis(methoxymethoxy)-3-methyl-3,4,9,10,11,12-hexahydro-1H-
benzo[l][1]oxa[7]azacyclotetradecine-1,7(8H)-dione (4.31) 
To the suspension of 60% NaH in mineral oil (146 mg, 
3.66 mmol) in anhydrous THF (2 mL) was added the 
solution of 4.24a (332 mg, 0.92 mmol) in THF (0.5 mL) 
at 0 °C and the mixture was stirred for 10 min then MOM-Cl (104 µL, 1.37 mmol) 
was added slowly. The mixture was stirred for another 90 min at 0 °C, quenched by 
addition of sat. NH4Cl, diluted with water and extracted with EtOAc (3mL x 3). The 
combined organic phases were  washed with brine, dried over MgSO4 and 
concentrated to give a crude product which was purified by column chromatography 
on silica gel (0-100% EtOAc in petroleum ether) to afford compound (4.31) (347 mg, 
93%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 6.67 (d, J = 2.2 Hz, 1H), 6.51 (d, 




J = 2.2 Hz, 1H), 6.04 (br s, 1H, NH), 6.00 (d, J = 11.8 Hz, 1H), 5.96 – 5.88 (m, 1H), 
5.44 – 5.37 (m, 1H), 5.15 (s, 2H), 5.15 (d, J = 6.7 Hz, 2H), 5.09 (d, J = 6.7 Hz, 1H), 
3.46 (s, 3H), 3.45 (s, 3H), 3.40 – 3.15 (m, 3H), 2.79 - 2.72 (m, 1H), 2.63 - 2.55 (m, 
1H), 2.36 – 2.28 (m, 1H), 1.68 – 1.47 (m, 4H), 1.44 (d, J = 6.5 Hz, 3H, CH3). 13C 
NMR (100 MHz, CDCl3) δ 167.9, 167.1, 159.0, 156.1, 142.7, 131.1, 128.8, 117.1, 
111.3, 101.4, 94.7, 94.3, 70.2, 56.3, 56.2, 38.1, 35.7, 32.9, 27.1, 26.6, 18.9. ESI-MS 




To a solution of 4.31 (30 mg, 0.074 mol) in THF (2 mL) 
was added freshly prepared LDA (1 M in THF, 184 L) 
dropwise over 30 min at -78 °C. At the same time, 
acetic anhydride (1 M in THF, 147 L) was also added dropwise over 30 – 40 min. 
The mixture was stirred for another 20 min at -78 °C then quenched by the addition of 
saturated aq. NH4Cl at ca 0 °C, then warmly up to room temperature followed by 
addition of EtOAc and water. The mixture was extracted with EtOAc, and the extract 
was washed with brine, dried over MgSO4 and concentrated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (0-80% 
EtOAc in petroleum ether) to afford compound (4.32) (19.5 mg, 59%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 6.68 (d, J = 2.2 Hz, 1H), 6.53 (d, J = 2.2 Hz, 1H), 6.45 
- 6.38 (m, 1H), 6.35 (dd, J = 11.7, 1.3 Hz, 1H), 5.53 – 5.45 (m, 1H), 5.19 – 5.12 (m, 
4H), 4.00 - 3.93 (m, 1H), 3.54 - 3.49 (m, 1H), 3.49 (s, 3H, OCH3), 3.48 (s, 3H, OCH3), 
3.16 (dt, J = 16.5, 9.1 Hz, 1H), 2.72 - 2.62 (m, 2H), 2.52 – 2.45 (m, 1H), 2.45 (s, 3H, 




CH3), 1.72 - 1.57 (m, 4H), 1.45 (d, J = 6.4 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) 
δ 173.2, 169.6, 168.0, 158.8, 155.1, 143.4, 141.5, 125.2, 118.9, 109.8, 101.1, 94.7, 





To a solution of 4.32 (2 mg, 0.0045 mmol) in DCM 
(1 mL) was added 1 M TFA in DCM (200 µL). The 
mixture was stirred at room temperature for 30 min, 
a few drops of sat. NaHCO3 was added to adjust the pH to ~7. After removal of DCM, 
EtOAc and water were added. The organic phase was extracted with EtOAc and the 
extracts were washed with brine, dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel (0-
50% EtOAc in petroleum ether) to afford compound (4.32) (1.3 mg, 70%) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 11.85 (s, 1H, OH), 6.50 (d, J = 2.5 Hz, 1H), 6.33 
(d, J = 2.5 Hz, 1H), 6.32 (dd, J =11.6, 1.9 Hz, 1H, overlapped), 6.12 (ddd, J = 11.6, 
10.2, 3.7 Hz, 1H), 5.55 - 5.47 (m, 1H), 5.16 (s, 2H), 4.08 – 4.02 (m, 1H), 3.46 (s, 3H, 
OCH3), 3.37 - 3.28 (m, 1H), 3.12 – 2.93 (m, 2H), 2.74 - 2.66 (m, 1H), 2.55 - 2.45 (m, 
1H), 2.43 (s, 3H, COCH3), 1.98 – 1.87 (m, 1H), 1.62 - 1.45 (m, 3H, overlapped), 1.43 
(d, J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 173.0, 171.3, 170.7, 165.8, 
161.6, 147.1, 140.4, 127.0, 111.0, 105.7, 101.8, 93.9, 72.3, 56.3, 44.4, 36.4, 36.0, 29.8, 
28.7, 26.2, 20.6. HRMS (ESI-TOF) m/z calc. for C21H26NO7 [M-H]
-: 404.1715, found 
404.1716. 





benzo[l][1]oxa[7]azacyclotetradecine-1,7(8H)-dione (4.34) and 
(S,E)-8-acetyl-14,16-dihydroxy-3-methyl-3,4,9,10,11,12-hexahydro-1H-
benzo[l][1]oxa[7]azacyclotetradecine-1,7(8H)-dione (4.35) 
To compound 4.32 (4.2 mg, 9.3 μmol) was added boron trichloride solution (0.16 M 
in DCM, 0.5 mL) at -10 °C. The mixture was stirred for 2 hours then quenched by 
addition of sat. NaHCO3 to pH ~7. After removal of DCM, EtOAc and water were 
added. The organic phase was extracted with EtOAc, washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel (0-50% EtOAc in petroleum ether) to afford a 
mixture of cis (4.34) and trans products (3.35) (2.2 mg, 65%) as white solids, which 
after HPLC purification gave two pure products separately.    
Compound 4.34: 1H NMR (400 MHz, CDCl3) δ 11.90 (s, 
1H, OH), 6.32 (dd, J = 11.6, 2.0 Hz, 1H), 6.28 (d, J = 2.6 
Hz, 1H), 6.18 (d, J = 2.6 Hz, 1H), 6.12 (ddd, J = 11.6, 
10.2, 3.7 Hz, 1H), 5.57 - 5.48 (m, 1H), 4.09 – 4.01 (m, 1H), 3.38 – 3.28 (m, 1H), 3.11 
– 2.93 (m, 2H), 2.73 – 2.66 (m, 1H), 2.52 – 2.45 (m, 1H), 2.43 (s, 3H, COCH3), 1.99 
– 1.87 (m, 1H), 1.60 - 1.45 (m, 3H, hidden),1.43 (d, J = 6.2 Hz, 3H, CH3). 13C NMR 
(100 MHz, CDCl3) δ 140.5, 127.0, 110.3, 101.7, 72.3, 44.4, 36.4, 35.9, 29.8, 28.6, 
26.2, 20.6 (quaternary carbons are not shown). HRMS (ESI-TOF) m/z calc. for 
C19H22NO6 [M-H]
-: 360.1453, found 360.1451. 
Compound 4.35: 1H NMR (400 MHz, CD3OD) δ 6.94 (dt, J 
= 15.3, 7.4 Hz, 1H), 6.66 (d, J = 15.3 Hz, 1H), 6.24 (d, J = 




2.4 Hz, 1H), 6.18 (d, J = 2.4 Hz, 1H), 5.56 - 5.49 (m, 1H), 3.93 – 3.85 (m, 1H), 3.74 – 
3.65 (m, 1H), 3.07 – 2.98 (m, 1H), 2.82 – 2.62 (m, 3H), 2.37 (s, 3H, COCH3), 1.87 – 
1.79 (m, 1H), 1.64 – 1.54 (m, 2H), 1.54 - 1.45 (m, 1H), 1.47 (d, J = 6.4 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 170.5, 147.3, 141.9, 128.5, 109.1, 101.1, 70.8, 43.3, 
38.2, 34.5, 29.5, 26.3, 26.2, 18.8 (some quaternary carbons are not shown). HRMS 
(ESI-TOF) m/z calc. for C19H22NO6 [M-H]
-: 360.1453, found 360.1469. 
(S,Z)-16-Hydroxy-14-methoxy-3-methyl-3,4,9,10,11,12-hexahydro-1H-
benzo[l][1]oxa[7]azacyclotetradecine-1,7(8H)-dione (4.45)  
Compound 4.45 was prepared from 4.38 following the 
same procedures for the synthesis of 4.25a. 1H NMR 
(400 MHz, CDCl3) δ 11.86 (s, 1H), 6.33 (d, J = 2.6 Hz, 
1H), 6.30 (d, J = 2.6 Hz, 1H), 5.99 (dd, J = 11.6, 1.8 Hz, 1H), 5.89 (td, J = 11.6, 4.4 
Hz, 1H), 5.53 (br s, 1H, NH), 5.40 - 5.32 (m, 1H), 3.80 (s, 3H, CH3), 3.84 - 3.75 (m, 
1H), 3.50 – 3.39 (m, 1H), 3.30 - 3.21 (m, 1H), 2.97 - 2.88 (m, 1H), 2.77 - 2.68 (m, 
1H), 2.43 – 2.37 (m, 1H), 1.94 – 1.61 (m, 4H), 1.43 (d, J = 6.3 Hz, 3H, CH3). 13C 
NMR (100 MHz, CDCl3) δ 171.3, 167.6, 166.0, 164.0, 146.8, 136.3, 127.0, 109.4, 
105.1, 98.7, 71.9, 55.3, 40.3, 35.9, 35.0, 27.1, 26.7, 21.1. HRMS (ESI-TOF) m/z calc. 
for C18H22NO5 [M-H]
-: 332.1503, found 332.1513.  
 
(S,Z)-8-Acetyl-16-hydroxy-14-methoxy-3-methyl-3,4,9,10,11,12-hexahydro-1H-
benzo[l][1]oxa[7]azacyclotetradecine-1,7(8H)-dione (4.48)  




Compound 4.48 was prepared from 4.45 following 
the same procedures for the synthesis of 4.33.  1H 
NMR (400 MHz, CDCl3) δ 11.98 (s, 1H, OH), 6.34 
(d, J = 2.6 Hz, 2H), 6.32 (dd, J = 11.6, 2.3 Hz, 2H), 6.24 (d, J = 2.6 Hz, 1H), 6.12 
(ddd, J = 11.6, 10.2, 3.7 Hz, 1H), 5.55 - 5.46 (m, 1H), 4.05 (dt, J = 14.0, 6.4 Hz, 1H), 
3.79 (s, 3H, OCH3), 3.36 – 3.27 (m, 1H), 3.12 – 2.93 (m, 2H), 2.73 - 2.66 (m, 1H), 
2.53 – 2.46 (m, 1H), 2.43 (s, 3H, COCH3)1.98 – 1.87 (m, 1H), 1.60 - 1.43 (m, 3H, 
hidden), 1.43 (d, J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 173.0, 171.4, 
170.7, 166.3, 164.1, 147.0, 140.4, 127.0, 110.3, 104.7, 99.0, 72.3, 55.3, 44.4, 36.4, 
36.0, 29.8, 28.7, 26.2, 20.6. HRMS (ESI-TOF) m/z calc. for C20H24NO6 [M-H]
-: 
374.1609, found 374.1596. 
6.4.1.4 Synthesis of 3'-hydroxy E-enamides 4.62 and 4.64 
 (S)-2,2,3,3,8,8,9,9-Octamethyl-5-vinyl-4,7-dioxa-3,8-disiladecane (4.53):  
n-BuLi (13.6 mL, 31.40 mmol) was added slowly to a solution of 
methyltriphenylphosphonium bromide (14.04 g, 39.23 mmol) in 
THF (100 mL) at -78 °C. The solution was stirred for 1 hour while warmed to room 
temperature, and D-glyceraldehyde acetonide (3.40 g, 26.15 mmol) in THF (20 mL) 
was added slowly via cannular at 0 °C. The mixture was stirred at room temperature 
for 20 hours, and sat. NH4Cl was added. The mixture was diluted with H2O and 
extracted with ether (200 mL x 3). The organic layer was washed with brine, dried 
over MgSO4, and filtrated. The crude product was re-dissolved in MeOH (10 mL) and 
H2O (5 mL), TFA (8 mL) was then added. The mixture was stirred at room 
temperature for 2 hours, then adjusted to pH 5~6 by addition of sat. NaHCO3. MeOH 




was removed under reduced pressure. The organic phase was extracted with EtOAc 
(30 mL x 5), solvent was then removed. The crude diol product was subjected to TBS 
protection directly using TBSCl (11.30 g, 75 mmol), imidazole (8.51 g, 125 mmol) in 
DCM (150 mL). After stirring at room temperature for 16 hours, the precipitate was 
filtered off via celite. DCM was carefully removed under mild vacuum (~500 - 600 
mbar at 40 °C). The crude product was purified by Silica gel column chromatography 
using pure n-pentane to give 4.53 (4.82 g, 58% in 3 steps) as colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 5.86 (ddd, J = 17.2, 10.5, 5.3 Hz, 1H), 5.26 (dt, J = 17.2, 1.7 Hz, 
1H), 5.13 – 5.08 (m, 1H), 4.19 - 4.13 (m, 1H), 3.54 (dd, J = 9.9, 6.5 Hz, 1H), 3.45 (dd, 
J = 9.9, 5.9 Hz, 1H), 0.91 (s, 9H, CH3x3), 0.90 (s, 9H, CH3x3), 0.07 (s, 3H, CH3), 
0.06 (s, 3H, CH3), 0.05 (s, 6H, CH3x2). 
13C NMR (100 MHz, CDCl3) δ 138.9, 114.8, 
74.5, 68.0, 26.0 (3C), 25.9 (3C), 14.0, -4.7, -4.7, -5.3, -5.4. 
(S)-2-((tert-Butyldimethylsilyl)oxy)but-3-en-1-ol (4.54) 
To a solution of 4.53 (1.10 g, 3.47 mmol) in MeOH (3 mL) and DCM 
(30 mL) was added pyridinium tribromide (92 mg, 0.29 mmol) at 0 °C, 
the mixture was warmed up the room temperature and stirred for 4 hours and 
quenched by addition of sat. NaHCO3. The mixture was concentrated under mild 
vacuum and then diluted with ether and H2O, the ether extracts (100 mL x 3) after 
concentration again was  subjected to Silica gel column chromatography using ether 
in n-pentane (0-30%) to give 4.54 (301 mg, 43%) as colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 5.80 (ddd, J = 17.2, 10.5, 6.0 Hz, 1H), 5.28 (dt, J = 17.2, 1.5 Hz, 1H), 5.18 
– 5.15 (m, 1H), 4.26 – 4.19 (m, 1H), 3.58 – 3.42 (m, 2H), 1.92 (dd, J = 7.5, 5.5 Hz, 
1H, OH), 0.92 (s, 9H, CH3x3), 0.09 (s, 3H, CH3), 0.07 (s, 3H, CH3). 
13C NMR (100 
MHz, CDCl3) δ 137.9, 116.3, 74.5, 66.8, 25.8 (3C), 18.2, -4.4, -4.9. 




Compounds 4.55 to 4.62 were synthesized following the similar procedures in the 
preparation of analogue 4.34 (see previous procedures). 
 
Compound 4.55: 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J 
= 15.4 Hz, 1H), 6.82 (d, J = 2.2 Hz, 1H), 6.54 (d, J = 2.4 
Hz, 1H), 6.07 (dd, J = 15.9, 6.8 Hz, 1H), 5.20 (s, 2H), 
4.48 – 4.42 (m, 1H), 3.67 - 3.55 (m, 2H), 3.49 (s, 3H, OCH3), 1.70 (s, 6H, CH3x2), 
0.93 (s, 9H, CH3x3), 0.14 (s, 3H, CH3), 0.13 (s, 3H, CH3).
  13C NMR (100 MHz, 
CDCl3) δ 162.5, 160.0, 158.6, 143.1, 133.6, 130.0, 110.2, 105.2, 104.8, 102.9, 94.2, 
74.1, 66.9, 56.5, 25.9 (3C), 25.8, 25.5, 18.2, -4.2, -4.9. ESI-MS m/z 461 [M+Na]+.  
 
Compound 4.56: 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J 
= 15.9 Hz, 1H), 6.83 (d, J = 2.3 Hz, 1H), 6.56 (d, J = 2.4 
Hz, 1H), 6.10 (dd, J = 15.8, 6.7 Hz, 1H), 5.21 (s, 2H), 4.56 
– 4.49 (m, 1H), 3.49 (s, 3H), 3.34 - 3.25 (m, 2H), 1.70 (s, 
6H, CH3x2), 0.94 (s, 9H, CH3x3), 0.16 (s, 3H, CH3), 0.13 (s, 3H, CH3). 
13C NMR 
(100 MHz, CDCl3) δ 162.5, 159.9, 158.6, 142.8, 133.5, 130.1, 110.2, 105.2, 104.9, 
103.0, 94.2, 73.4, 57.3, 56.5, 25.8, 25.7, 25.6, 18.1, -4.4, -5.0. ESI-MS m/z 486 
[M+Na]+. 
 
Compound 4.58: 1H NMR (400 MHz, CDCl3) δ 7.43 
(d, J = 15.8 Hz, 1H), 6.74 (d, J = 2.1 Hz, 1H), 6.55 




(d, J = 2.4 Hz, 1H), 6.44 (br s, 1H, NH), 5.93 (dd, J = 15.8, 6.0 Hz, 1H), 5.21 (s, 2H), 
4.47 - 4.43 (m, 2H), 4.08 – 3.98 (m, 1H), 3.60 – 3.53 (m, 1H), 3.38 - 3.32 (m, 1H), 
2.53 (dd, J = 17.0, 4.3 Hz, 1H), 2.42 (dd, J = 17.0, 6.8 Hz, 1H), 1.72 (s, 3H, CH3), 
1.71 (s, 3H, CH3), 1.27 (d, J = 6.2 Hz, 3H, CH3), 0.93 (s, 9H, CH3x3), 0.13 (s, 3H, 
CH3), 0.12 (s, 3H, CH3). ESI-MS m/z 570 [M+Na]
+. 
 
Compound 4.59: 1H NMR (400 MHz, CDCl3) δ 7.43 
(d, J = 15.8 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 6.60 (br 
s, 1H, NH), 6.55 (d, J = 2.4 Hz, 1H), 6.18 - 6.11 (m, 
1H), 6.06 (d, J = 11.6 Hz, 1H), 5.98 (dd, J = 15.8, 5.8 
Hz, 1H), 5.21 (s, 1H), 4.50 – 4.45 (m, 1H), 3.98 - 3.92 (m, 1H), 3.65 – 3.56 (m, 1H), 
3.49 (s, 3H, OCH3), 3.39 – 3.33 (m, 1H), 2.68 - 2.62 (m, 2H), 1.72 (s, 3H, CH3), 1.71 
(s, 3H, CH3), 1.23 (d, J = 6.2 Hz, 3H, CH3), 0.93 (s, 9H, CH3x3), 0.12 (s, 6H, CH3x2). 
13C NMR (100 MHz, CDCl3) δ 167.3, 162.7, 160.3, 158.6, 143.4, 140.2, 134.4, 130.0, 
125.8, 110.5, 105.4, 104.7, 102.8, 94.2, 71.4, 67.0, 56.5, 45.1, 37.8, 25.9, 25.7, 25.6, 
25.5, 23.5, 18.2, -4.5, -4.9. ESI-MS m/z 572 [M+Na]+. 
Compound 4.60: 1H NMR (400 MHz, CDCl3) δ 
11.73 (s, 1H, OH), 7.44 (dd, J = 15.4, 1.7 Hz, 1H), 
6.58 (d, J = 2.5 Hz, 1H), 6.52 (d, J = 2.5 Hz, 1H), 
6.08 (br s, 1H), 5.89 (dd, J = 11.9, 1.5 Hz, 1H), 5.83 – 5.74 (m, 2H), 5.38 – 5.27 (m, 
1H), 5.21 (d, J = 6.8 Hz, 1H), 5.18 (d, J = 6.8 Hz, 1H), 4.76 - 4.73 (m, 1H), 3.77 – 
3.71 (m, 1H), 3.47 (s, 3H, OCH3), 3.27 - 3.17 (m, 2H), 2.34 – 2.26 (m, 1H), 1.49 (d, J 
= 6.2 Hz, 3H, CH3), 0.95 (s, 9H, CH3x3), 0.15 (s, 3H, CH3), 0.14 (s, 3H, CH3). 
13C 




NMR (100 MHz, CDCl3) δ 171.2, 166.9, 165.4, 161.9, 142.8, 133.1, 132.9, 131.5, 
128.4, 108.6, 104.5, 103.0, 93.9, 72.6, 69.3, 56.3, 45.0, 36.2, 25.9, 21.4, 18.3, -4.9, -
5.0. ESI-MS m/z 490 [M-H]-. 
 
Compound 4.61: 1H NMR (400 MHz, CDCl3) δ 6.84 
(d, J = 2.1 Hz, 1H), 6.75 (d, J = 2.1 Hz, 1H), 6.54 (d, 
J = 15.6 Hz, 1H), 6.05 - 5.97 (m, 1H), 5.96 - 5.89 (m, 
2H), 5.63 (br s, 1H, NH), 5.51 – 5.43 (m, 1H), 5.20 - 5.12 (m, 4H), 4.72 - 4.65 (m, 
1H), 3.78 - 3.72 (m, 1H), 3.47 (s, 3H, OCH3), 3.46 (s, 3H, OCH3), 3.35 – 3.26 (m, 
1H), 2.97 - 2.90 (m, 1H), 2.48 - 2.42 (m, 1H), 1.43 (d, J = 6.5 Hz, 3H), 0.91 (s, 9H, 
CH3x3), 0.12 (s, 3H, CH3), 0.10 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 166.9, 
166.2, 159.1, 155.9, 136.6, 134.1, 133.7, 129.1, 127.3, 117.5, 105.7, 103.3, 94.8, 94.4, 
71.1, 70.0, 56.2, 56.2, 45.5, 34.3, 25.8, 18.5, 18.2, -4.4, -4.7. ESI-MS m/z 536 [M+H]+, 
558 [M+Na]+. 
 
Compound 4.62: 1H NMR (400 MHz, CD3OD) δ 7.30 (dd, 
J = 15.6, 1.7 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 6.22 (d, J 
= 2.5 Hz, 1H), 5.96 (ddd, J = 11.6, 10.8, 5.0 Hz, 1H), 5.89 
(dd, J = 11.6, 1.2 Hz, 1H), 5.85 (dd, J = 15.6, 3.4 Hz, 1H), 5.30 - 5.22 (m, 1H), 4.63 - 
4.59 (m, 1H), 3.55 (d, J = 3.5 Hz, 1H), 3.46 (dd, J = 13.8, 2.8 Hz, 1H), 3.40 - 3.32 (m, 
1H), 2.46 - 2.40 (m, 1H), 1.46 (d, J = 6.2 Hz, 3H, CH3). 
13C NMR (100 MHz, CD3OD) 
δ 172.6, 170.5, 166.1, 164.1, 144.8, 137.0, 133.3, 132.5, 127.5, 109.3, 104.4, 102.9, 








Compound 4.63: 1H NMR (400 MHz, CDCl3) δ 6.81 
(d, J = 2.1 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 6.41 (d, J 
= 11.8 Hz, 1H), 6.27 (d, J = 15.7 Hz, 1H), 6.28 - 6.20 
(m, 1H), 5.96 (dd, J = 15.7, 8.4 Hz, 1H), 5.60 – 5.53 (m, 1H), 5.16 - 5.12 (m, 4H), 
4.82 - 4.75 (m, 1H), 3.95 (dd, J = 13.3, 9.2 Hz, 1H), 3.80 (dd, J = 13.3, 6.4 Hz, 1H), 
3.47 (s, 3H, OCH3), 3.44 (s, 3H, OCH3), 3.38 – 3.30 (m, 1H), 2.62 - 2.52 (m, 1H), 
2.21 (s, 3H, COCH3), 1.39 (d, J = 6.6 Hz, 3H, CH3), 0.91 (s, 9H, CH3x3), 0.11 (s, 3H, 
CH3), 0.08 (s, 3H, CH3). 
13C NMR (100 MHz, CDCl3) δ 173.4, 168.4, 166.9, 158.9, 
155.2, 137.8, 135.0, 132.4, 128.1, 128.0, 118.3, 105.3, 102.9, 94.7, 94.5, 72.2, 69.9, 
56.2, 56.2, 50.0, 33.7, 27.1, 25.9, 18.4, 18.1, -4.4, -4.7.  
 
Compound 4.64: 1H NMR (400 MHz, CD3OD) δ 6.72 
(dd, J = 15.7, 1.9 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 
6.33 (ddd, J = 11.6, 11.2, 5.0 Hz, 1H), 6.24 (dd, J = 11.6, 1.5 Hz, 1H), 6.22 (d, J = 2.4 
Hz, 1H), 6.07 (dd, J = 15.7, 2.8 Hz, 1H), 5.65 - 5.60 (m, 1H), 5.16 - 5.07 (m, 1H), 
3.73 (dt, J = 14.2, 11.2 Hz, 1H), 3.53 (dd, J = 14.2, 3.8 Hz, 1H), 3.47 (dd, J = 14.2, 
6.6 Hz, 1H), 2.32 – 2.24 (m, 1H), 1.94 (s, 3H, COCH3) 1.34 (d, J = 6.0 Hz, 3H, CH3). 
13C NMR (100 MHz, CD3OD) δ 173.7, 172.8, 167.7, 165.6, 164.2, 142.9, 141.6, 
130.7, 126.9, 124.4, 108.8, 105.6, 103.5, 74.9, 74.4, 43.0, 35.1, 22.5, 21.3. HRMS 
(ESI-TOF) m/z calc. for C19H20NO7 [M-H]
-: 374.1245, found 374.1230. 




6.4.2 Proton NMR studies of selected enamides with cysteamine  
Test compounds (typically a few milligrams) were dissolved in DMSO-d6 (0.5 
mL) in a standard NMR tube and the 1H NMR spectrum was recorded. Cysteamine 
(~10 equivalents) was added to the solution and the proton spectra of the mixture 
were recorded at a few time-points from 5 minutes to 1 day, depending on the 
reactivity of the compound as judged by the spectra obtained.  
6.4.3 Experimental section for biological studies 
6.4.3.1 Protein mass spectroscopy analysis 
10 μM of the test compounds (or DMSO as a negative control) were incubated 
with 5 μM of unactivated MNK1/2 in Tris buffer for 3 hours at room temperature on a 
shaker before being subjected to MS analysis. The treated protein samples were 
analyzed on an Agilent LC 1200 series coupled to an Agilent LC/TOF 6224.  5 μL of 
the protein sample were eluted from a Zorbax column (SB-C18 5 μM, 150x0.5 mmID) 
at a flow rate of 20 μL/min, column temperature of 45 °C, with a linear gradient from 
10% to 90%B over 7 min, mobile phase A being 0.2% formic acid in water and 
mobile phase B being 0.2% formic acid in acetonitrile. The spectra were acquired 
with a dual ESI source having a capillary voltage set at 3500V and using the reference 
mass of 922.009798 and 121.050873. The molecular weight of the proteins was 
determined by deconvolution using Agilent MassHunter Qualitative Analysis B.04 
Software. 
6.4.3.2 MNK kinase activity assay  




MNK1 and MNK2 genes were cloned into PGEX-6P-1 (cloning sites: BamHI-
SalI) by GenScript USA Inc. The plasmids were transformed into BL21 (DE3) cells. 
MNK 1 and MNK 2 were induced with 1.0 mM IPTG and grown at 25 °c for 6 hours. 
The proteins were purified using affinity chromatography on a Bio-Scale Mini 
Profinity GST cartridge. The GST tag was cleaved using PreScission protease. The 
proteins were concentrated to 10-15 mg/mL (equivalent to 285-428 μM) and flash-
frozen in liquid nitrogen and stored in buffer at -80 oC. The IMAP 10000-tp FP assay 
kit was purchased from Molecular Devices and JH3 peptide (5-FAM-
TATKSGSTTKNRFVV-NH2) was synthesized by GenScript USA Inc. Buffer B 
contains: 20 mM HEPES/KOH pH 7.4, 10 mM MgCl2, 0.5 mM DTT. IMAP 
progressive binding solution was prepared freshly on the assay day according to the 
description in the assay kit.  
2.0 μL of 5.0 μM activated MNK 2 (or 4.0 μL of 5.0 μM activated MNK 1), 
2.0 μl of compound at 10X concentrations, and buffer B to a total volume of 20 μL 
were added to a 384-well plate and incubated at 30 °C for 1 hour. 2.0 μL of 1.0 μM 
JH3 and 2.0 μL of 200 μM ATP were then added to each well and the plate was 
incubated at 30 oC for another 2 hours for MNK2 (or 6 hours for MNK1). The 
reaction was terminated with 60 μL of 1xIMAP binding solution. After 30 min 
incubation at room temperature, fluorescence polarization was measured by the 
Safire2 microplate reader. The raw data were analyzed using GraphPad Prism 5.0.  
6.4.3.3 Alphascreen® SureFire® eIF4E p-Ser209 assay  
Hela cells were cultured in DMEM (Invitrogen) supplemented with 10% (v/v) 
Fetal Bovine Serum (FBS)-US grade (Invitrogen), 100 UmL-1 penicillin (Invitrogen), 




and 100 gmL-1 streptomycin (Invitrogen). Cells were cultured in a humidified 5% 
CO2 incubator at 37 °C, and then seeded at 30,000 cells per well in a 96-well plate 
and incubated for 24 hours before treatment with compounds. After 24 hours, the 
culture media was removed and the cells were treated with various concentration of 
compound (61nM – 100 μM) at a final concentration of 1% DMSO for 2 hours in a 
humidified 5% CO2 incubator at 37 °C prior to cell lysis. The compounds were 
maintained in the DMEM media (without FBS and antibiotics) for the duration of the 
experiment. At the end of the 2 hours incubation, the medium was removed and the 
cells were lysed with freshly prepared 1x lysis buffer (supplied in the Alphascreen® 
SureFire® Kit) and agitated on a plate shaker at 350 rpm for 20 mins at room 
temperature.  
The Alphascreen® SureFire® assay (Perkin Elmer, cat#TGREIF4S500) was 
performed in 384 well white Proxiplates according to the manufacturer instructions. 4 
μL of lysate were incubated with 5 μL of Acceptor Mixture for 2 hours at room 
temperature before 2 μL of Donor Mixture was added under subdued lighting. Plates 
were further incubated for 2hours at room temperature and read using a PerkinElmer 
EnVision plate reader using AlphaScreen® settings. Raw data were presented as 
‘Envision Units’. Percentage inhibition were calculated based on the % reduction in 
‘Envision Units’ after treatment with 10 μM of compound as compared to 1% DMSO 
control. IC50 measurements were performed using GraphPad Prism Version 5.0. 
6.4.3.4 Cell anti-proliferative assay (WST-8) 
HeLa, A549, K562 and MCF-7 cells were grown in RPMI media (Invitrogen) 
with 5% fetal bovine serum added with 1% penicillin- streptomycin (Invitrogen). The 




cells were grown till 70% confluence, cultured in a humidified 5% CO2 incubator at 
37 °C, then harvested and seeded at 7500 cells per well in a 96 well plate. The plate 
was incubated for the cells to attach for 24 hours. The drug was dosed into the plate 
with 8 dilution points starting from 100 µM with 3 fold serial dilution. Drug controls 
and blank controls with media alone were prepared alongside the sample. The plate 
was then left to incubate for another 48 hours. After that, the reagent from the WST-8 
cell proliferation analysis kit (Bio Vision) was added to all wells and was left to 
incubate according to manufacturer’s protocol for 4 hours. At the end of the 
incubation time, the absorbance of the added reagent was measured with a 
spectrophotometer (Tecan Infinte M1000) at 440 nm. Viable cells will cleave the 
tetrazolium salt in the reagent to formazan by cellular mitochondrial dehydrogenase. 
The eventual formazan dye is measured and is proportional to the amount of viable 
cells. The raw data were analyzed again using GraphPad Prism 5.0.  
6.5 Experimental details for Chapter 5 
6.5.1 Synthetic procedures and data characterization of FLT3 inhibitors 
6.5.1.1 Representative synthesis of intermediate compounds 
 
7-Hydroxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl 
trifluoromethanesulfonate (5.1)  
To compound 4.1 (1.16 g, 3.00 mmol) in DCM (20 mL) was added 
TFA (690 µL, 9.00 mmol). The mixture was stirred at room 
temperature overnight. The solvent was removed under reduced 
pressure and the crude product was purified by column chromatography on silica gel 




(0-70% EtOAc in petroleum ether) to afford the title compound (5.1) (855 mg, 83%) 
as white solid. 1H NMR (400 MHz, methanol-d4) δ = 6.52 (d, J = 2.2 Hz, 1H), 6.47 (d, 
J = 2.2 Hz, 1H), 1.72 (s, 6H); 13C NMR (100 MHz, methanol-d4) δ = 165.5, 158.8, 
157.9, 150.1, 118.8 (q, J = 320.0 Hz), 106.5, 105.5, 103.0, 99.1, 24.2 (2C); MS 
(APCI): m/z 341 [M-H]- (100%). 
 
2,2-Dimethyl-7-(3-morpholinopropoxy)-4-oxo-4H-benzo[d][1,3]dioxin-5-yl 
trifluoromethanesulfonate (5.2)  
A mixture of compound 5.1 (1.03 g, 3.00 mmol), 4-(3-
hydroxypropyl)morpholine (498 µL, 3.60 mmol) and 
triphenylphosphine (1.57 g, 6.00 mmol) was dissolved in 
THF (15 mL). The solution was degassed well under argon 
and diisopropyl azodicarboxylate (883 mg, 4.50 mmol) was then added. The mixture 
was stirred at room temperature for 18 hours under argon. The solvent was then 
removed under reduced pressure and the crude product was purified by column 
chromatography on silica gel (0-100% EtOAc in petroleum ether) to afford the title 
compound (5.2) (784 mg, 56%) as a colorless gum. 1H NMR (400 MHz, CDCl3) δ = 
6.52 (d, J = 2.3 Hz, 1H), 6.49 (d, J = 2.3 Hz, 1H), 4.09 (t, J = 6.3 Hz, 2H), 3.73 – 3.69 
(m, 4H), 2.53 – 2.43 (m, 6H), 2.03 – 1.95 (m, 2H), 1.73 (s, 6H); 13C NMR (100 MHz, 
CDCl3) δ = 165.0, 158.8, 157.0, 149.9, 118.7 (q, J = 321.1 Hz), 106.5, 105.6, 101.5, 
100.8, 67.4, 66.9 (2C), 54.9, 53.7 (2C), 25.9, 25.5 (2C); MS (ESI): m/z 470 [M+H]+ 
(72%). 
 





trifluoromethanesulfonate (5.3)  
Compound 5.3 was prepared from compound 5.1 (1.03 
g, 3.00 mmol) and 4-fluorophenylethanol (451 µL, 3.60 
mmol) following the same procedure for the synthesis 
of 5.2. The crude product was purified by column chromatography on silica gel (0-
30% EtOAc in petroleum ether) to afford the title compound (5.3) (1.30 g, 93%) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ = 7.22 (dd, J = 8.7, 5.3 Hz, 1H), 7.02 (t, J 
= 8.7 Hz, 1H), 6.51 (d, J = 2.3 Hz, 1H), 6.45 (d, J = 2.3 Hz, 1H), 4.19 (t, J = 6.8 Hz, 
1H), 3.09 (t, J = 6.8 Hz, 1H), 1.72 (s, 6H); 13C NMR (100 MHz, CDCl3) δ = 164.6, 
161.9 (C-F coupling, d, J = 245.1 Hz), 158.8, 156.9, 149.9, 132.8, 130.4 (d, J = 8.0 
Hz, 2C), 118.7 (q, J = 321.1 Hz), 115.5 (d, J = 21.4 Hz, 2C), 106.6, 105.5, 101.7, 
101.1, 69.8, 34.5, 25.5 (2C); MS (APCI): m/z 465 [M+H]+ (100%). 
 
tert-Butyl allylcarbamate   
To a solution of allylamine (3.74 mL, 50.00 mmol) in DCM (250 mL) 
was added triethylamine  (10.43 mL, 75.00 mmol) followed by the addition  of 
(Boc)2O portion-wise  at 0 °C. The mixture was initially stirred at 0 °C and then 
slowly raised to room temperature and kept stirred for 5 hours, the mixture was 
concentrated under reduced pressure and the crude product was purified by silica gel 
column chromatography (0-25% diethyl ether in petroleum ether) to give the title 
compound (7.82 g, 99%) as a colorless solid to liquid. 1H NMR (400 MHz, CDCl3) δ 
5.90 – 5.77 (m, 1H), 5.21 – 5.06 (m, 2H), 4.59 (br s, 1H), 3.73 (br s, 2H), 1.44 (s, 9H). 




13C NMR (100 MHz, CDCl3) δ 155.8, 134.9, 115.7, 79.4, 43.1, 28.4 (3C). ESI-MS 
m/z 158 [M+H]+ (100%). 
 
(E)-4-(Diethylamino)but-2-enoic acid (5.18) 
A mixture of trans-methyl 4-bromo-2-butenoate (895 mg, 5.00 
mmol), diethylamine (1.56 mL, 15.00 mmol) and potassium 
carbonate (1.38 g, 10.00 mmol) in THF (10 mL) was stirred at 50 °C in a sealed tube 
for 16 hours then cooled to room temperature. The mixture was filtered through Celite 
and the solvent and the excess diethylamine were removed under reduced pressure, 
the residue was re-dissolved in THF (5 mL), 4N NaOH (1 mL) was then added. The 
mixture was stirred for 5 hours at 50 °C, cooled to room temperature, 6N HCl was 
then added dropwise to adjust the pH to about 7. The solvents were removed again 
from the mixture under reduced pressure, the resulting residue was triturated by 
addition of 10% MeOH in DCM (5 mL x 2) and stirred vigorously until the NaCl salt 
was precipitated out thoroughly. The salt was filtered off and the solvents were 
removed from the filtrate under reduced pressure to give the title compound (E)-4-
(diethylamino)but-2-enoic acid (740 mg, 94%) as light-yellow solid. 1H NMR (400 
MHz, methanol-d4) δ = 6.49 (dt, J = 15.5, 7.2 Hz, 1H), 6.22 (d, J = 15.5 Hz, 1H), 3.79 
(d, J = 7.2 Hz, 2H), 3.14 (q, J = 7.3 Hz, 4H), 1.30 (t, J = 7.3 Hz, 6H); 13C NMR (100 
MHz, methanol-d4) δ = 172.8, 137.8, 130.2, 53.8, 48.4 (2C), 9.5 (2C); MS (ESI): m/z 
156 [M-H]- (100%). MS (ESI): m/z [M+H]+ 158.5 (100%). 
tert-Butyl-(E)-(3-(7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-
yl)allyl)carbamate (5.9)  




To a solution of aryl triflate 5.5 (850 mg, 2.39 mmol) and 
tert-butyl allylcarbamate (563 mg, 2.87 mmol) in DMF (10 
mL) was added the Pd2(dba)3 (105 mg, 5 mol%) and then 
diisopropylethylamine (830 µL, 4.78 mmol), the mixture was degassed under reduced 
pressure and refilled with argon (repeat 3 times), stirred at 110 °C (equipped with a 
condenser) for 36 hours before being cooled down. The palladium precipitate was 
filtered off through a pad of Celite and washed with EtOAc. The solvent was removed 
under reduced pressure and the crude product was purified by column 
chromatography on silica gel (0-70% diethyl ether in petroleum ether) to afford the 
title compound (5.9) (colorless gum, 355 mg, 37%). 1H NMR (400 MHz, CDCl3) δ = 
7.51 (d, J = 15.8 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H), 6.35 (d, J = 2.5 Hz, 1H), 6.14 (dt, 
J = 15.8, 5.7 Hz, 1H), 3.94 (d, J = 5.7 Hz, 2H), 1.69 (s, 6H), 1.45 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ = 164.9, 160.2, 158.7, 155.8, 143.1, 130.6, 129.5, 108.6, 105.1, 





To the suspension of 60% NaH in mineral oil (229 mg, 
5.72 mmol) in anhydrous THF (10 mL) was added 
isopropanol (110 µL, 1.43 mmol) at 0 °C and stirred for 
10 min, followed by the addition of a solution of 5.9 (260 mg, 0.72 mmol) in THF (1 
mL) slowly over 30 minutes. The mixture was stirred for 30 minutes at 0 °C and then 
quenched by addition of saturated NH4Cl until the mixture is neutral. The organic 




phase was extracted with Et2O (20 mL x 3), washed with brine, dried over MgSO4 
and concentrated to give a crude product which was purified by column 
chromatography (0-40% diethyl ether in petroleum ether) to afford N-Boc-5.10 (223 
mg, 85%) as a colorless gum. 1H NMR (400 MHz, CDCl3) δ = 11.72 (s, 1H), 7.12 (d, 
J = 15.6 Hz, 1H), 6.43 (d, J = 2.6 Hz, 1H), 6.39 (d, J = 2.6 Hz, 0H), 5.85 (dt, J = 15.5, 
4.5 Hz, 1H), 5.31 – 5.21 (m, 1H), 4.61 (br s, 1H), 3.91 (br s, 2H), 3.81 (s, 3H), 1.46 (s, 
9H), 1.39 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.6, 165.0, 163.9, 
155.7, 142.3, 132.8, 127.7, 108.2, 104.2, 100.2, 79.5, 69.6, 55.4, 42.5, 28.4 (3C), 22.1 
(2C); MS (ESI): m/z 388 [M+Na]+ (100%). 
 
Isopropyl (E)-2-(3-aminoprop-1-en-1-yl)-6-hydroxy-4-methoxybenzoate (5.10) 
To a solution of N-Boc-5.10 (200 mg, 0.55 mmol) in DCM 
(10 mL) was added trifluoroacetic acid (2 mL) and the 
mixture was refluxed for 3 hours and cooled down. DCM 
and TFA were removed under reduced pressure and the crude product was purified by 
column chromatography on silica gel (0-8% DCM in methanol with 0.2% 
triethylamine) to afford the title compound (5.10) (144 mg, quantitative yield) as 
colorless gum. 1H NMR (400 MHz, CDCl3) δ = 11.59 (s, 1H), 7.28 (d, J = 15.6 Hz, 
1H), 6.45 (d, J = 2.6 Hz, 1H), 6.37 (d, J = 2.6 Hz, 1H), 5.93 (dt, J = 15.6, 7.1 Hz, 1H), 
5.27 – 5.16 (m, 1H), 3.75 (s, 3H), 3.70 (d, J = 6.9 Hz, 2H), 1.34 (d, J = 6.2 Hz, 6H); 
13C NMR (100 MHz, CDCl3) δ = 170.1, 164.8, 164.0, 141.1, 138.2, 121.6, 108.3, 
104.2, 101.1, 69.9, 55.4, 41.7, 21.8 (2C); MS (ESI): m/z 266 [M+H]+ (100%). 
 
6.5.1.2 Synthesis of substituted acrylamide derivatives 






To a solution of compound 5.10 (22 mg, 0.083 mmol) 
in anhydrous DCM (1 mL) was added the 
triethylamine (24 µL, 0.17 mmol) and stirred for 10 
min. Crotonyl chloride (1M in DCM, 108 µL) was 
then added dropwise at 0 °C over 20 minutes. The mixture was stirred for another 20 
minutes and then quenched by the addition of saturated NH4Cl. DCM was removed 
and EtOAc (3 mL) and water (3 mL) were added. The organic phase was extracted 
with EtOAc, washed with brine, dried over Na2SO4 and concentrated to give a crude 
product which was purified by column chromatography on silica gel (0-50% EtOAc 
in petroleum ether) to afford the title compound (5.32) (13 mg, 47%) as a colorless 
gum. 1H NMR (400 MHz, CDCl3) δ = 11.69 (s, 1H), 7.14 (d, J = 15.4 Hz, 1H), 6.95 – 
6.83 (m, 1H), 6.42 (d, J = 2.6 Hz, 1H), 6.39 (d, J = 2.6 Hz, 1H), 5.91 – 5.80 (m, 2H), 
5.31 – 5.20 (m, 1H), 4.10 (d, J = 5.5 Hz, 2H), 3.80 (s, 3H), 1.86 (d, J = 6.3 Hz, 3H), 
1.37 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.5, 165.8, 164.9, 163.9, 
142.2, 140.6, 133.7, 126.9, 124.7, 108.3, 104.2, 100.3, 69.7, 55.4, 41.5, 22.0 (2C), 
17.7; HRMS (ESI-TOF): m/z calc. for C18H23NO5 [M-H]




A mixture of compound 5.10 (11 mg, 
0.042 mmol), (E)-4-(diethylamino)but-2-
enoic acid (26 mg, 0.17 mmol), EDC.HCl 




(12 mg, 0.062 mmol) and HOBt (8.4 mg, 0.062 mmol) was dissolved in anhydrous 
DMF (1.5 mL), followed by the addition of diisopropylethylamine (21 µL, 0.12 
mmol). The mixture was stirred at room temperature under argon for 24 hours. DMF 
was then removed under reduced pressure  and the crude product was purified by 
column chromatography on silica gel (0-10% MeOH in DCM) to afford the title 
compound (5.35) (8 mg, 47%) as a colorless gum. 1H NMR (400 MHz, methanol-d4) 
δ = 7.09 (d, J = 15.6 Hz, 1H), 6.84 (dt, J = 15.4, 6.6 Hz, 1H), 6.51 (d, J = 2.6 Hz, 1H), 
6.39 (d, J = 2.6 Hz, 1H), 6.16 (dt, J = 15.4, 1.5 Hz, 1H), 5.95 (dt, J = 15.6, 5.8 Hz, 
1H), 5.29 – 5.21 (m, 1H), 4.03 (dd, J = 5.8, 1.6 Hz, 2H), 3.81 (s, 3H), 3.31 – 3.27 (m, 
2H, overlapped), 2.59 (q, J = 7.2 Hz, 4H), 1.37 (d, J = 6.3 Hz, 6H), 1.08 (t, J = 7.2 Hz, 
6H); 13C NMR (100 MHz, methanol-d4) δ = 170.3, 166.3, 163.8, 163.6, 141.8, 139.8, 
132.0, 127.0, 126.0, 106.9, 105.2, 99.8, 69.5, 54.5, 53.3, 46.6, 40.8 (2C), 20.8 (2C), 
10.2 (2C); HRMS (ESI-TOF) m/z for C22H31N2O5 [M-H]
-: 403.2255, found 403.2238. 
 
Other substituted acrylamide derivatives given below were synthesized according to 




Pale-yellow solid, 1H NMR (400 MHz, 
CDCl3) δ = 11.67 (s, 1H), 7.23 (dd, J = 8.7, 
5.4 Hz, 2H), 7.15 (d, J = 15.6 Hz, 1H), 
7.04 – 6.97 (m, 2H), 6.41 (d, J = 2.6 Hz, 1H), 6.38 (d, J = 2.6 Hz, 1H), 6.32 (dd, J = 
17.0, 1.4 Hz, 1H), 6.12 (dd, J = 17.0, 10.3 Hz, 1H), 5.87 (dt, J = 15.5, 6.2 Hz, 1H), 




5.69 (dd, J = 10.3, 1.4 Hz, 1H), 5.62 (br s, 1H), 5.30 – 5.22 (m, 1H), 4.16 (t, J = 6.8 
Hz, 2H), 4.12 (td, J = 6.0, 1.5 Hz, 2H), 3.06 (t, J = 6.8 Hz, 2H), 1.37 (d, J = 6.3 Hz, 
6H); 13C NMR (100 MHz, CDCl3) δ = 170.4, 165.2, 164.9, 163.0, 161.8 (C-F 
coupling, d, J = 244.8 Hz), 142.1, 133.8, 133.5, 130.6, 130.4 (d, J = 7.9 Hz, 2C), 
126.9, 126.7, 115.3 (d, J = 21.3 Hz, 2C), 108.7, 104.3, 100.9, 69.7, 68.7, 41.5, 34.7, 
22.0 (2C); HRMS (ESI-TOF): m/z calc. for C24H26FNO5 [M-H]






Pale-yellow gum, 1H NMR (400 MHz, CDCl3) δ 
= 11.68 (s, 1H), 7.16 (d, J = 15.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 6.40 (d, J = 2.6 
Hz, 1H), 6.32 (dd, J = 17.0, 1.4 Hz, 1H), 6.12 (dd, J = 17.0, 10.3 Hz, 1H), 5.89 (dt, J 
= 15.5, 6.2 Hz, 1H), 5.69 (dd, J = 10.3, 1.4 Hz, 1H), 5.66 (br s, 1H), 5.29 – 5.23 (m, 
1H), 4.12 (td, J = 6.0, 1.5 Hz, 2H), 4.05 (t, J = 6.3 Hz, 2H), 3.79 – 3.72 (m, 4H), 2.61 
– 2.48 (m, 6H), 2.06 – 1.96 (m, 2H), 1.38 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ = 170.4, 165.3, 164.9, 163.1, 142.2, 133.8, 130.6, 126.8, 126.8, 108.6, 104.3, 
100.9, 69.7, 66.3 (2C), 66.0, 55.4 (2C), 53.4, 41.5, 25.6, 22.1 (2C); HRMS (ESI-
TOF): m/z calc. for C23H33N2O6 [M+H]








Colorless gum, 1H NMR (400 MHz, 
CDCl3) δ = 11.67 (s, 1H), 7.14 (d, J = 
15.6 Hz, 1H), 6.94 – 6.83 (m, 1H), 6.43 
(d, J = 2.6 Hz, 1H), 6.37 (d, J = 2.6 Hz, 
1H), 5.89 (dt, J = 15.6, 6.2 Hz, 1H), 5.83 
(dd, J = 15.2, 1.7 Hz, 1H), 5.57 (br s, 1H), 5.32 – 5.21 (m, 1H), 4.14 – 4.05 (m, 4H), 
3.94 (br s, 4H), 2.85 (br s, 6H), 2.19 (br s, 2H), 1.87 (dd, J = 6.9, 1.7 Hz, 3H), 1.38 (d, 
J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.4, 165.7, 164.8, 162.7, 142.4, 
140.4, 133.5, 127.3, 124.8, 108.3, 101.0, 69.8, 65.4 (2C), 55.4 (2C), 52.9, 41.4 (2C), 
22.0 (2C), 17.7 (two carbons are missing); HRMS (ESI-TOF) m/z calc. for 
C24H33N2O6 [M-H]




White solid, 1H NMR (400 MHz, 
acetone-d6) δ = 11.56 (s, 1H), 7.41 
– 7.35 (m, 2H), 7.16 (d, J = 15.6 
Hz, 1H), 7.10 – 7.04 (m, 2H), 6.78 
(dt, J = 15.4, 6.0 Hz, 1H), 6.50 (d, J = 2.5 Hz, 1H), 6.40 (d, J = 2.5 Hz, 1H), 6.19 (d, J 
= 15.4 Hz, 1H), 5.98 (dt, J = 15.6, 5.8 Hz, 1H), 5.30 – 5.20 (m, 1H), 4.28 (t, J = 6.7 
Hz, 2H), 4.05 (td, J = 5.7, 1.6 Hz, 2H), 3.23 (br d, J = 5.7 Hz, 2H), 3.09 (t, J = 6.7 Hz, 
2H), 2.53 (q, J = 7.0 Hz, 4H), 1.38 (d, J = 6.3 Hz, 6H), 1.02 (t, J = 7.1 Hz, 6H); 13C 
NMR (100 MHz, acetone-d6) δ = 170.6, 164.6, 163.2, 162.8, 142.7, 134.4, 131.7, 
130.8 (d, J = 7.9 Hz, 2C), 128.8, 128.6, 114.9 (d, J = 21.3 Hz, 2C), 107.8, 104.5, 




100.6, 69.7, 68.6, 53.8, 46.9 (2C), 40.7, 34.3, 21.2 (2C), 11.4 (2C); HRMS (ESI-TOF) 
m/z calc. for C29H36FN2O5 [M-H]




White solid, 1H NMR (400 MHz, CDCl3) δ = 11.69 (s, 1H), 
7.13 (d, J = 15.5 Hz, 2H), 6.42 (d, J = 2.6 Hz, 2H), 6.40 (d, 
J = 2.6 Hz, 1H), 5.84 (dt, J = 15.5, 6.2 Hz, 1H), 5.57 (br s, 
1H), 5.32 – 5.21 (m, 1H), 4.03 (td, J = 6.0, 1.5 Hz, 2H), 3.81 
(s, 3H), 2.03 (s, 3H), 1.39 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.5, 
169.9, 165.0, 163.9, 142.1, 133.9, 126.8, 108.4, 104.2, 100.3, 69.7, 55.4, 41.7, 23.3, 
22.1 (2C); HRMS (ESI-TOF) m/z calc. for C16H20NO5 [M-H]





Colorless gum, 1H NMR (400 MHz, CDCl3) δ = 11.69 (s, 
1H), 7.15 (d, J = 15.5 Hz, 2H), 6.43 (d, J = 2.6 Hz, 1H), 
6.40 (d, J = 2.6 Hz, 1H), 6.32 (dd, J = 17.0, 1.4 Hz, 1H), 
6.12 (dd, J = 17.0, 10.3 Hz, 1H), 5.88 (dt, J = 15.5, 6.1 
Hz, 1H), 5.68 (dd, J = 10.3, 1.4 Hz, 1H), 5.32 – 5.20 (m, 1H), 4.12 (td, J = 6.0, 1.5 Hz, 
2H), 3.81 (s, 3H), 1.37 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.5, 
165.2, 165.0, 163.9, 142.1, 133.9, 130.7, 126.8, 126.6, 108.4, 104.2, 100.3, 69.7, 55.4, 




41.5, 22.0 (2C); HRMS (ESI-TOF) m/z calc. for C17H20NO5 [M-H]




hydroxybenzoate  (5.33) 
White solid, 1H NMR (400 MHz, 
CDCl3) δ = 11.67 (s, 1H), 7.25 – 7.20 
(m, 2H), 7.12 (d, J = 15.6 Hz, 1H), 
7.03 – 6.97 (m, 2H), 6.93 – 6.83 (m, 
1H), 6.41 (d, J = 2.6 Hz, 1H), 6.38 (d, J = 2.6 Hz, 1H), 5.87 (dt, J = 15.5, 6.0 Hz, 1H), 
5.86 – 5.77 (m, 1H), 5.50 (br s, 1H), 5.30 – 5.20 (m, 1H), 4.15 (t, J = 6.8 Hz, 2H), 
4.09 (td, J = 6.0, 1.4 Hz, 2H), 3.05 (t, J = 6.8 Hz, 2H), 1.87 (dd, J = 6.9, 1.7 Hz, 3H), 
1.37 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ = 170.4, 165.7, 164.9, 163.0, 
161.8 (C-F coupling, d, J = 244.6 Hz), 142.2, 140.4, 133.6, 130.4 (d, J = 7.8 Hz, 2C), 
127.0, 124.8, 115.3 (d, J = 21.2 Hz, 2C), 108.6, 104.3, 100.9, 69.7, 68.6, 41.4, 34.7, 






Colorless gum, 1H NMR (400 MHz, CDCl3) δ = 
11.85 – 11.76 (m, 1H), 7.17 (d, J = 15.5 Hz, 1H), 
6.43 (d, J = 2.6 Hz, 1H), 6.41 (d, J = 2.6 Hz, 1H), 
6.31 (dd, J = 17.0, 1.4 Hz, 1H), 6.11 (dd, J = 17.0, 




10.3 Hz, 1H), 5.89 (dt, J = 15.5, 6.3 Hz, 1H), 5.68 (dd, J = 10.3, 1.4 Hz, 1H), 5.64 (br 
s, 1H), 5.12 – 5.01 (m, 1H), 4.12 (td, J = 6.2, 1.5 Hz, 2H), 3.81 (s, 3H), 1.93 (td, J = 
6.8, 5.5 Hz, 1H), 1.29 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.8 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ = 170.7, 165.2, 165.2, 164.0, 142.1, 134.3, 130.6, 
126.8, 126.7, 108.5, 104.2, 100.4, 77.3, 55.5, 41.6, 32.6, 18.2, 18.0, 16.7; HRMS 
(ESI-TOF): m/z calc. for C19H24NO5 [M-H]
-: 346.1660, found 346.1677. 
(S)-3-Methylbutan-2-yl 2-((E)-3-((E)-4-(diethylamino)but-2-enamido)prop-1-en-
1-yl)-6-hydroxy-4-methoxybenzoate (5.35) 
Colorless gum, 1H NMR (400 MHz, CDCl3) δ = 
11.80 (s, 1H), 7.17 (d, J = 15.5 Hz, 1H), 6.87 
(dt, J = 15.4, 6.2 Hz, 1H), 6.44 (d, J = 2.6 Hz, 
1H), 6.41 (d, J = 2.6 Hz, 1H), 6.07 (d, J = 15.4 
Hz, 1H), 5.88 (dt, J = 15.5, 6.4 Hz, 1H), 5.74 (br s, 1H), 5.11 – 5.03 (m, 1H), 4.10 (td, 
J = 6.4, 1.4 Hz, 4H), 3.82 (s, 3H), 3.32 (dd, J = 6.2, 1.4 Hz, 2H), 2.65 (q, J = 7.2 Hz, 
4H), 1.98 – 1.88 (m, 1H), 1.29 (d, J = 6.4 Hz, 3H), 1.11 (t, J = 7.2 Hz, 6H), 0.98 (d, J 
= 6.7 Hz, 2H), 0.96 (d, J = 6.7 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ = 170.7, 
165.1, 165.0, 164.0, 142.1, 139.5, 134.3, 126.8, 126.6, 108.5, 104.2, 100.4, 77.3, 55.5, 
53.5, 47.1 (2C), 41.7, 32.6, 18.2, 18.0, 16.7, 11.3 (2C);  HRMS (ESI-TOF): m/z calc. 
for C24H35N2O5 [M-H]
-: 431.2551, found 431.2570. 
 








To a solution of compound 5.10 (36 mg, 0.14 mmol) in anhydrous DCM (2 mL) was 
added triethylamine (42 µL, 0.30 mmol) and stirred for 10 min. 2-
Chloroethanesulfonyl chloride (1M in DCM, 120 µL) was then added dropwise at 
0 °C over 20 minutes. The mixture was stirred for another 40 minutes and then 
quenched by addition of saturated NH4Cl solution. DCM was removed and EtOAc (5 
mL) and water (5 mL) were added. The organic phase was extracted with EtOAc, 
washed with brine, dried over NaSO4 and concentrated to give a crude product which 
was purified by column chromatography on silica gel (0-50% EtOAc in petroleum 
ether) to afford the title compound (5.24) (12.2 mg, 34%) as a colorless gum. 1H 
NMR (400 MHz, CDCl3) δ = 11.70 (s, 1H), 7.20 (d, J = 15.5 Hz, 1H), 6.56 (dd, J = 
16.6, 9.9 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 6.40 (d, J = 2.6 Hz, 1H), 6.29 (d, J = 16.6 
Hz, 1H), 5.97 (d, J = 9.9 Hz, 1H), 5.83 (dt, J = 15.5, 6.2 Hz, 1H), 5.31 – 5.22 (m, 1H), 
4.44 (br s, 1H), 3.82 (s, 3H), 3.84 – 3.79 (m, 2H), 1.39 (d, J = 6.3 Hz, 6H); 13C NMR 
(100 MHz, CDCl3) δ = 170.3, 165.1, 164.0, 141.6, 136.2, 134.8, 126.8, 125.6, 108.5, 
104.2, 100.5, 69.8, 55.5, 45.1, 22.1 (2C); HRMS (ESI-TOF): m/z calc. for 
C16H21NO6SNa [M+Na]
+:378.0982, found 378.0981. 
 
Isopropyl 2-hydroxy-4-(2-morpholinoethoxy)-6-(3-
(vinylsulfonamido)propyl)benzoate (5.25)  
 
To a solution of 5.8 (551 mg, 1.19 mol) in EtOAc (12 mL) was added 10% Pd/C (126 
mg, 10 mol%). After degassing with hydrogen gas, the mixture was stirred under 
hydrogen atmosphere at room temperature for 16 hours. The solvent was removed and 
the residue was purified by a silica gel column chromatography with 15% MeOH in 




DCM to give the hydrogenated product. In another RBF, isopropanol (190 µL, 2.48 
mmol) was added to a suspension of 60% NaH (130 mg, 3.25 mmol) at 0 °C, after 
stirring for 10 min, the hydrogenated product (380 mg, 0.82 mmol) dissolved in THF 
(5 mL) was added dropwise into above mixture and kept stirring for 1 hour, then 
quenched by addition of saturated NH4Cl. The organic phase was extracted with 
EtOAc, washed with brine, dried over MgSO4 and concentrated to give a crude 
product which was purified by column chromatography (0-100% EtOAc in petroleum 
ether) to afford intermediate compound 5.49 (145 mg, 27% in 2 steps) as a colorless 
gum. The final product 5.25 was synthesized by deprotection of NHBoc on 5.49 using 
TFA and then sulfonamide formation following the procedures for the synthesis of 
5.10 and 5.24.   
Compound 5.25: colorless gum, 1H NMR (400 MHz, CDCl3) δ = 11.78 (s, 1H), 6.50 
(dd, J = 16.6, 9.9 Hz, 1H), 6.34 (d, J = 2.6 Hz, 1H), 6.28 (d, J = 2.6 Hz, 1H), 6.25 (d, 
J = 16.6 Hz, 1H), 5.94 (d, J = 9.9 Hz, 1H), 5.37 – 5.29 (m, 1H), 4.13 – 4.09 (m, 2H), 
3.75 – 3.71 (m, 4H), 3.06 (dd, J = 13.3, 7.0 Hz, 2H), 2.97 – 2.91 (m, 2H), 2.79 (t, J = 
5.7 Hz, 2H), 2.59 – 2.55 (m, 4H), 1.89 – 1.80 (m, 2H), 1.40 (d, J = 6.3 Hz, 6H); 13C 
NMR (100 MHz, CDCl3) δ = 170.5, 165.7, 163.0, 145.7, 136.0, 126.7, 111.3, 105.1, 
100.0, 69.5, 66.9 (2C), 65.9, 57.4, 54.1 (2C), 42.7, 33.6, 31.9, 22.0 (2C); HRMS (ESI-
TOF): m/z calc. for C21H33N2O7S [M+H]




Pale-yellow solid, 1H NMR (400 MHz, CDCl3) δ = 11.52 
(s, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 




7.04 (d, J = 15.5 Hz, 1H), 6.50 (dd, J = 16.5, 9.9 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 
6.38 (d, J = 2.6, 1H), 6.25 (d, J = 16.5 Hz, 1H), 5.95 (d, J = 9.9 Hz, 1H), 5.79 (dt, J = 
15.5, 6.2 Hz, 1H), 5.30 (s, 2H), 4.04 (br t, J = 6.0 Hz, 1H), 3.82 (s, 3H), 3.61 (td, J = 
6.2, 1.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ = 170.5, 165.3, 164.4, 141.8, 136.2, 
134.5, 134.3, 132.0 (2C), 130.5 (2C), 126.7, 126.1, 122.9, 108.8, 103.4, 100.5, 66.6, 
55.5, 44.8; HRMS (ESI-TOF): m/z calc. for C20H20BrNO6SNa [M+Na]
+: 504.0087, 
506.0066, found 504.0105, 506.0079. 
 
4-Fluorobenzyl (E)-2-hydroxy-4-methoxy-6-(3-(vinylsulfonamido)prop-1-en-1-
yl)benzoate (5.27)  
White solid, 1H NMR (400 MHz, CDCl3) δ = 11.55 (s, 
1H), 7.44 (dd, J = 8.7, 5.3 Hz, 2H), 7.12 (t, J = 8.7 Hz, 
2H), 7.03 (d, J = 15.5 Hz, 2H), 6.48 (dd, J = 16.5, 9.9 Hz, 
1H), 6.42 (d, J = 2.6 Hz, 1H), 6.38 (d, J = 0.5 Hz, 1H), 6.24 (d, J = 16.6 Hz, 1H), 5.94 
(d, J = 9.9 Hz, 1H), 5.77 (td, J = 15.6, 6.1 Hz, 1H), 5.31 (s, 2H), 3.97 (t, J = 6.1 Hz, 
1H), 3.82 (s, 3H), 3.59 (td, J = 6.2, 1.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ = 
170.6, 165.3, 164.3, 162.9 (C-F coupling, d, J = 248.4 Hz), 141.8, 136.2, 134.6, 131.1, 
130.9 (d, J = 8.2 Hz, 2C), 126.7, 126.0, 115.8 (d, J = 21.5 Hz, 2C), 108.8, 103.5, 
100.4, 66.7, 55.5, 44.8; HRMS (ESI-TOF): m/z calc. for C20H20FNO6SNa [M+Na]
+: 








Pale-yellow solid, 1H NMR (400 MHz, CDCl3) δ = 
11.71 (s, 1H), 7.18 (d, J = 15.5 Hz, 1H), 6.56 (dd, J = 
16.6, 9.9 Hz, 1H), 6.43 – 6.40 (m, 2H), 6.29 (d, J = 
16.6 Hz, 1H), 5.97 (d, J = 9.9 Hz, 1H), 5.86 (dt, J = 15.5, 6.5 Hz, 1H), 4.41 (t, J = 6.3 
Hz, 1H), 4.15 (d, J = 6.2 Hz, 2H), 3.82 (s, 3H), 3.82 – 3.78 (m, 2H), 1.83 – 1.67 (m, 
6H), 1.37 – 1.15 (m, 4H), 1.11 – 0.98 (m, 2H); 13C NMR (100 MHz, CDCl3) δ = 
170.0, 164.2, 163.1, 140.6, 135.3, 134.1, 125.8, 125.0, 107.7, 103.0, 99.5, 69.9, 54.5, 
44.2, 36.1, 28.9 (2C), 25.3, 24.6 (2C); HRMS (ESI-TOF): m/z calc. for 
C20H27NO6SNa [M+Na]




White solid, 1H NMR (400 MHz, CDCl3) δ = 11.63 (s, 1H), 
7.38 – 7.32 (m, 2H), 7.27 (d, J = 7.1 Hz, 3H), 6.83 (d, J = 15.5 
Hz, 1H), 6.52 (dd, J = 16.6, 9.9 Hz, 1H), 6.40 (d, J = 2.6 Hz, 
1H), 6.35 (dd, J = 2.6, 0.5 Hz, 2H), 6.26 (d, J = 16.6 Hz, 1H), 5.94 (d, J = 9.9 Hz, 1H), 
5.74 (dt, J = 15.4, 5.7 Hz, 1H), 4.54 (dd, J = 11.0, 6.6 Hz, 1H), 4.45 (dd, J = 11.0, 7.9 
Hz, 1H), 4.22 (t, J = 6.2 Hz, 1H), 3.80 (s, 3H), 3.57 – 3.52 (m, 2H), 3.30 – 3.22 (m, 
1H), 1.35 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.8, 165.2, 164.1, 
143.1, 141.7, 136.4, 134.5, 128.8 (2C), 127.2 (2C), 126.9, 126.5, 126.3, 108.6, 103.7, 
100.5, 70.1, 55.5, 44.9, 38.8, 18.8; HRMS (ESI-TOF): m/z calc. for C22H25NO6SNa 
[M+Na]+: 454.1295, found 454.1312. 
 
6.5.1.3 Synthesis of maleimide derivatives 






yl)-4-methoxybenzoate  (5.40a) 
To a solution of compound 5.10 (64 mg, 0.24 mmol) in 
THF (3 mL) was added the maleic anhydride (54 mg, 
0.48 mmol), the mixture was stirred at room temperature 
for 1 hour, and the solvent was removed under reduced pressure. The residue was re-
dissolved in acetic anhydride (2 mL) and sodium acetate (20 mg, 0.24 mmol) was 
added and the mixture was stirred at 80 °C for 18 hours before being cooled down. 
The acetic anhydride was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (0-50% EtOAc in petroleum ether) 
to afford the title compound (5.40a) (26 mg, 28%) as a colorless solid. 1H NMR (400 
MHz, CDCl3) δ = 6.85 (d, J = 2.5 Hz, 1H), 6.82 (d, J = 15.8 Hz, 1H), 6.72 (s, 2H), 
6.56 (d, J = 2.5 Hz, 1H), 6.06 (dt, J = 15.8, 6.4 Hz, 1H), 5.26 – 5.18 (m, 1H), 4.26 (dd, 
J = 6.4, 1.4 Hz, 2H), 3.81 (s, 3H), 2.26 (s, 3H), 1.35 (d, J = 6.3 Hz, 6H); 13C NMR 
(100 MHz, CDCl3) δ = 170.1, 168.9, 165.3, 161.1 (2C), 150.1, 138.1, 134.3 (2C), 
131.0, 126.2, 118.4, 109.9, 108.4, 69.1, 55.6, 39.4, 21.8 (2C), 20.9; HRMS (ESI-
TOF): m/z calc. for C20H21NO7Na [M+Na




A mixture of 5.40a (5 mg, 0.013 mmol), tosylic acid 
monohydrate (15 mg, 0.079 mmol) and silicon oxide (15 
mg) in toluene (1 mL) was stirred at 80 °C for 3 hours then 




cooled down. The solvent was removed under reduced pressure and the crude product 
was purified by column chromatography on silica gel (0-40% EtOAc in petroleum 
ether) to afford the title compound (5.41) (3.5 mg, 56%) as a colorless gum. 1H NMR 
(400 MHz, CDCl3) δ = 11.78 (s, 1H), 7.20 (d, J = 15.5 Hz, 1H), 6.73 (s, 2H), 6.41 (dd, 
J = 2.6, 0.5 Hz, 1H), 6.40 (d, J = 2.6 Hz, 1H), 5.84 (dt, J = 15.5, 6.4 Hz, 1H), 5.34 – 
5.24 (m, 1H), 4.26 (dd, J = 6.4, 1.4 Hz, 2H), 3.80 (s, 3H), 1.41 (d, J = 6.3 Hz, 6H); 
13C NMR (100 MHz, CDCl3) δ = 170.6, 170.2, 165.0, 163.9, 141.7, 134.9, 134.3 (2C), 
124.5, 108.5, 104.3, 100.5, 69.8, 55.4, 39.5, 21.9 (2C). The two identical carbonyl 
carbons are not assigned; HRMS (ESI-TOF): m/z calc. for C18H19NO6Na [M+Na]
+: 




White solid. 1H NMR (400 MHz, CDCl3) δ = 11.92 (s, 1H), 
6.68 (s, 2H), 6.33 (d, J = 2.6 Hz, 1H), 6.30 (d, J = 2.6 Hz, 1H), 
5.37 – 5.29 (m, 1H), 3.80 (s, 3H), 3.61 – 3.54 (m, 2H), 2.92 – 
2.86 (m, 2H), 1.92 – 1.82 (m, 2H), 1.44 (d, J = 6.3 Hz, 6H); 13C 
NMR (100 MHz, CDCl3) δ = 170.8, 170.7, 165.8 (2C), 163.9, 145.8, 134.1 (2C), 
110.6, 105.0, 99.4, 69.6, 55.3, 37.8, 34.0, 30.5, 21.9 (2C). The two identical carbonyl 
carbons are not identified; HRMS (ESI-TOF): m/z calc. for C18H21NO6Na [M+Na]
+: 
370.1261, found 370.1257. 
 







Colorless gum, 1H NMR (400 MHz, CDCl3) δ = 
11.77 (s, 1H), 7.20 (d, J = 15.5 Hz, 1H), 6.73 (s, 2H), 
6.40 (d, J = 2.6 Hz, 1H), 6.39 (d, J = 2.6 Hz, 1H), 
5.84 (dt, J = 15.5, 6.4 Hz, 1H), 5.33 – 5.25 (m, 1H), 
4.26 (dd, J = 6.4, 1.4 Hz, 2H), 4.03 (t, J = 6.3 Hz, 2H), 3.77 – 3.70 (m, 4H), 2.57 – 
2.43 (m, 6H), 2.02 – 1.92 (m, 2H), 1.41 (d, J = 6.3 Hz, 6H); 13C NMR (100 MHz, 
methanol-d4) δ = 170.7, 170.3, 163.7, 163.0 (2C), 141.4, 134.2 (2C), 133.1, 125.2, 
107.4, 105.2, 100.7, 69.6, 66.0 (2C), 65.8, 55.1, 53.2 (2C), 38.7, 25.4, 20.8 (2C); 
HRMS (ESI-TOF) m/z calc. for C24H31N2O7 [M+H]




Colorless gum. 1H NMR (400 MHz, methanol-
d4) δ = 6.79 (s, 2H), 6.37 (d, J = 2.6 Hz, 1H), 
6.33 (d, J = 2.6 Hz, 1H), 5.35 – 5.25 (m, 1H), 
4.15 (t, J = 5.5 Hz, 2H), 3.73 – 3.69 (m, 4H), 3.55 (t, J = 7.3 Hz, 2H), 2.89 – 2.83 (m, 
2H), 2.80 (t, J = 5.5 Hz, 2H), 2.62 – 2.57 (m, 4H), 1.89 – 1.80 (m, 2H), 1.42 (d, J = 
6.3 Hz, 6H); 13C NMR (100 MHz, methanol-d4) δ = 172.6, 171.9, 165.8, 164.2 (2C), 
147.2, 135.4 (2C), 111.3, 107.3, 101.1, 70.9, 67.6 (2C), 66.5, 58.5, 55.1(2C), 38.5, 
34.7, 31.7, 22.1 (2C); HRMS (ESI-TOF): m/z calc. for C23H31N2O7 [M+H]
+: 447.2126, 
found 447.2113. 







White solid, 1H NMR (400 MHz, CDCl3) δ = 11.55 (s, 
1H), 7.52 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 
7.10 (d, J = 15.5 Hz, 1H), 6.68 (s, 2H), 6.39 (s, 2H), 5.80 
(dt, J = 15.4, 12.4 Hz, 1H), 5.35 (s, 2H), 4.17 (dd, J = 6.2, 
1.4 Hz, 2H), 3.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.7, 170.2, 165.3 (2C), 
164.3, 141.9, 134.9, 134.7, 134.2 (2C), 131.8 (2C), 130.2 (2C), 124.6, 122.5, 108.8, 
103.6, 100.5, 66.1, 55.5, 39.3; HRMS (ESI-TOF): m/z calc. for C22H19BrNO6 
[M+H]+: 472.0390, 474.0370, found 472.0382, 474.0371. 
 
4-Fluorobenzyl (E)-2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)prop-1-en-1-yl)-6-
hydroxy-4-methoxybenzoate  (5.44) 
White solid, 1H NMR (400 MHz, CDCl3) δ = 11.59 (s, 
1H), 7.50 – 7.46 (m, 2H), 7.13 – 7.04 (m, 2H), 6.69 (s, 
2H), 6.40 – 6.38 (m, 2H), 5.79 (dt, J = 15.4, 6.3 Hz, 
1H), 5.36 (s, 2H), 4.15 (dd, J = 6.3, 1.4 Hz, 2H), 3.80 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.8, 170.2, 165.2 (2C), 164.3, 162.8 (C-F 
coupling, d, J = 247.2 Hz), 141.9, 135.0, 134.2 (2C), 131.5, 130.7 (d, J = 8.2 Hz, 2C), 
124.5, 115.6 (d, J = 21.5 Hz, 2C), 108.7, 103.7, 100.5, 66.2, 55.5, 39.3; HRMS (ESI-
TOF): m/z calc. for C22H18FNO6Na [M+Na]
+: 434.1010, found 434.1018. 
 






Pale-yellow solid, 1H NMR (400 MHz, CDCl3) δ = 11.76 (s, 
1H), 7.21 (d, J = 15.5 Hz, 1H), 6.73 (s, 2H), 6.40 (s, 3H), 5.84 
(dt, J = 15.5, 6.4 Hz, 1H), 4.25 (dd, J = 6.4, 1.4 Hz, 2H), 4.18 
(d, J = 6.4 Hz, 2H), 1.87 – 1.66 (m, 5H), 1.38 – 1.17 (m, 4H), 
1.14 – 0.99 (m, 2H); 13C NMR (100 MHz, CDCl3) δ = 171.2, 170.2, 165.1 (2C), 164.0, 
141.7, 135.2, 134.2 (2C), 124.5, 108.6, 104.0, 100.5, 70.8, 55.4, 39.5, 37.0, 29.9 (2C), 







Pale-yellow solid, 1H NMR (400 MHz, CDCl3) δ = 11.66 
(s, 1H), 7.37 – 7.30 (m, 4H), 7.27 – 7.22 (m, 1H), 6.93 (d, 
J = 15.5 Hz, 1H), 6.71 (s, 2H), 6.39 (d, J = 2.6 Hz, 1H), 6.36 (d, J = 2.6 Hz, 1H), 5.76 
(dt, J = 15.4, 6.5 Hz, 1H), 4.54 – 4.43 (m, 2H), 4.17 – 4.05 (m, 2H), 3.79 (s, 3H), 3.40 
– 3.29 (m, 1H), 1.37 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ = 170.9, 
170.2, 165.2 (2C), 164.1, 143.0, 141.9, 135.0 (2C), 134.2, 128.7 (2C), 127.3 (2C), 
126.9, 124.6, 108.6, 103.8, 100.4, 70.2, 55.4, 39.5, 38.7, 18.6; HRMS (ESI-TOF) m/z 
calc. for C24H23NO6Na [M+Na]
+: 444.1418, found 444.1421. 




6.5.2 Computational docking studies 
The FLT3 (PDB: 1rjb) and KIT-ADP (PDB: 1pkg) crystal structures were 
obtained from the RCSB Protein Data Bank. The active-form homolog of FLT3 
structure was built using interactive modeling method based on KIT-ADP crystal 
structure as the template. The receptor map for docking experiment was generated 
using the soft vw method. The ligand molecules were prepared by drawing the 2D 
structures in ChemBioDraw Ultra 13 and then saved in SDF format. The library of 
compounds was then imported into ICM-VLS which automatically generated the 3D 
conformers and assigned MMFF charges to the structures. Docking was firstly 
performed in a batch mode and selected compounds were further docked using 
interactive docking. The results were evaluated based on the ICM score and energy. 
6.5.3 NMR study with cysteamine/L-glutathione  
The NMR study was performed based the previously described method in 
Section 6.4.2. Typically the 1H NMR spectra of the mixture of the test compound and 
cysteamine or L-glutathione dissolved in DMSO-d6 (0.5 mL) was recorded at a few 
interval time points from minimal 10 minutes to 24 hours and analyzed.  
6.5.4 Kinase inhibition assays on FLT3, FLT3-D835Y and FLT3-ITD kinases 
The kinase inhibition assays for FLT3 and FLT3-D835Y kinases were 
performed according to the LanthaScreen™ Eu kinase binding assay protocol from 
Invitrogen. The materials and reagents including recombinant enzymes FLT3, FLT3-
D835Y, Eu-anti-His antibody and kinase tracer 236 were purchased from Invitrogen, 
kinase buffer A were prepared according to the recipe described in the protocol. 
Briefly, 5 µL of test compound, 5 µL of kinase (5 nM for FLT3, 1 nM for FLT3-




D835Y)/antibody (2 nM) and 5µL of tracer (5 nM for FLT3, 1 nM for FLT3-D835Y) 
were mixed in a 384-well white plate (Corning) and incubated at room temperature 
for 1 hour. The TR-FRET signal was then read by Tecan Infinite M1000 plate reader, 
and data was analyzed using Prism 5.0. 
The kinase inhibition assay for FLT3-ITD was carried out by ReactionBiology 
using RBC kinase assay protocol and the inhibition curves and the IC50 values were 
provided by the company. It should be noted that due to the non-availability of FLT3-
ITD enzyme from Invitrogen, this assay was utilized as an alternative. 
6.5.5 Determination of koff rate on FLT3 
The dissociation off-rate of complexed ligand from FLT3 receptor was 
measured using LanthaScreen™ Eu kinase binding assay based on the method of 
simple off-rate measurements provided in Invitrogen application note. Briefly, the 
experiment was carried out by first incubating the kinase with a saturating amount of 
inhibitor to form a kinase/inhibitor complex which was then diluted with a saturating 
concentration of tracer. Following dilution, the samples were read kinetically to 
monitor the change in signal over time. During experiment, first, 5 µL of test 
compound at concentration of about 80 times of its IC50 (the concentration should be 
made that after dilution with tracer solution, its concentration is near or below its IC50 
value), 2.5 µL (720 nM) of kinase and 2.5 µL (600 nM) of antibody were mixed and 
pre-incubated to form a complex solution. 1 µL of inhibitor/kinase/antibody complex 
was then added to 39 µL (50 nM) of tracer to make 40 times dilution. The mixture 
was then read immediately along the time up to 4 hours. The dilution was carried out 
in a 384-well plate, with triplicate for each test compound. The data was analyzed by 




Prism 5 using Equations under “one phase exponential association”: Y = Ymax * [1 – 
e^(-kobs * X)], t1/2,obs = 0.693/kobs. 
6.5.6 Cell anti-proliferation assay 
MV4-11, THP-1, HL-60 (all AML derived cell lines), K562 (CML derived 
cell line) and Hek293T cells were originally purchased from ATCC (American Type 
Culture Collection, Manassas, VA). The AML and CML cells were cultured with 
RPMI-1640 media supplemented with 10% FBS at 37˚C and 5% CO2. Hek293T was 
cultured with high glucose DMEM media supplemented with 10% FBS at 37˚C and 
5% CO2. 
Cell proliferation assays were performed using CellTiter-Glo Luminescent 
Cell Viability Assay (Promega) following manufacturer’s instructions. 50 µL of serial 
dilutions of compounds were added into 96-well plates. Cell suspension in media (50 
µL) were added to each well (10 000 cells/well). Plates were incubated for 72 hours at 
37 °C in 5% CO2. After 72 hours, an equal volume of Cell Titer Glo reagent was 
added. Plates were rocked on a rotator for 2 hours. 100 µL of each well were 
transferred to a 96 well opaque plate, and total light emitted was measured on the 
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Chapter Seven Concluding Remarks & Future Perspectives 
 
In this PhD project, we investigated natural occurring and synthetic analogues 
of resorcylic acid lactones as inhibitors of a range of kinases.  
The successful synthesis of aigialomycin D and a series of its macrocyclic 
analogues enabled the biological studies of these compounds in their inhibition of 
CDK2. Kinase profiling of aigialomycin D led to the discovery of MNK2 as the most 
promising kinase target within a pool of 96 kinases tested. In the development of 
covalent MNK1/2 kinase inhibitors, we have synthesized some novel enamide-based 
RAL analogues and also demonstrated that the covalent binding ability of RAL 
enamides to MNK1/2 kinases can be tuned by attaching an electron-withdrawing 
motif to increase the electrophilicity of the enamides as warhead. The covalent 
binding abilities were strongly implicated by the dramatic decreases in kinase 
activities observed and were later confirmed by mass spectrometry analysis of the 
protein-ligand complex. Based on our design strategy and docking studies, the amino 
acid residue that is covalently modified is presumably C225 which is adjacent to the 
highly conserved DFG motif. However, in order to unambiguously confirm this, more 
studies are needed. For example, protein digestion experiments could be carried out. 
In particular, the MNK2-enamide complex could be digested with trypsin, and the 
resulting peptide fragments can be analyzed by mass spectrometry (e.g. MALDI-TOF 
MS). Alternatively, site-directed mutagenesis of C225 to other non-nucleophilic 
amino acid residues could also help to prove our hypothesis. 
In our continuous efforts directed towards exploring the structural scope of 
RALs analogues as kinase inhibitors, some simplified ring-opened resorcylic acid 
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analogues were also developed as inhibitors of FLT3 kinases. Three different 
electrophilic warheads (i.e., acrylamide, vinylsulfonamide and maleimide) have been 
incorporated as Michael acceptors, and potent inhibition (in the nano-molar range of 
IC50 values) of FLT3 and its mutants was observed for some of the compounds. 
Unexpectedly, the acrylamides and vinylsulfonamide analogues are found to be 
reversible FLT3 inhibitors while their maleimide counterparts are irreversible ones. In 
this context, the synthesis and investigation of more diverse ring-opened analogues 
could be critical in the development of acrylamides- or vinylsulfonamide- based 
covalent FLT3 inhibitors.  
Overall, extensive synthetic chemistry on RALs and analogues have been 
achieved, these compounds have been investigated in terms of activities as kinase 
inhibitors. Moving forward, future work could use selected compounds for more in-
depth biological studies. These could include, for example, studies on target inhibition 
at the cellular level (e.g, western blotting analysis), and in vivo investigations of the 
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Company Indication Target kinase 
1999 sirolimus Rapamune Wyeth Renal transplant KFBP12/mTOR 
2001 imatinib Gleevec Novartis chronic myeloid leukemia (CML) Abl, c-Kit, PDGFRα/β 
2003 gefitinib Iressa AstraZeneca non-small-cell lung carcinoma 
(NSCLC)  
EGFR 
2004 erlotinib Tarceva Genetech OSI NSCLC, pancreatic cancer  EGFR 
2005 sorafenib Nexavar Bayer, Onyx hepatocellular carcinoma, renal cell 
carcinoma (RCC)  
Raf, VEGFR2/3, c-Kit, PDGFRβ 
2006 sunitinib Sutent Pfizer gastrointestinal stromal tumor 
(GIST), RCC  
c-Kit, VEGFR, PDGFR, FLT3 
2006 dasatinib Sprycel Bristol-Myers 
Squibb 
CML  Abl, c-Kit, PDGFR, Src 
2007 nilotinib Tasigna Novartis CML  Abl, c-Kit, PDGFR, Src, ephrin 
2007 lapatinib Tykerb GSK breast cancer  EGFR, ErbB2 
2007 temsirolimus Torisel Wyeth RCC FKBP12/mTOR 
2009 pazopanib Votrient GSK RCC  VEGFR, PDGFRα/β, c-Kit 
2009 everolimus Afinitor Novartis RCC, breast cancer etc FKBP12/mTOR 
2011 vandetanib Caprelsa AstraZeneca thyroid cancer VEGFR, EGFR, RET 
2011 vemurafinib Zelboraf Roche, 
Plexxicon 
CML  Abl, c-Kit, PDGFR, Src, ephrin 
2011 crizotinib Xalkori Pfizer NSCLC (ALK +ve)  ALK, MET 
2011 ruxolitinib Jakafi Incyte myelofibrosis  JAK1/2 
2012 axitinib Inlyta Pfizer RCC  VEGFR, PDGFRβ, c-Kit 
2012 bosutinib Bosulif Wyeth CML BCR-Abl, Src, Lyn, Hck 
2012 cabozantinib Cometriq Exelixis Metastatic medullary thyroid cancer 
 
RET, Met, VEGFR1/2/3, Kit, TrkB, 
Flt3, Axl, Tie2 
2012 dabrafenib Tafinlar GSK Melanoma B-Raf 
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2012 ponatinib Iclusig Ariad CML, chromosome positive ALL 
 
BCR-Abl, VEGFR, PDGFR, FGFR, 
Eph, Src, Kit, RET, Tie2, Flt3 
2012 regorafenib Stivarga Bayer CRC BCR-Abl, B-Raf, VEGFR, PDGFR, 
FGFR, Eph2A, Kit, RET, Tie2 
2013 tofacitinib Xeljanz Pfizer Rheumatoid arthritis JAK3 





2013 ibrutinib Imbruvica Pharmacyclics
/J&J 
mantle cell lymphoma Bruton’s kinase 
2013 trametinib Mekinist GSK Melanoma MEK1/2 
2014 idelalisib Zydelig Gilead Relapsed CLL, follicular B-cell 
NHL and small lymphocytic 
lymphoma 
PI3K belta 








Appendix Table -2. Kinase profiling of aigialomycin D (2.1, at 10 µM) against 96 
kinases performed by Ambit Biosciences, KINOMEscan™  
Ambit Gene Symbol Percent Control Ambit Gene Symbol Percent Control 
ABL1(E255K)-phosphorylated 20 LKB1 100 
ABL1(T315I)-phosphorylated 52 MAP3K4 100 
ABL1-phosphorylated 40 MAPKAPK2 100 
ACVR1B 39 MARK3 100 
ADCK3 58 MEK1 41 
AKT1 100 MEK2 61 
AKT2 100 MET 75 
ALK 24 MNK1 31 
AURKA 54 MNK2 0.15 
AURKB 34 MLK1 80 
AXL 4.7 p38-alpha 100 
BMPR2 33 p38-beta 100 
BRAF 63 PAK1 86 
BRAF(V600E) 46 PAK2 57 
BTK 84 PAK4 84 
CDK11 100 PCTK1 100 
CDK2 63 PDGFRA 57 
CDK3 84 PDGFRB 14 
CDK7 31 PDPK1 99 
CDK9 100 PIK3C2B 95 
CHEK1 100 PIK3CA 87 
CSF1R 94 PIK3CG 61 
CSNK1D 50 PIM1 30 
CSNK1G2 99 PIM2 57 
DCAMKL1 72 PIM3 42 
DYRK1B 12 PKAC-alpha 100 
EGFR 100 PLK1 94 
EGFR(L858R) 78 PLK3 86 
EPHA2 49 PLK4 9.6 
ERBB2 79 PRKCE 7.2 
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ERBB4 85 RAF1 100 
ERK1 100 RET 93 
FAK 79 RIOK2 90 
FGFR2 23 ROCK2 73 
FGFR3 18 RSK2(Kin.Dom.1-N-terminal) 76 
FLT3 7.1 SNARK 69 
GSK3B 100 SRC 47 
IGF1R 100 SRPK3 100 
IKK-alpha 100 TGFBR1 61 
IKK-beta 100 TIE2 73 
INSR 69 TRKA 37 
JAK2(JH1domain-catalytic) 56 TSSK1B 80 
JAK3(JH1domain-catalytic) 35 TYK2(JH1domain-catalytic) 82 
JNK1 97 ULK2 83 
JNK2 95 VEGFR2 93 
JNK3 82 YANK3 100 
KIT 75 ZAP70 45 
KIT(D816V) 40   
KIT(V559D,T670I) 100   
 
Appendix Table-3. S-score of aigialomycin D (2.1) for selectivity measurement 











S(35) 15 90 10 0.167 
S(10) 5 90 10 0.056 











Appendix Figure-1(a-b). 1H NMR studies for the reactions of cysteamine with cis and 








4.35  in DMSO-d6  
4.35   + cysteamine, after 5 min  
4.35    + cysteamine, after 2  h  
4.34 in DMSO-d6  
4.34 + cysteamine, after 5 min  
4.34  + cysteamine, after 2  h  
7,8-olefinic protons (1a) 
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Appendix Figure-2. Mass spectra of MNK1/2 incubated with covalent inhibitors (cis N-
acetyl enamide 4.34 and trans N-acetyl enamide 4.35). The mass peaks are corresponding 




36251.43 (MNK2 + 4.34) (MNK
2 ) 
35064.09 (MNK1 + 4.34) 
(MNK1
) 
36251.19 (MNK2 + 4.35) 
(MNK
2 ) 





Appendix Table-4. Kinase profiling of enamide 4.48 (at 10 µM) against 50 kinases 
performed by Ambit Biosciences, KINOMEscan™ 
Gene Symbol Percent Controla Gene Symbol Percent Controla 
AXL 82 KIT-autoinhibited 100 
CDK2 97 MAPKAPK2 100 
CDK5 100 MAPKAPK5 100 
CDKL1 100 MEK1 19 
CDKL2 53 MEK2 24 
EGFR 85 MEK3 67 
EGFR(L858R) 78 MEK4 8.1 
ERBB2 100 MEK5 22 
ERBB3 90 MEK6 72 
ERBB4 79 MET 100 
ERK1 100 MNK1 99 
ERK2 100 MNK2 28 
FLT1 65 PDGFRA 10 
FLT3 1.8 PDGFRB 6.4 
FLT3(D835H) 15 PLK1 80 
35063.81 (MNK1 + 4.35) 
(MNK1) 
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FLT3(ITD) 9.4 PLK3 100 
FLT3(N841I) 17 PLK4 55 
FLT3-autoinhibited 79 PRKCE 100 
GAK 7.8 PRKD1 100 
GSK3A 100 PRKD2 100 







KIT(D816V) 14 TAK1 90 
KIT(V559D) 7 VEGFR2 36 
a Lower value indicate higher inhibition 











S(35) 15 50 10000 0.23 
S(10) 6 50 10000 0.11 
 
 
 
